Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page 2 of 149 
Confidential and Proprietary  27 May 2021 INVESTIGATOR SIGNATURE [CONTACT_804584]: A Phase 2, single-arm study of bempegaldesleukin (NKTR-214) in 
combination with nivolumab in cisplatin ineligible, locally adv anced or 
metastatic urothelial cancer patients 
Protocol Number: 18-214-10 
Protocol Amend ment Number: 5.0 
Protocol Amendment Date: 27 May 2021 
Sponsor: Nektar Therapeutics 
[ADDRESS_1110341] South 
San Francisco, CA [ZIP_CODE] [LOCATION_003] 
 
PRINCIPAL INVESTIGATOR [INVESTIGATOR_329603] 
I, the undersigned Principal Investigator, submit this statemen t of commitment as evidence that I 
understand my responsibilities pursu ant to the Code of Federal Regulations (21 CFR § 312) and 
ICH E6 Good Clinical Practice guidelines, as well as with any a nd all applicable federal, state 
and/or local laws and regulati ons, and agree to conduct the stu dy in accordance with the protocol 
referenced herein. 
  
Principal Investigator [INVESTIGATOR_804484]:  
Position:  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page [ADDRESS_1110342] OF APPENDICES .............................................................................................................10  
ABBREVIATIONS ......................................................................................................................11  
1.0 STUDY SYNOPSIS .........................................................................................................17  
1.1 Study Schematic.....................................................................................................22  
1.2 Schedule of Events ............................................ .....................................................23  
2.0 INTRODUCTION............................................................................................................28  
2.1 Background ............................................................................................................28  
2.1.1  Bladder Cancer ......................................................................................28  
2.1.2  NKTR-214 ...................................................... ......................................29  
2.1.3  Nivolumab .............................................................................................33  
2.1.4  Clinical Experience with NKTR-214 in Combination with 
Nivolumab .............................................................................................35  
2.1.5  Recent Developments in Immunotherapy in Bladder Cancer ........ .......38  
2.2 Study Rationale ......................................................................................................40  
2.3 Benefit/Risk Aspects .......................................... ....................................................42  
2.3.1  NKTR-214 Safety Profile .....................................................................42  
2.3.2  Nivolumab Safety Profile ......................................................................42  
2.3.3  NKTR-214 and Nivolumab Ben efit and Risk Assessment ............ .......42  
2.3.4  Independent Data Monitoring Committee ............................................43  
3.0 STUDY OBJECTIVES ....................................................................................................44  
3.1 Primary Objective ............................................. .....................................................44  
3.2 Secondary Objectives .............................................................................................44  
  
4.0 INVESTIGATIONAL PLAN .........................................................................................46  
4.1 Study Design ..........................................................................................................46  
4.1.1  Screening Period ...................................................................................47  
4.1.2  Treatment Period ...................................................................................47  
4.1.3  End of Treatment ..................................................................................48  

Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page 6 of 149 
Confidential and Proprietary  27 May 2021 4.1.4  End of Study ..........................................................................................50  
4.1.5  Treatment After End of Study .................................. .............................50  
4.1.6  Patients Enrolled onto Gemcita bine/Carboplatin (GemCarbo) 
Treatment in an Earlier Version of the Protocol ............... ....................51  
4.2 Rationale for Study Design Elements ........................... .........................................51  
4.2.1  Choice of Endpoints ..............................................................................51  
4.2.2  Duration of Treatment wit h Nivolumab / NKTR-214 ............... ...........51  
4.2.3  Justification for Dose ............................................................................53  
4.2.4  Rationale for Open-label Design ...........................................................54  
4.2.5  Choice of PD-L1 Assays ........................................ ...............................54  
5.0 SELECTION OF STUDY POPULATION ...................................................................55  
5.1 Inclusion Criteria ............................................ .......................................................55  
5.2 Exclusion Criteria ..................................................................................................57  
6.0 STUDY TREATMENTS .................................................................................................60  
6.1 Administration of Study Drugs ..............................................................................60  
6.1.1  Bempegaldesleukin (NKTR-214) .........................................................60  
6.1.2  Drug Description and Formulation .............................. .........................60  
6.1.3  Drug Packaging and Labeling ................................... ............................61  
6.1.4  Drug Reconstitution and Handling............................... .........................61  
6.1.5  Nivolumab .............................................................................................62  
6.2 Monitoring, Vital Signs, a nd Hydration Guidelines ............. .................................62  
6.2.1  Frequent Vital Signs ..............................................................................63  
6.2.2  Hydration Guidelines ............................................................................63  
6.2.3  Hypotension Guidelines ........................................ ................................64  
6.3 Method of Treatment Assignment .........................................................................64  
6.4 Blinding..................................................................................................................65  
6.5 Dosage Modification ........................................... ...................................................65  
6.5.1  NKTR-214 Dose Modifications and Delays .........................................65  
6.5.2  Nivolumab Dose Delay Criteria ............................................................66  
6.5.3  Dose Modification Criteria fo r NKTR-214 and Nivolumab for 
Cycle 1 ALT/AST Elevations ...............................................................67  
6.5.4  Criteria to Resume NKTR-214 a nd/or Nivolumab Dosing............ .......68  
6.5.5  Permanent Treatment Dis continuation Criteria .................. ..................68  
6.6 Management of Specific Adverse Events ..............................................................70  
6.6.1  Management Algorithms for I mmune-mediated AEs and Cytokine-
release Syndrome Associate d with Immuno-Oncology Agents............70  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page 7 of 149 
Confidential and Proprietary  27 May 2021 6.6.2  Monitoring and Management of  Adrenal Insufficiency and 
Hypophysitis .........................................................................................71  
6.6.3  Monitoring and Management of Eosinophilia ..................... .................71  
6.6.4  Treatment of Study Drug-Related Infusion Reactions for NKTR-214/Nivolumab ......................................................................................[ADDRESS_1110343] of NKTR-214 on PK of C oncomitant Medications............ ........75  
6.7.4  Prohibited Concomitant Medications ............................ ........................75  
6.8 Study Drug Accountability and Reconciliation .................. ...................................76  
7.0 STUDY ASSESSMENTS AND PROCEDURES ..........................................................77  
7.1 Tumor and Radiographic Assessments ..................................................................77  
7.1.1  Central Imaging ............................................... ......................................78  
7.2 Pharmacokinetic and Immunoge nicity Measurements ............... ...........................78  
7.3 PD-L1 Assay ..........................................................................................................81  
7.4  
7.5 Tumor Tissue Specimens .......................................................................................82  
7.5.1  Tumor Mutation Burden ......................................... ..............................83  
  
  
7.6 Sample Collection and Storage ..............................................................................84  
7.7 Health-Related Quality of Life (HRQoL) ........................ ......................................[ADDRESS_1110344], MRI ................................................................................................88  
8.2.3  Tumor Markers ................................................. ....................................88  
8.2.4  Cytology, Histology ..............................................................................88  
8.3 Tumor Response Evaluation ..................................... .............................................88  

Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page 8 of 149 
Confidential and Proprietary  27 May 2021 8.3.1  Assessment of Overall Tumor Burden at Baseline and Measurable Disease ....................................................... ...........................................88
 
8.3.2  Baseline Documentation of ‘Targ et’ and ‘Nontarget’ Lesions .............[ADDRESS_1110345] 1.1 ............................ ........................................90  
8.4.1  Evaluation of Target Lesions ................................................................90  
8.4.2  Evaluation of Nontarget Lesions ............................... ............................90  
8.4.3  Duration of Response .......................................... ..................................91  
8.5 Blinded Independent Central Review ............................ ........................................91  
9.0 ASSESSMENT OF SAFETY ..........................................................................................92  
9.1 Adverse Events ......................................................................................................92  
9.1.1  AE Definition and Assessment .............................................................92  
9.1.2  Monitoring AEs .....................................................................................92  
9.1.3  Grading of AEs .....................................................................................93  
9.1.4  Causality Relationship of AEs ..............................................................93  
9.1.5  AE Reporting and Follow-up .................................... ............................94  
9.2 Serious Adverse Events ........................................ .................................................94  
9.2.1  SAE Definition ......................................................................................94  
9.2.2  Serious AE Reporting ...........................................................................95  
9.2.3  Serious AE Follow-up ...........................................................................96  
9.3 Disease Progression – Not Reportable as an AE ...................................................[ADDRESS_1110346] ............................ ............................................97  
9.7 Pregnancy Tests/Pregnancy ..................................... ..............................................[ADDRESS_1110347] .................... ..................................99  
9.11  Clinical Laboratory Tests ..................................... ................................................100  
9.12  Physical Examinations .........................................................................................100  
9.13  Vital Signs ................................................... .........................................................101  
9.14  Electrocardiograms ............................................ ..................................................101  
9.15  Echocardiograms................................................ ..................................................101  
10.0  STATISTICAL PLAN ...................................................................................................102  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page 9 of 149 
Confidential and Proprietary  27 May 2021 10.1  General Considerations ........................................ ................................................102  
10.2  Determination of Sample Size .............................................................................102  
10.3  Analysis Sets ................................................. .......................................................102  
10.4  Demographics and Baseline Characteristics ........................................................103  
10.5  Efficacy ................................................................................................................103  
10.5.1  Primary Analysis .................................................................................103  
10.5.2  Secondary Analyses ............................................ ................................104  
  
10.6  Safety ...................................................................................................................104  
10.6.1  Study Drug Exposure ........................................... ...............................105  
10.6.2  Adverse Events and Laboratory Evaluations ..................... .................105  
10.6.3  Other Safety Evaluations.....................................................................105  
10.7  Pharmacokinetics .............................................. ...................................................105  
10.8  Health-Related Quality of Life (HQRoL) ........................ ....................................106  
10.9   
10.10  Missing Data ........................................................................................................106  
10.11  Independent Data Monitoring Com mittee (IDMC)/Sponsor Executive 
Committee (SEC) ............................................... ..................................................[ADDRESS_1110348] Access to Source Data/Doc uments for Audits and Inspectio ns ................109  
13.0  ETHICAL CONSIDERATIONS ........................................ ..........................................110  
13.1  IRB/IEC Approval ...............................................................................................[ADDRESS_1110349] KEEPI[INVESTIGATOR_1645] .............................. ..........................111  
14.1  Data Collection Instruments and Source Documents .............. ............................111  
14.1.1  Study Records .....................................................................................111  
14.1.2  Data Collection Instruments ................................................................111  
14.2  Retention of Essential Documents .......................................................................111  
14.3  Confidentiality .....................................................................................................112  
14.4  Security Measures ............................................. ...................................................112  
15.0  PUBLICATION PLAN .............................................. ...................................................113  
16.0  REFERENCES ...............................................................................................................114  
 

Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page [ADDRESS_1110350] 
AIDS acquired immuno deficiency syndrome 
ALT (SGPT) alanine aminotransfer ase (serum glutamic pyruvic tra nsaminase) 
ANC absolute neutrophil count 
AST (SGOT) aspartate aminotransferase (serum glutamic oxaloacet ic transaminase) 
AUC area under the curve 
bempegaldesleukin (bempeg, BEMPEG) International Nonproprietary Name (INN) for NKTR-214 
BP blood pressure 
BICR blinded independent central review  
BUN blood urea nitrogen 
Cavgss steady state average concentration  
CFR Code of Federal Regulations 
cHL classical Hodgkin’s lymphoma  
CI confidence interval 
CL clearance 
Cmax maximum concentration 
CMV cytomegalovirus 
CNS central nervous system 
CPI [INVESTIGATOR_804485]. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page [ADDRESS_1110351] oral anticoagulation 
DOR duration of response 
DVT deep vein thrombosis 
DWI diffusion-weighted imaging 
EC 50 50% effective dose 
ECG electrocardiogram 
ECHO echocardiogram 
ECLA electrochemiluminescence assay 
ECOG Eastern Cooperative Oncology Group 
eCRF electronic case report form 
EDC electronic data capture 
EMA European Medicines Agency 
EORTC European Organization for the Research and Treatment of C ancer 
EORTC QLQ-C30 European Organization for the Re search and Treatment of Cancer Quality of 
Life Questionnaire 
EOT end of treatment 
EQ-5D-3L EuroQol Group’s EQ-5D questionnaire 
ESMO European Society for Medical Oncology  
EU European Union 
FACIT GP5 Functional Assessment of Chronic Illness Therapy GP5 item 
FDA Food and Drug Administration 
FFPE formalin-fixed paraffin-embedded 
GCP Good Clinical Practice 
GFR glomerular filtration rate 
GemCarbo gemcitabine/carboplatin  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page 13 of 149 
Confidential and Proprietary  27 May 2021 Abbreviation or Term Definition 
HBsAg hepatitis B surface antigen 
HBV hepatitis B virus 
HCG human chorionic gonadotropin 
HCV hepatitis C virus 
high PD-L1  high programmed cell death ligan d 1 (PD-L1) expression (i.e., C ombined 
Positive Score [CPS] ≥ 10) 
HIV human immunodeficiency virus 
HR hazard ratio 
HRQoL health-related quality of life 
HUS hemolytic uremic syndrome 
IC50 50% inhibitory dose 
ICF informed consent form 
ICH International Council for Harmonisation 
IDMC Independent Dat a Monitoring Committee 
IEC Independent Ethics Committee 
IFNγ interferon gamma 
IHC immunohistochemistry 
IL interleukin 
IL-2 interleukin-2. For bempegaldesleukin (NKTR-214), IL-[ADDRESS_1110352] 
IRT Interactive Response Technology 
IV Intravenous 
kg kilogram 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page 14 of 149 
Confidential and Proprietary  27 May 2021 Abbreviation or Term Definition 
KPS Karnofsky performance status 
LDH lactate dehydrogenase 
LMWH low molecular weight heparin  
low PD-L1  low programmed cell death ligand 1 (PD-L1) expression (i.e., Co mbined 
Positive Score [CPS] < 10) 
LVEF left ventricula r ejection fraction 
M-CAVI methotrexate, carboplatin, and vincristine  
MDSC myeloid derived suppressor cells  
mDOR median duration of response 
MedDRA Medical Dictionary for Regulatory Activities 
min minute(s) 
mg milligram 
mL milliliter 
MLR mixed lymphocyte reaction 
mm Hg millimeters of mercury 
MMR measles, mumps, rubella  
MRI magnetic resonance imaging 
MTD maximum tolerated dose 
mUC metastatic urothelial carcinoma 
MUGA multigated acquisition  
NCCN National Comprehensive Cancer Network 
NCI National Cancer Institute 
NK natural killer 
NKTR-214-AC NKTR-[ADDRESS_1110353]  
NSAID nonsteroidal anti-inflammatory drug 
NSCLC non-small cell lung cancer 
NYHA [LOCATION_001] Heart Association 
ORR objective response rate  
OS overall survival 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page 15 of 149 
Confidential and Proprietary  27 May 2021 Abbreviation or Term Definition 
OTC over-the-counter 
PBMC peripheral blood mononuclear cell 
PD progressive disease 
PD-1 programmed cell death protein 1 
PD-L1 programmed cell death ligand 1 
PE pulmonary embolism 
PEG polyethylene glycol 
PFS progression-free survival 
PK pharmacokinetic(s) 
PPK population pharmacokinetics 
PR partial response 
PRO patient-reported outcomes 
PSA prostate-specific antigen 
q14d every [ADDRESS_1110354] Response Evaluation Criteria in Solid Tumors 
rhIL-2 recombinant human interleukin 2. For bempegaldesleukin (NKTR-214), IL-[ADDRESS_1110355] operating procedure 
SAR serious adverse reaction 
SARS-CoV-2; COVID-19 severe acute respi[INVESTIGATOR_179893] 2  
t1/2 half-life
TCC transitional cell carcinoma

Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page [ADDRESS_1110356] upper limit of normal
US [LOCATION_002]
VAS visual analo gue scale
Vd volume of distribution
WBC white blood cell
WOCBP woman of childbearing potential 
 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page 20 of 149 
Confidential and Proprietary  27 May 2021 Pharmacokinetic Evaluation: Blood samples for PK will be co llected from patients at multipl e scheduled 
sampling times. Pharmacokinetic par ameters such as maximum conc entration 
(Cmax), time to C max (Tmax), area under the curve (AUC), clearance (CL), 
volume of distribution (V d), and half-life (t 1/2) will be estimated  from plasma or 
serum concentration-time data where possible. 
Efficacy Evaluation: Tumor measurements will be perfo rmed every 9 weeks ± 7 days. Th e primary 
endpoint is: 
• ORR by [CONTACT_804511]-L1 expression 
The secondary endpoints are: • ORR per BICR in all treated patients 
• DOR by [CONTACT_804512] h ave low 
PD-L1 expression 
• ORR and DOR by [CONTACT_804513]-L1 expression 
All response and progression endp oints will be determined by [CONTACT_804514] 1.1. Patients will be assessed for response by [CONTACT_20420] 
(CT) or magnetic resonance imaging (MRI) until progression or t reatment 
discontinuation, which ever occurs later.  
After the first 12 months, tumo r assessments will be done every  12 weeks 
(± 7 days). A scan should also be done at end of treatment (unl ess a scan was 
done within the prior 4 weeks). Patients who continue treatment  beyond 
progression should continue to have scans every 9 weeks (± 7 days) for the 
first [ADDRESS_1110357]-progression and every 12 week s (± 7 days) in 
the second year of treatment post-progression. Tumor assessment s in the 
follow-up period should be done e very 90 days (± 10 days) from the last scan 
and are only needed if the patie nt discontinued treatment witho ut radiographic 
disease progression. 
Safety Evaluation: Assessment of safety will be deter mined by [CONTACT_804515]: 
• Adverse events, including inciden ce of treatment emergent AEs ( TEAEs), 
incidence of treatment  related AEs, serious AEs (SAEs), AEs lea ding to 
drug discontinuation 
• Clinical laboratory tests (blood and urine sampling) 
• Vital signs 
• Physical examination 
In addition to routine safety monitoring and pharmacovigilance activities, an 
Independent Data Monitoring Committee (IDMC) provided an initia l safety 
review; subsequently a Sponsor  Executive Committ ee (SEC) will p rovide 
formal safety reviews. The IDMC/SEC are described further in Se ction  10.[ADDRESS_1110358] 2 cycles of study treatment 
(6 weeks) with NKTR-214 and nivolumab were included in the init ial planned 
safety review condu cted by [CONTACT_31849]. 
Statistical Methods General Considerations: 
In general, continuous data will be summarized by [CONTACT_335832] s tatistics, 
including number of patients, mean, standard deviation, median,  minimum, and 
maximum. Categorical data will be  summarized by [CONTACT_804516]. 
Efficacy:  ORR is defined as the percentage  of patients with a confirmed best 
overall response of complete response (CR) or partial response (PR) b y 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0  bempegaldesle ukin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page [ADDRESS_1110359] 1.1 per BICR. The ORR and its corresponding 95% exact co nfidence 
interval (CI) will be calculate d by [CONTACT_39715]-Pearson method.  
DOR is defined for patients who have a confirmed CR or PR as th e date from 
first documented CR or PR per RECIST 1.[ADDRESS_1110360] evalua ble tumor assessment. The media n DOR will be 
estimated using the Kaplan-Meier method with corresponding 95% CI and 
range. 
Sample Size:  The total patient enrollment for this study is expected to be a  
maximum of 190 patient s, including 2 patie nts who received GemC arbo under 
Amendment 2.0 of this protocol. (With Amendment 5.0, enrollment  is 
complete at 2 patients who receiv ed GemCarbo and 190 patients w ho received 
NKTR-214/nivolumab). The study will evaluate the totality of th e data 
including DOR, ORR, and CR rate. The number of patients to rece ive 
NKTR-[ADDRESS_1110361] that  approximately 
70% of patients have PD-L1 low tumors, while 30% have PD-L1 hig h tumors 
using the PD-L1 IHC 22C3 pharmDx assay ( Vuky 2018 ; KEYTRUDA® 
Prescribing Information, 2018; TECENTRIQ® Prescribing Information, 2018). 
Utilizing this assumption,  at least [ADDRESS_1110362] 
tumors that are PD-L1 low. The null hypothesis is that the ORR among the 
PD-L1 low patients is ≤ 21%. The alternative hypothesis is that  the ORR is 
> 21%. Assuming an ORR rate of at least 34%, with at least [ADDRESS_1110363] more than 82% pow er to demonstrate that the low er limit of the 
95% two-sided confidence interva l (CI) for ORR exceeds 21%, whe re the CI is 
calculated by [CONTACT_804517].  
Safety:  Safety assessments will include A Es, clinical laboratory tests,  vital 
signs, and physical examinations. All safety data will be summa rized for the 
All Treated Population using desc riptive statistics. An IDMC wa s utilized for 
the planned safety review of the  first [ADDRESS_1110364] 2 cycles 
of NKTR-214 in combination with nivolumab. Subsequently a Spons or 
Executive Committee (SEC) will pr ovide formal safety reviews. 
 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 23 of 149 
Confidential and Proprietary 27 May 2021 1.2 Schedule of Events 
Table 1: Schedule of Events (Excluding Pharmacokinetic, Immunogenicity, and  Sampling) 
Procedure / Period: Screening Treatment Post-treatment 
Cycle 1 Only Cycle 2 and  
Beyond  End of  
Treatmentw Follow-upx Survival  
Follow-upy 
Study Daysa: Day -28 
to -1 Day 
1 Day 3 
(- 1 day)Day 5
(-1 
or -2 
days) Day 8
(± 3 
days) Days 
14 to 
21 Day 1 
(± 3 
days) Day 3  
(+ 2 
days) (± 7 days) [ADDRESS_1110365] 
dose 
(± 7 days) [ADDRESS_1110366] 
dose 
(± 7 days) Every 
3 months 
(± 14 days) 
Informed consent X            
Inclusion/ exclusion 
criteria X            
Medical history X            
Physical examinationb X X     X  X X X  
Vital signsc X X X  X  X  X X X  
ECOG performance status
d X X     X  X X X  
ECGe X             
ECHO/MUGAf X            
Pregnancy testg X X     X  X X X  
Hematologyh X  X    X   X   X     
Coagulationh X  X    X   X   X     
Serum chemistryi X  X      X   X     
Additional laboratory assessments
j X      Xj   X     
Local labs prior to dosing
k  X      X       

Protocol No. 18 -214-10 / CA045 -012 Amendment 5 .0 bempegaldesleukin (NKTR -214) and nivolumab  
Nektar Therapeutics   Page 24 of 149 
Confidential and Proprietary  27 May  2021  Table 1:  Schedule of Events (Excluding Pharmacokinetic, Immunogenicity, and  Sampling)  (Contd)   
Procedure / Period:  Screening  Treatment  Post-treatment  
Cycle 1 Only  Cycle 2 and  
Beyond  End of  
Treatmentw Follow -upx Survival  
Follow -upy 
Study Daysa: Day -28 
to -1 Day 1  Day 3  
(- 1 day) Day 5  
(-1 
or -2 
days)  Day 8  
(± 3 
days)  Days  
14 to 
21 Day 1  
(± 3 
days)  Day 3  
(+ 2 
days)  (± 7 days)  [ADDRESS_1110367] 
dose  
(± 7 days)  [ADDRESS_1110368] 
dose  
(± 7 days)  Every 
3 months  
(± 14 days)  
Urinalysis (dipstick)l X X     X  X    
Serologyi X            
Tumor biopsy/ PD -L1 
statusm X     X       
PK and immunogenicity 
assessments   Refer to Table  3 
   
 
 
 
             
Tumor assessmento X Every 9 weeks  
(± 7 days) for the first 12 months ; and then  every 12 weeks (± 7 days)   X X  
Brain Imagingp X • Patients with a history of brain metastasis or symptoms should have 
surveillance MRI with and without contrast per standard of care. CT of 
the brain (with contrast) can be performed if MRI is contraindicated or 
not available. If contrast is contraindicated in the patient, CT of the brai n 
without contrast can be performed.  
• Assessments every 9 weeks (± 7 days) from the date of enrollment 
through 12  months of treatment, then every 12 weeks (± 7 days) or 
sooner if clinically indicated.  • For patients without BICR  confirmed 
progression, continue to have 
surveillance MRI/ CT with an d without 
contrast per standard of care every, 90 
days (±  10 days) or sooner if clinically 
indicated.  

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 25 of 149 
Confidential and Proprietary 27 May 2021 Table 1: Schedule of Events (Excluding Pharmacokinetic, Immunog enicity, and  Sampling) (Contd) 
Procedure / Period: Screening Treatment Post-treatment 
Cycle 1 Only Cycle 2 and 
Beyond  End of 
Treatmentw Follow-upx Survival 
Follow-upy 
Study Daysa: Day -28 
to -1 Day 1 Day 3 
(- 1 day)Day 5
(-1 
or -2 
days) Day 8
(± 3 
days) Days 
14 to 
21 Day 1 
(± 3 
days) Day 3  
(+ 2 
days) (± 7 days) [ADDRESS_1110369] 
dose 
(± 7 days) [ADDRESS_1110370] 
dose 
(± 7 days) Every 
3 months 
(± 14 days) 
Administer IV fluidsq  X     X      
NKTR-214 and 
nivolumab 
administrationr  X      X       
Oral hydration follow-up
s    X     X      
AE assessment X X X  X Xz X  X X X  
Review of concomitant medications/procedures X X X  X X
z X   X     
Health-related quality of life assessments
t X X     X  X X X X 
Follow-upu          X X  
Subsequent medications          X X  
Subsequent anti-cancer therapy
v          X  X  X  
Survival follow-up (by [CONTACT_756])            X  
AE = adverse events; CT = computed tomography; CVA = cerebrovas cular accident; ECG = electrocard iogram; ECHO = echocardiogram;  ECOG = Eastern 
Cooperative Oncology Group; EORTC QLQ-C30 = European Organizati on for the Research and Treatme nt of Cancer Quality of Life Que stionnaire; EOT = end 
of treatment; EQ-5D-3L = EuroQol Group’s EQ-5D questionnaire; F FPE = formalin-fixed paraffin-embedded; IV = intravenous; LVEF =left ventricular ejection 
fraction; MRI = magnetic resonance imaging; MUGA = multigated a cquisition; Nivo = nivolumab; PD-L1 = programmed cell death lig and 1; 
PK = pharmacokinetics; SAE = serious adverse event.  
a. The acceptable visit window for  Cycle 2 and beyond is ± 3 da ys for Day 1. Cycle intervals less than 21 days (e.g., 21 days - 3 days) should only occur if the 
Investigator believes there are no safety concerns with dosing the patient 1 to 3 days prior to a 21-day cycle. Additional vis it windows are:  ± [ADDRESS_1110371]-treatment a nd ± 7 days for EOT visit. Visits may be skipped or postponed i f prospectively identified by [CONTACT_737] (e.g., national 
holidays, patient holidays). All procedures and examinations sh ould be performed before the administration of study drug(s), e xcept as indicated. 

Protocol No. 18 -214-10 / CA045 -012 Amendment 5 .0 bempegaldesleukin (NKTR -214) and nivolumab  
Nektar Therapeutics   Page [ADDRESS_1110372] occur within 5 days prio r to administering study 
drugs; see Section 9.12. Body weight measurement must be performed on the day of dosing . 
c. Some clinic visits will have more frequent vital sign measurements. Vital signs are to be monitored during Cycle 1 on Day 1 p redose (within 2 hours of 
infusion). For Cycle  2 and beyond, vital signs should be monitored predose (within 30 minutes) and approx imately [ADDRESS_1110373] be done within 14 days of Day 1. Cycle 1 Day 3  (see 
Table  3). Hematology and coagulation assessments for Day [ADDRESS_1110374] be provided within 5 days prior to administering study drugs.  
m. Unstained FFPE, tumor tissue sections on slides (a minimum of 10 slides, p referably 15 to 25) or a FFPE tumor tissue block, collected within 12  months 
prior to enrollment and without intervening therapy, are acceptable in lieu of a fresh tumor biopsy prior to treatment. See S ection 7.5. An optional 
on-treatment tumor tissue sample will be collected prior to Cycle 2 Day 1, on Days 14 to 21 of Cycle 1. Sample collection upon d isease progression is 
optional but highly recommen ded. PD -L1 status is described in Section 7.3.  
n.  
 
 
 
o. Tumor assessments at Screening and every 9 weeks (± 7 days) from Cy cle 1 Day 1 (C1D1) for the first 12 months. Beyond 12  months, tumor assessments 
will decrease in frequency to every 12 weeks (± 7 days). A scan should also be done at EOT unless a scan was done within 4 we eks (Section 7.0). Patients 
who continue treatment beyond progression should continue to have scans every 9 weeks (± 7 days) for the first [ADDRESS_1110375] -progression and 
every 12 weeks (± 7 days) in the second year of treatment post -progression  (for a maximum treatment duration of 2 years from  C1D1 ). Tumor assessments 
in the follow -up period are only needed if the patient discontinued treatment without radiographic ally diagnosed disease progression (Section [IP_ADDRESS] ). 
Patients who discontinue study treatment and do not have BICR -confirmed disease progression should continue to have scans every 90 days (±  10 days)  
during the follow -up period  if clinically feasible, until disease progression is confirmed by [CONTACT_19377]. Scans should continue to be collected even if a new 
antineoplastic regimen has been initiated . Confirmation of tumor response is discuss ed in Section 8.3. Scans will be sent to  the imaging vendor.  

Protocol No. 18 -214-10 / CA045 -012 Amendment 5 .0 bempegaldesleukin (NKTR -214) and nivolumab  
Nektar Therapeutics   Page [ADDRESS_1110376] of the brain (with contrast) can be performed if MRI is contraindicated or not available. If cont rast is contraindicated in the patient, CT of the brain 
without contrast can be performed. See Section 7.[ADDRESS_1110377] the patient (by [CONTACT_804518]) to remind the patient of the oral hydration guidelines, to assess for any symptomatology and complianc e with the guidelines, and document the results 
of the discussion. Following subsequent NKTR -214 administrations, the oral hydration follow -up should be conducted as clinically indicated for patients 
receiving NKTR -214 (see Section  6.2.2 ). 
t.  At each visit specified, prior to any other study assessments, health -related quality of life will be assessed using the EORTC QLQ -C30; general health status 
will be measured using the EQ -5D-3L and treatment burden will be captured by [CONTACT_804519]5. During survival follow -up, the EQ -5D-3L will be administered 
by [CONTACT_756]. See Section 7.7. Note, FACIT GP5 is not required to be performed at the Screening visit. FACIT GP5 must be performed after dosing on 
Cycle 1 Day 1; at all other study visits specified, FACIT GP5 should be performed prior to any other study assessments.  
u. See Section [IP_ADDRESS] .  
v. Additio nal subsequent cancer therapy details such as regimen, setting of the regimen, line of therapy, start date and end date of ea ch regimen, best response 
to the regimen, and date of progression to subsequent anti -cancer therapi[INVESTIGATOR_12308].  
w. See Sec tion 4.1.[ADDRESS_1110378] dose (± 7 days) or 
can be performed on the date of discontinuation if that date is greater than [ADDRESS_1110379] dose . Follow -up Visit 1 can be combined with the EOT Visit 
if the visits are within 7 days of each other. Follow -up Visit 2 occur s approximately 100 days (± 7 days) from the last dose of all study drugs. Both follow -up 
visits should be conducted at the clinic. See Section  [IP_ADDRESS] . 
y. All patients will be contact[CONTACT_257781] -study therapy(ies) and survival every 3 months (± 14 days) following the Day [ADDRESS_1110380]. See Section  [IP_ADDRESS] . 
z. If the patient is not visiting the clinic for the optional biopsy or for an unscheduled visit on Days 14 -21, review of AEs and concomitant 
medications /procedures  may be conducted by [CONTACT_756].  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 28 of 149 
Confidential and Proprietary  27 May 2021 2.0 INTRODUCTION 
2.1 Background 
2.1.1 Bladder Cancer  
Urothelial bladder cancer (UBC) is the most common cancer of the urinary system worldwide, 
with transitional cell carcinom a (TCC) of the bladder being the  predominant histologic type and 
location. TCC accounts for greater than 90% of all UBC cases in  the industrialized world, 
whereas non-urothelial subtypes, i ncluding squamous cell, adenocarcinoma, and small cell 
carcinoma are more frequent in other areas of the world (Chalasani, 2009) . It is estimated that in 
2020, there will be 81,400 new UBC cases and 17,980 deaths from UBC in the US (Siegel, 2020). Worldwide estimates for 2018 included 549,393 new cases and 199,922 deaths 
(Bray, 2018). UBC tends to be a cancer of olde r age with the average age a t the time of diagnosis 
being 73 years ( ACS, 2018). 
The overall survival (OS) of blad der cancer varies widely based  on stage and grade, but for 
metastatic UBC, the  5-year OS is 4.8% ( Noone, 2018 ). Poor prognostic fact ors for survival in 
patients with metastatic UBC incl ude Karnofsky performance status (KPS) less than 80% and 
visceral (defined as lung, liver  or bone) metastasis. Median su rvival for patients who had zero, 
one, or two risk factors were 33, 13.4, and 9.[ADDRESS_1110381] ively ( Bajorin, 1999 ). 
The preferred initial treatment f or metastatic UBC is cisplatin -based combination regimens. 
However, approximately 50% of patients are not appropriate cand idates for cisplatin-based 
therapi[INVESTIGATOR_014]. A consensus working gr oup has defined these medicall y frail patients, who are 
predisposed to increased toxicit y from cisplati n, as those who meet any one of the following 
criteria ( Galsky, 2011): 
• Eastern Cooperative Oncology Group (ECOG) performance status of  2 or above 
• Creatinine clearance less than 60 mL/min 
• Grade ≥ 2 hearing loss 
• Grade ≥ 2 neuropathy 
• [LOCATION_001] Heart Association (NYHA) Class III heart failure 
Within this cisplatin-ineligible population, c arboplatin-based combination chemotherapy is 
generally regarded as the preferred initial treatment. For pati ents who are unable to receive 
carboplatin-based doublets, single-agent treatment or best supp ortive care is recommended. The 
benefit of carboplatin-based the rapy in medically “unfit” patie nts was demonstrated in the 
European Organization for the Research and Treatment of Cancer (EORTC) Trial [ZIP_CODE] 
(De Santis, 2012 ). This study evaluated 238 patients with previously untreated advanced or 
metastatic UBC who were unfit for  cisplatin-based treatment bec ause of either poor performance 
status or impaired renal func tion, or both. Patients were rando mized to receive treatment with 
either gemcitabine/carboplatin ( GemCarbo) or methotrexate, carboplatin, and vincristine 
(M-CAVI). The confirmed objective response rate (ORR) was 36% f or GemCarbo and 21% for 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 29 of 149 
Confidential and Proprietary  27 May 2021 M-CAVI. The median OS was 9.3 m onths in the GemCarbo arm and 8. 1 months in the M-CAVI 
arm (p=0.64). Severe acute toxi city (death, Grade 4 thrombocyto penia with bleeding, Grade 3 or 
4 renal toxicity, neutropenic feve r or mucositis) was observed in 9.3% of patients receiving 
GemCarbo and 21.2% of patients receiving M-CAVI. Ultimately, it  was concluded that while 
there was no significant diffe rence in efficacy between the two  treatment arms, the increased 
toxicity with M-CAVI warrante d preferential use of GemCarbo.  
While chemotherapy has historica lly been the mainstay of treatment for metastatic bladder 
cancer, the advent of immunothera py, specifically checkpoint in hibitors (CPIs), has drastically 
changed the treatment landscape.  
2.1.2 NKTR-214 
Bempegaldesleukin is the Inter national Nonproprietary Name (INN ) for NKTR-214. 
[IP_ADDRESS] Mechanism of Action  
Bempegaldesleukin (NKTR-214) is a prodrug of a conjugated cancer immunotherapy cytokine 
that exerts its biological ac tivity by [CONTACT_802638] (IL)-2 receptor and subsequent 
activation of effector T-cells. A s a PEGylated human recombinan t IL-2 molecule of aldesleukin 
with an average of six releasable  polyethylene glycol (PEG) cha ins, NKTR-214 can be 
administered convenien tly in the outpatient setting using an an tibody like dosing regimen. Upon 
intravenous (IV) administration, the PEG chains slowly release to generate the active cytokine 
species (2-PEG-IL-2 and 1-PEG-IL -2) that have a peak plasma con centration 24 to 48 hours after 
infusion. The slow generation of the 2-PEG-IL-2 and 1-PEG-IL-2 significantly mitigates the 
rapid-onset, systemic cytokine-r elated toxicities associated with high dose IL-2.  
The polymer conjugation of NKTR- 214 promotes biased signaling t hrough the IL-2 beta gamma 
receptor (IL-2Rβγ). Specificall y, the location of the NKTR-[ADDRESS_1110382] of activating 
intra-tumoral regulatory T-cells  (Tregs) in the t umor while con tinuing to permit binding to the 
IL-2Rβγ (CD122) receptor. Upon i nfusion, NKTR-214 preferentially increases the proliferation, 
activation, and effector function of tumor an tigen-specific CD8 + T-cells and natural killer (NK) 
cells within the tumor microenvironment (TME) without expanding  unwanted intra-tumoral 
Tregs that are activated through the IL-2 receptor alpha beta g amma (IL-2Rαβγ) 
(Charych, 2016a ; Charych, 2016b).  
NKTR-214 also correspondingly promotes expression of programmed  cell death 
protein 1 (PD-1) on the surface  of CD8+ T-cells and induction o f a Type II interferon gene 
signature [CONTACT_602250], driving c ell surface expression of programmed cell death ligand 1 (PD-L1) 
on tumor cells (Diab, 2017).  
The immunological properties  of NKTR-214 with the induction of tumor-infiltrating 
lymphocytes and upregulation of th e PD-1/PD-L1 axis makes NKTR- 214 a potentially 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 30 of 149 
Confidential and Proprietary  27 May 2021 promising combination therapy for  use with chec kpoint inhibitor s that target and inhibit the 
PD-1/PD-L1 pathway. Moreover, the safety profile of NKTR-214 ge nerally does not overlap 
with that of checkpoint inhib itors, further supporting the use of NKTR-214 as a potentially 
complimentary combination partner with checkpoint inhibitors. 
[IP_ADDRESS] Preclinical Effects 
Nonclinical studies have shown t hat NKTR-214 as a single agent is efficacious in multiple 
murine tumor models, showing superi or anti-tumor efficacy compared to aldesleukin, even when 
given less frequently and at lower doses (Charych, 2016a ; Charych, 2017). Moreover, 
NKTR-214 shows apparent synergisti c effects in combination with  CPIs ( Charych, 2016a; 
Charych, 2016b ; Charych, 2016c ) as well as adoptive cell transfer ( Parisi, 2017 ) and provides a 
significant survival benefit comp ared to IL-2 when combined wit h a therapeutic peptide vaccine 
(Sharma, 2016). After IV administration, tumo r concentrations of NKTR-214 ar e sustained and 
mirror those observed in plasma , while distribution to other ti ssues is low.  
Nonclinical toxicology studies  with NKTR-214 indicate biologica l activity in rats and monkeys 
when given at doses up to the no obs erved adverse effects level  (0.1 mg/kg in rats and 
0.03 mg/kg in monkeys) once every 1 4 days (q14d) for a duration of up to [ADDRESS_1110383] also been reported for IL-2 ( Anderson, 1989; 
Anderson, 1993; Harada, 1993 ; Ihara, 1989 ). Unlike aldesleukin, t here was no indication of 
hypotension, vascular leak, or pul monary edema, and no cardiova scular changes (blood pressure 
or electrocardiogram [ECG]) af ter administration of NKTR-214 ex cept for an increase in heart 
rate in the monkey that was smal l in magnitude and transient. T here were no toxicities associated 
with PEG at 10 mg/kg (q14d × 3).  
[IP_ADDRESS] Clinical Experience with NKTR-214 Monotherapy 
NKTR-214 has been investigated as monotherapy in a completed Phase 1 study sponsored by 
[CONTACT_192983]: 
Study 15-214-01 (EXCEL), a Phase 1 open-label, multicenter, dos e escalation study of NKTR-
214 in patients with locally advan ced or metastatic solid tumor s (n=28).  
The objectives of the study were to evaluate the safety and tol erability of NKTR-214 to 
determine the maximu m tolerated dose (MTD) as well as to assess  the ORR at or below the 
MTD, or to identify the recomme nded Phase 2 dose (RP2D). NKTR-214 was administered as a 
15-minute IV infusion at dose levels of 0.003, 0.006, 0.009, an d 0.012 mg/kg every 3 weeks 
(q3w) and 0.006 mg/kg every 2 weeks (q2w).  A total of 28 patients with a mean age of 57.9 years were enrolled. All patients had received 
prior anti-cancer treatment and 16 (57.1%) had received immunot herapy. The majority of 
patients had a diagnosis of metast atic renal cell carcinoma (RC C) (15; 53.6%) or melanoma 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 31 of 149 
Confidential and Proprietary  27 May 2021 (7; 25.0%). Patients received a median of 3 infusions of NKTR-2 14 (range:  1 to 25), with a 
median duration of exposure  of 64.5 days (range:  8 to 533 days).  
A summary of the clinical pharmacology, efficacy, and safety of NKTR-214 is provided below; 
additional informati on (including updated clinical data) is ava ilable in the Investigator’s 
Brochure. 
[IP_ADDRESS].1 Clinical Pharmacology of NKTR-214  
Blood samples were analyzed for  NKTR-214 related cytokines (NKT R-214-RC), NKTR-214 
active cytokines (NKTR-214-AC ), unconjugated IL-2, and PEG to characterize the 
pharmacokinetics (PK) and metabolism of NKTR-214.  
Maximal concentrations of NKTR-214-RC were achieved shortly aft er the end of the first 
infusion of NKTR-214 and declined  monoexponentially thereafter,  remaining detectable for 8 to 
11 days postdose and resulting in mean half-life values of approximately 10 hours across dose 
levels. NKTR-214-RC maximum  plasma concentrations (C max) and area under the curve (AUC) 
increased linearly with dose.  
NKTR-214-AC concentrations incre ased gradually after dosing, ac hieving a mean time to 
Cmax (Tmax) between Day 2 (24 hours) and 3 (48 hours) postdose. After rea ching C max, 
NKTR-214-AC declined monoexponentially in parallel to the decli ne in NKTR-214-RC, and 
remained detectable for 8 days postdose. NKTR-214-RC and NKTR-214-AC exposure were similar across patien ts within a dose cohort 
and between cycles, without indication of accumulation with eit her the q3w or q2w 
administration schedules, as e xpected based on the half-life. N KTR-214-AC and NKTR-214-RC 
exposure increased linearly wit h dose over the dose range studi ed. 
Unconjugated IL-2 was only sporadically detected, and when dete cted, was present only at low 
concentrations (0.5 to 7.1 ng/mL, w ith the majorit y near the quantitation limit of 0.5 ng/mL), 
indicating that unconjugated IL-[ADDRESS_1110384] dose of NKTR-214, maximal total PEG concentrations were achieved shortly after 
the end of the infusion and declin ed biexponentially thereafter . Total PEG concentrations 
remained detectable for 15 da ys (336 hours) to 21 days (504 hours) postdose, i.e., prior to the 
next dosing cycle.  
Total-PEG concentrations increased in proportion to dose. Total  PEG concentrations remained 
detectable for 21 days, without l eading to accumulation with re peat dosing.  
 
 
 

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 32 of 149 
Confidential and Proprietary  27 May 2021  
  
Lymphocytes exhibited a profile characterized by [CONTACT_710917] (D ay 3) followed by [CONTACT_804520] (which peaked on Days 8 to 1 1) following NKTR-214 
administration. This is consistent  with similar ob servations after high-dose IL-2 administration 
(Cesana, 2006 ; Gottlieb, 1989). These changes in lymphocyte c oncentrations were observed at 
all dose levels and with each treatment cycle, indicative of co ntinuous immune system activation 
with each t
reatment cycle. In the EXCEL study, lymphocyte chang es were observed, in one case, 
over 17 months of treatment. I n the ongoing Study 16-214-02 (PI [INVESTIGATOR_12964]-02), lymphocyte changes 
were observed, in several cases , over [ADDRESS_1110385] of 
NKTR-214 on lymphocytes, as char acterized by [CONTACT_48657] 8 to Day 3  ratios, increased with dose.  
[IP_ADDRESS].2 Clinical Efficacy and Safety of NKTR-214 Monotherapy 
All 28 patients in Study 15-214-01 (EXCEL) were evaluable for safety and 26 were included in 
the Response Evaluable Population (i.e., all patients who met a ll eligibility c riteria, had 
measurable disease [per Response Evaluation Criteria in Solid T umors version 1.1, RECIST 1.1] 
at baseline, and also had at least one post-baseline assessment  of tumor response).  
All 28 patients had treatment-emerg ent adverse events (TEAEs), with 26 (92.9%) having adverse 
events (AEs) that were considered  to be related to treatment. T he most common treatment-
related AEs were fatigue (20 [ 71.4%]), pruritus (18 [64.3%]), a nd hypotension (16 [57.1%]). The 
MTD of NKTR-214, based on pre-defined dose limiting toxicity (D LT) criteria, was 
0.009 mg/kg administe red q3w. At a higher dose (0.012 mg/kg), 1  patient experienced DLTs of 
Grade 3 hypotension and Grade 3 syncope, which were rapi[INVESTIGATOR_804486]; this patient continued on study and rece ived two additional doses of  NKTR-214 at 0.006 mg/kg q3w 
and tolerated treatment well . One patient who had a prior history of an infusion-related reaction 
to an immuno-oncology agent di scontinued the study due to a ser ious adverse event (SAE) of 
Grade 3 infusion-related reacti on (diaphoresis, rash, shortness of breath, chest t ightness, tingling 
in tongue, low blood pressure [47 /44 mm Hg], and hyperglycemia)  after the first dose of NKTR-
214 (0.009 mg/kg). The reaction resol ved with treatment (oxygen , epi[INVESTIGATOR_238], and 
antihistamines).  
Hypotension, which is a known AE associated with both IL-[ADDRESS_1110386] infusion, coinciding w ith the peak plasma concentrati on of the active cytokines formed 
after administration of NKTR-214. Grade 3 hypotension (in 4 of 28 [14%] patients) was rapi[INVESTIGATOR_804487] (IV, oral, or both) and guid elines to prevent hypotension were 
subsequently developed (see Section 6.2.2).  
Other treatment-related AEs included flu-like symptoms (chills [12 patients, 42.9%], pyrexia 
[10, 35.7%], and influenza-like illn ess [7, 25%]) as well as ra sh (maculo-papular [6, 21.4%], 
macular [5, 17.9%], erythematous [4, 14.3%]¸ papular [3, 10.7%]) and pruritus (18, 64.3%), all 

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 33 of 149 
Confidential and Proprietary  27 May 2021 of which were predictable, man ageable, and short-lived. These low-grade cytokine-related AEs 
generally occurred 1 to 4 days a fter dosing and corresponded to  the time of peak plasma 
concentration of the active cytoki nes. The flu-like symptoms we re managed with acetaminophen 
and nonsteroidal anti-inflammatory  drugs (NSAIDs) and the cases  of rash/pruritus were either 
self-limiting or treated with an ti-histamines. The median durat ion of flu-like symptoms including 
fever was 3 days, and with subsequent cycles after initiating t reatment with NKTR-214, these 
symptoms became less pronounced. It is noted that no cases of i mmune-mediated AEs (except 
one case of hypothyroidism), co mmonly associated with the use o f checkpoint inhibitors, such as 
colitis, nephritis, pneumonitis, dermatitis, or hepatitis have been reported from this study. 
A best overall response of stabl e disease occurred in 14 patien ts (50%) including the only patient 
with bladder cancer in the study; none had a complete response (CR) or partial response (PR). 
One patient with metastatic melan oma, who was previously treate d with ipi[INVESTIGATOR_164] a BRAF 
inhibitor and progressed, receiv ed 25 cycles of NKTR-214 and ha d durable stable disease for 
18 months. A second patient with m etastatic RCC, who had progre ssed on high dose IL-2 and 
was refractory to single agent OX40 and nivolumab, was treated with 19 cycles of NKTR-214 
and had durable stable disease for 14 months. While no objectiv e responses were observed, 
9 patients experienced tumor s hrinkage between 1% and 30%, and 2 patients, after progressing 
on multiple prior therapi[INVESTIGATOR_014], had durable stable disease > [ADDRESS_1110387] pos t baseline scan. Given the 
biological properties of NKTR- 214 and nivolumab, these observat ions further supported the 
rationale for combini ng these two agents.  
2.1.3 Nivolumab 
Nivolumab (Opdivo®) is approved for the treatment of  several types of cancer in m ultiple regions 
including the [LOCATION_002] (US;  December 2014), the European U nion (EU; January 2015) and 
Japan (July 2014). Nivolumab is also being investigated in vari ous other types of cancer as 
monotherapy or in combinati on with other therapi[INVESTIGATOR_014]. 
[IP_ADDRESS] Mechanism of Action 
Cancer immunotherapy rests on the p remise that tumors can be re cognized as fore ign rather than 
as self and can be effectively a ttacked by [CONTACT_20397]. An effective immune 
response in this setting is t hought to rely on immune surveilla nce of tumor antigens expressed on 
cancer cells that ultimately results in an adaptive immune resp onse and cancer cell death. 
Meanwhile, tumor progression may depend upon acquisition of tra its that allow cancer cells to 
evade immunosurveillance and esc ape effective innate and adapti ve immune responses 
(Pardoll, 2003; Zitvogel, 2006 ; Dunn, 2002). Current immunotherapy efforts attempt to break the 
apparent tolerance of the immune  system to tumor cells and anti gens by [CONTACT_20400]. CD8+ T-cell stimulati on is a complex process involving the integration of numerous 
positive as well as negative co-stimulatory signals in addition  to antigen recognition by [CONTACT_396563]. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 34 of 149 
Confidential and Proprietary  27 May 2021 CD8+ T-cell receptor (TCR) ( Greenwald, 2004). Collectively, these s ignals govern the balance 
between CD8+ T-cell activation and tolerance.  
PD-1 is a member of the CD28 family of CD8+ T-cell co-stimulato ry receptors that also includes 
CD28, CTLA-4, ICOS, and BTLA ( Freeman, 2000). PD-1 signaling has been shown to inhibit 
CD-28-mediated upregulation of IL-2, IL-10, IL-13, interferon-γ  (IFN-γ) and Bcl-xL. PD-1 
expression has also been noted to inhibit T-cell activation, an d expansion of previously activated 
cells. Evidence for a negative re gulatory role of PD-1 comes from studies of PD-1 deficient 
mice, which develop a variety of autoimmune phenotypes ( Sharpe, 2007). These results suggest 
that PD-1 blockade has the potential to activate anti-self CD8+  T-cell responses, but these 
responses are variable and dependent upon various host genetic factors. Thus, PD-1 deficiency or 
inhibition is not accompanied by a universal loss of tolerance to self-antigens. 
In vitro, nivolumab (BMS-936558)  binds to PD-1 with high affini ty (50% effective dose 
[EC 50] 0.39-2.62 nM), and inhibits the binding of PD-1 to its ligands PD-L1 and PD-L2 (50% 
inhibitory dose [IC 50] ± 1 nM). Nivolumab binds sp ecifically to PD-[ADDRESS_1110388] by 
[CONTACT_102428] a reproducible enhancement of both prolife ration and IFN-γ release in the 
mixed lymphocyte reaction (MLR). Using a cytomegalovirus (CMV) re-stimulation assay with 
human peripheral blood mononuclear cells (PB MCs), the effect of nivolumab on antigen specific 
recall response indicates that nivolumab augmented IFN-γ secret ion from CMV specific memory 
T-cells in a dose-dependent manner  versus isotype-matched control. In vivo blockade of PD-1 by 
a murine analog of nivolumab enhances the anti-tumor immune res ponse and result in tumor 
rejection in several immunocompe tent mouse tumor models (MC38, SA1/N, and PAN02) 
(Wolchok, 2009 ). 
[IP_ADDRESS] Nivolumab in Bladder Cancer 
In Checkmate-275 ([STUDY_ID_REMOVED]), 270 patients with locally advanced or metastatic urothelial carcinoma (mUC) who had disease progression during or following  platinum-containing 
chemotherapy or who had disease progression within 12 months of treatment with a  
platinum-containing neoadjuvant o r adjuvant chemotherapy regime n were treated with 
nivolumab 3mg/kg every  two weeks. The ORR was 19.6% with a median duration of response 
(mDOR) of 10.3 months. Further evaluating the data by [CONTACT_4002]-L1 rev ealed a response rate of 
15.1% in patients with PD-L1 expr ession < 1% of tu mor cells and 25% in patients with PD-L1 
expression in ≥ 1% of tumor cells . These results ultimately led  to approval by [CONTACT_3361] (FDA) and European Medicines Agency (EMA) in a second-line mUC population. Evaluation of nivolumab treatment in a first-line m etastatic setting is currently 
ongoing in the Checkmate 901 study ([STUDY_ID_REMOVED]).  
Nivolumab has also been evaluat ed in combination with ipi[INVESTIGATOR_162] b in bladder cancer 
(NCT 02553642) ( Callahan, 2017 ). Forty patients with advanced or metastatic urothelial 
carcinoma were treated with nivolumab 3 mg/kg every 2 weeks. For patients who had a 
confirmed progression with monotherapy nivolumab, the study off ered the option to continue 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 35 of 149 
Confidential and Proprietary  27 May 2021 treatment with combination nivolum ab plus ipi[INVESTIGATOR_125] (1 mg/kg every 3 weeks). The 
combination was dosed every three weeks for four doses followed  by [CONTACT_53930]. 
Ten patients who were refractory to nivolumab monotherapy were treated with the combination. 
One patient achieved a confirmed partial response. Three additi onal patients achieved stable 
disease after documented progres sion, suggesting that the combi nation may have clinical activity 
in urothelial carcinoma (UC) pa tients who fail to respond to mo notherapy checkpoint inhibition. 
The available data also suggest that immuno-oncology doublets m ay provide added benefit over 
monotherapy treatment in bladder cancer.  
2.1.4 Clinical Experience with NKTR-214 in Combination with Nivolumab 
Study 16-214-02 (PI[INVESTIGATOR_12964]-02; [STUDY_ID_REMOVED]) is an ongoing Phase 1/[ADDRESS_1110389] locally 
advanced or metastatic solid tum or malignancies. Part 1 of the study was a dose escalation phase 
to evaluate the safety and tolerability, and to define the MTD or RP2D of NKTR-214 in 
combination with nivolumab. Fo llowing determina tion of the RP2D  (0.006 mg/kg NKTR-214 
q3w plus 360 mg nivolumab q3w), Part 2 of the study is evaluating the safety and tolerability as 
well as the efficacy of the c ombination by [CONTACT_804521]2D. The indications 
studied in Part 2 are melanoma, RCC, non-small cell lung cancer (NSCLC), bladder cancer, breast cancer, gastric cancer, colorectal cancer, and small cel l lung cancer. Parts 3 and 4 are 
schedule-finding and dose expansion for the triplet, studying t he safety and tolerability of 
NKTR-214 in combination with nivolu mab (360 mg flat dose q3w) and ipi[INVESTIGATOR_125] (1 mg/kg) in 
patients with metastatic RCC, UC, melanoma, or NSCLC who are tr eatment-naïve.  
[IP_ADDRESS] Clinical Pharmacology 
The effect of nivolumab on NKT R-214 PK was assessed based on NKTR-214-RC exposure. 
Pharmacokinetics of NKTR-214-RC in combination with nivolumab a ppear similar to those after 
NKTR-214 monotherapy, suggestin g no drug-drug interaction betwe en NKTR-214 and 
nivolumab. See Section [IP_ADDRESS].1 for additional NKTR-214 clinical  pharmacology in formation. 
[IP_ADDRESS] Clinical Efficacy and Safety of N KTR-214 in Combination with Ni volumab 
As of 29 October 2018, a total of  358 patients had been treated  with NKTR-214 in combination 
with nivolumab in the ongoing S tudy 16-214-02 (PI[INVESTIGATOR_12964]-02). A tot al of 322 (89.9%) patients 
had treatment-related AEs, the majority of which were mild to moderate in severity; 78 of 358 patients (34.6%) had Grade 3 tre atment-related AEs. The mos t common treatment-related 
AEs (experienced by ≥ 20% of patien ts) were flu- like symptoms ( in 62.3% of patients), rash 
(49.7%), fatigue (48.6%), pruritus (34.6%), nausea (28.5%), dec reased appetite (26.5%) and 
arthralgia (20.9%). Grade ≥ 3 AEs that were considered related to NKTR-214 or nivolumab, or 
both, occurred in 78 patients (21.8 %). These included hypotensi on (11 patients, 3.1%), rash 
(7 patients, 2.0%) diarrhea (5 patients, 1.4%), flu -like sympto ms, dehydration, myalgia and 
vomiting (each:  4 patients, 1.1%), a rthralgia, fatigue and nau sea (each 3 patients, 0.8%), 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 36 of 149 
Confidential and Proprietary  27 May 2021 asthenia and dyspnea (each 2 pati ents, 0.6%) and decreased appe tite and pruritus (each 1 patient, 
(0.3%).  
One hundred forty-nine patients ha d serious adverse events (41. 6%). Of these, 58 patients 
(16.2%) had serious AEs that were  considered related. Related treatment-emergent SAEs that 
were experienced by [CONTACT_804522]:  flu-like sy mptoms (10 of 358 patients 
(2.8%), hypotension (7 of 358 patients, 2.0%), atrial fibrillation and dehydration (4 of 358 
patients, 1.1% each), hyponatremia, pneumonitis and rash (3 of 358 patients, 0.8% each) and 
cerebrovascular accident, dyspnea,  myocarditis, nausea and vomiting (2 of 358 patients, 0.6% 
each).  
The NKTR-214 + nivolumab dose es calation portion of Study 16-214-02 (PI[INVESTIGATOR_12964]-02) has been 
completed (n = 38), with the saf ety results of NKTR-214 at 0.006 mg/kg in combination with 
nivolumab 360 mg every 3 weeks indicating no DLTs and no Grade ≥ 3 treatment-related AEs. 
NKTR-214 0.006 mg/kg in c ombination with nivolumab [ADDRESS_1110390] into expansion coh orts in Part 2. 
Tumor response data are availab le for the dose escalation patie nts as well as several of the dose 
expansion cohorts (melanoma, RCC, and mUC). As of 29 October 2018, 38 patients had been 
enrolled into the dose escala tion cohorts of Study 16-214-02 (P IVOT-02) and 37 patients 
(11 patients with metastatic m elanoma, 21 with RCC, and 5 with NSCLC) were efficacy 
evaluable. The remaining one pati ent was not considered evaluab le for efficacy due to 
discontinuation of study due to progressive disease (PD) prior to an on-treatment CT scan. Of 
these 37 patients, 21 (56.8%) ach ieved a response by [CONTACT_393] 1.[ADDRESS_1110391] line (1L) RCC e fficacy patients were effi cacy evaluable (n = 48 enrolled; 
n = [ADDRESS_1110392]-baseline on treatment scan). A 
46% (12 of 26 patients) ORR was not ed. Responses were seen in b oth PD-L1 (+) (29%, 2 of 
7 patients) and PD-L1 (–)  (53%, 9 of 17 patients) ( Diab, 2018a). 
As of 11 October 2018, 38 of 41 IL mela noma patient s who met th e pre-specified efficacy 
parameters were considered effi cacy evaluable. Three patients w ere considered not efficacy 
evaluable (all three patients discontinued prior to first scan due to an unrelated TEAE [n = 1] and 
patient decision [n = 2]). A 53% (20 of 38 patients) ORR was seen via independent central 
radiology review with a 24% (9 of  38 patients) CR rate. Respons es were seen in both the 
PD-L1 (+) (defined as PD-L1 expr ession ≥ 1% on tumor cells) and PD-L1 (–) (defined as < 1% 
PD-L1 expression on tumor cells) populations with an ORR of 68% in the PD-L1 (+) population 
(13 of 19 patients) and 43% in the P D-L1 (–) population (6 of 1 4 patients) (Diab, 2018b). 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 37 of 149 
Confidential and Proprietary  27 May 2021 [IP_ADDRESS].1 Observed Events of Cerebrovascular Accident  
[IP_ADDRESS].1.1 Initial Analysis of Cerebrovascula r Accident Events in Study 16 -214-02 
(PI[INVESTIGATOR_12964]-02) 
Serious events of cerebrovascul ar accident (CVA), including one  fatal event, have been observed 
in patients who have received NKTR-[ADDRESS_1110393] et combinati on with nivolumab and 
ipi[INVESTIGATOR_125], in the doublet comb ination with nivolumab, and in t he combination of NKTR-214, 
nivolumab, and other an ti-cancer therapy.  
As of 28 October 2019, 3 of 43 patients (7.0%) who received tri plet therapy in Study 16-214-02 
(PI[INVESTIGATOR_12964]-02) had CVA events, inclu ding one fatal event, all of wh ich were considered by [CONTACT_804523]-214, nivolumab, and ipi[INVESTIGATOR_125]. 
Additionally, 9 of 488 patients ( 1.8%) who received doublet therapy (NKTR-214 and 
nivolumab) had [ADDRESS_1110394] one of the study treatment s in 4 patients (3 related to t he doublet therapy and 1 related to 
nivolumab only); and one of 10 (10.0%) patients who received co mbined NKTR-214, 
nivolumab, and other an ti-cancer therapy (platinum-based chemotherapy) had a CVA event, 
which was considered by [CONTACT_804524]. 
[IP_ADDRESS].1.2 Updated Analysis of CVA Events Observed with NKTR-214 
A cumulative search of the NKTR- 214 global safety database was conducted on 
28 October 2020, which included 1345 patients who received NKTR-214 in triplet combinations with nivolumab plus ipi[INVESTIGATOR_602134]-262 (a toll-like receptor agonist 
7/8); in doublet combi nations with checkpoint inhibitors; in a doublet combination (NKTR-214 
with nivolumab) plus chemotherapy, and in combination with NKTR -262 from the following 
studies: 15-214-01, 16-214-02, 16-214-05, 17-214-09, 18-214-10,  20-214-29, CA045 001 
(17-214-08), CA045-009 (18-214-03 ), CA043-010 (18-214-14), SP-I ND, and [ZIP_CODE]-01. 
Overall, 1.9% (26 of 1345) of pati ents exposed to NKTR-[ADDRESS_1110395] CVA event was 218.7 days (range 4 to 727 days; median 158 days). Twenty of 
the 26 patients with CVA events received a doublet combination with a checkpoint inhibitor, 
which included 1.7% (19 of 1116) of  patients who received nivolumab, 1.3% (1 of 76) who 
received pembrolizumab, and 0% (0 of 23) who received atezolizu mab. 
Based on these events, CVA was escalated to an adverse event of special interest (AESI) in [ADDRESS_1110396] been put in p lace to reduce the risk of CV A. These mitigations include 
implementation of a CVA adverse event management algorithm (Appendix 4) and updates to the 
exclusion criteria, renal func tion and hydration assessment, hy dration guidelines, concomitant 
and prohibited medications, dose modification guidelines, and d iscontinuation criteria. 
Additional information on the cli nical safety and risk of CVA is found in the NKTR-214 
Investigator’s Brochure. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 38 of 149 
Confidential and Proprietary  27 May 2021 [IP_ADDRESS].2 Mitigation Measures 
Following the comprehensive rev iew of the entire NKTR-214 clini cal program, additional safety 
measures and analyses were imple mented to mitigate the risk of CVA events and to expedite 
reporting of CVA events by [CONTACT_804525]. These sa fety measures and analyses 
are reflected in changes to the  following protocol sections:  s tudy exclusion criteria (Section  5.2), 
hydration guidelines (Sections 1.2 and 6.2.2), CVA AE management algorithm ( Appendix 4), 
 
 criteria to delay, resume, o r permanently discontinue study drug (Section  6.5), 
thromboembolism prophylaxis and treatment (Section  [IP_ADDRESS] ), prohibited medications 
(Section 6.7.4 ), and reporting AESI (Section 9.6). 
[IP_ADDRESS] Clinical Efficacy of NKTR-[ADDRESS_1110397] of care trea tment were enrolle d in Study 16-214-02 (PI [INVESTIGATOR_12964]-02; [STUDY_ID_REMOVED]). The 
median age of these 41 patients was 70 years (range:  41 to 91) ; 29 were male (71%) and 12 were 
female (29%); 13 had PD-L1 expre ssion ≥ 1% on tumor cells (32%)  and 13 had PD-L1 
expression of < 1% on tumor cells  (32%), with 15 patients (37%)  having unknown PD-L1 
expression. The majority (22 of 41 patients [54%]) had an ECOG performance status of [ADDRESS_1110398]-ba seline (follow-up) scan and w ere considered efficacy 
evaluable. Of the other 14 patie nts, 1 patient was excluded fro m the efficacy analysis due to non-
eligibility (no measurable diseas e), [ADDRESS_1110399] scan (1 patient decision, 1 had clinical progression; and 1 had death 
from disease). Among the 27 efficac y evaluable patients, the OR R (defined as a best overall 
response of CR or PR) was 13/27 (48%). Notably, this benefit ap peared agnostic of PD-L1 status 
with 50% (6/12) of PD-L1(+) pa tients responding and 45% (5/11) of PD-L1(–) patients 
responding. As of the data cut-o ff, the median duration of foll ow-up was 5.[ADDRESS_1110400] restricted labelli ng in both the 
EU and the US to high PD-L1 expression subpopulations ( EMA, 2018; FDA, 2018).  

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 39 of 149 
Confidential and Proprietary  27 May 2021 Prior to the announcements restricting usage in low PD-L1 expre ssion patients, monotherapy 
atezolizumab treatment was evalu ated in cisplatin-ineligible lo cally advanced/mUC patients in 
Cohort 1 of the Phase 2, non-ra ndomized IMvigor 210 study (NCT0 2951767). A total of 
119 patients received treatment  and an ORR of 23.5% was observe d (TECENTRIQ® Prescribing 
Information, 2018). The mDOR in patients who responded has yet to be reached; however, the 
range is currently reported to be 3.7 to 16.6+ months. The medi an OS is 16.3 months 
(Balar, 2018 ). Further dividing this group ba sed on PD-L1 expression by [CONTACT_804526]-L1 
(SP142) assay (PD-L1+ defined as ≥ 5% PD-L1 expression on tumor  infiltrating immune cells 
and PD-L1– defined as < 5% expr ession) revealed an ORR of 28.1%  in the PD-L1+ subgroup 
and an ORR of 21.8% in the PD-L1– subgroup. A confirmatory Phase 3 study (IMvigor 130, [STUDY_ID_REMOVED]) compared the followi ng treatments in first-line me tastatic urothelial carcinoma 
(Galsky, 2020 ): 
• atezolizumab with platinum-based chemotherapy (Group A) 
• atezolizumab monotherapy (Group B)  
• placebo plus platinum-base d chemotherapy (Group C)  
Addition of atezolizumab to platin um-based chemotherapy prolong ed progression-free survival 
(PFS):  median PFS was 8.2 months (95% CI 6.5–8.3) in Group A a nd 6.3 months (6.2–7.0) in 
Group C (stratified hazard ratio [HR] 0.82, 95% CI 0.70–0.96; one-sided p=0.007). Median overall survival (OS) was als o prolonged with t he addition of a tezolizumab:  16.0 months  
(13.9–18.9) in Group A and 13.4 months (12.0–15.2) in Group C ( 0.83, 0.69–1.00; one-sided 
p=0.027). Median overall survival showed a nonsignificant trend  toward superiority of 
atezolizumab alone over chem otherapy:  15.7 months (13.1–17.8) for Group B and 13.1 months 
(11.7–15.1) for Group C (1.02, 0.83–1.24). There were 212 (47%) confirmed objective responses (complete response [CR] + partia l response [PR]) in Group A (95 % CI 43–52), compared to 82 
(23%) (95% CI 19–28) in Group B  and 174 (44%) (95% CI 39–49) in  Group C. The mDOR was 
8.5 months (95% CI 7.2–10.4) in Gro up A, not estimable (NE) (95% CI 15.9–NE) in Group B, 
and 7.6 months (95% CI 6.3–8.5) in Group C. An unplanned analys is of the early survival data 
led to discontinuation of further  accrual of patients with low PD-L1 expression to atezolizumab 
monotherapy (Group B).  
Pembrolizumab monotherapy was also evaluated prior to the recen t health authority 
announcements in the open label , non-randomized Phase 2 Keynote-052 study ([STUDY_ID_REMOVED]). 
Keynote-052 enrolled 370 cisplatin -ineligible patients with loc ally advanced/mUC. Long-term 
follow-up data for Keynote-[ADDRESS_1110401] patient 
enrolled ( Vuky, 2020). Forty patients with CR or P R completed 2 years of study treatment, and 
32 had ongoing response at completi on. The overall response rat e was 28.6% (95% CI, 24.1% to 
33.5%). The mDOR was 30.1 months (95% CI, 18.1 months to not re ached [NR]). Median OS 
was 11.3 months (95% CI, 9.7 to 13.1 months). Among patients wi th PD-L1 combined positive 
score (CPS) ≥ 10 (n = 110), ORR wa s 47.3%; 22 patients (20.0%) had CRs, and 30 patients 
(27.3%) had PRs. Among those w ith PD-L1 CPS < 10 (n = 251), ORR was 20.3%. Median DOR 
for the CPS ≥ 10 and CPS < 10 subgroups was NR (95% CI, 18.1 mo nths to NR) and 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 40 of 149 
Confidential and Proprietary  27 May 2021 18.2 months (95% CI, 9.7 months to NR), respectively; 57.0% and  45.0% had responses 
≥ 24 months. In the CPS ≥ 10 and CPS < 10 subgroups, median OS was 18.5 months (95% CI, 
12.2 to 28.5 months) and 9.7 months  (95% CI, 7.6 to 11.5 months), respectively; 24-month OS 
rates were 47.0% and 24.0%, respectively. 
A confirmatory Phase 3 study suppo rting the previously granted accelerated approva l is currently 
ongoing (Keynote-361; [STUDY_ID_REMOVED]). Similar to ate zolizumab, however, enrollment of PD-L1 
low patients has been halted in the monotherapy pembrolizumab a rm and is currently only 
ongoing in combination with platin um-based chemotherapy. 
EMA and FDA statements released in June 2018 ( EMA, 2018; FDA, 2018 ) indicate that 
preliminary data show reduced survival for both pembrolizumab a nd atezolizumab when used as 
monotherapy for the fir st-line treatment of cisplatin-ineligibl e mUC patients with “low 
expression of PD-L1” as compar ed to chemotherapy. On recommenda tion from both Agencies, 
the labeled indications for pemb rolizumab and atezolizumab for this population were 
subsequently modified to indicate  that monotherapy treatment should only be considered in 
cisplatin-ineligible patients whos e tumors express PD-L1 with a CPS ≥ 10 (pembrolizumab) or 
whose tumors have a PD-L1 e xpression ≥ 5% (atezolizumab) (EMA, 2018; FDA, 2018 ; 
KEYTRUDA® Prescribing Information, 2018; TECENTRIQ® Prescribing Information, 2018 ). 
Subsequently the labels were modi fied in the US to also allow m onotherapy treatment in patients 
who are not eligible for any plati num-based therapy (cisplatin or carboplatin), and in the EU to  
also allow monotherapy treatment in patients who have had prior  platinum-containing 
chemotherapy (KEYTRUDA® prescribing information, 2021 ; TECENTRIQ® prescribing 
information 2021;  KEYTRUDA® Summary of Product Characteristics ; TECENTRIQ® Summary 
of Product Characteristics ). 
The above announcements leave a significant gap in the treatmen t of low PD-L1 expression, 
first-line, cisplati n ineligible mUC patients and suggests that additional therapi[INVESTIGATOR_804488] y of CPIs. While chemotherapy does result in significant response 
rates, the duration of response (DOR) is limited and the OS rem ains under a year. In addition, the 
available chemotherapy options come with significant toxicity in an older, medically frail 
population. These factors highlight  the need for further combin ation immunotherapy 
development with the aim of improving not only efficacy but als o quality of life. 
2.[ADDRESS_1110402] historically been chemotherapy and surgery. However, the emerging clinical d ata for single agent CPI [INVESTIGATOR_804489]. While the treatment  with monotherapy CPIs provides c linically meaningful durable 
responses in second-line (2L) and PD-L1 high 1L patients, only 20% to 45% of patients respond, 
suggesting that combination trea tment is needed to further enha nce the benefit of 
immunotherapy. Furthermore, patient s with low PD-L1 expression have significant unmet need 
due to the restriction of PD-L1/PD-1 inhibitors in this populat ion as 1L therapy.  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 41 of 149 
Confidential and Proprietary  27 May 2021 Accumulating evidence suggests that patients with low baseline CD8+ T-cells within the tumor 
microenvironment (TILs) predict poor response to CPI [INVESTIGATOR_804490] ( Daud, 2016a ; 
Daud, 2016b); thus, agents designed to spe cifically activate and expand CD 8+ T-cells may 
improve clinical outcomes i n patients with low TILs.  
NKTR-[ADDRESS_1110403] (IL-2Rβɣ) to preferentially activate and expand 
NK and effector CD8+ T-cells over Treg cells. Preliminary analy ses of patients’ blood and tumor 
by [CONTACT_804527]-214, as a singl e agent, increases activated 
CD4+ and CD8+ T-cells in periphe ral blood, with an increase in T-cell infiltrates within the 
tumor tissue after one dose of NKTR-214.  
In addition, NKTR-214 increases P D-1 expression on T-cells in the blood and tumor after 
treatment with NKTR-214. In t he ongoing Study 16-214-02 (PI[INVESTIGATOR_12964]- 02), at the 3 December 
2018 data cut-off, 13 matched tumor tissue samples from baseline and Cycle 1 Days 15 to 21 in 
UC patients were available for e valuation. Of th ese matched samples, 10 had PD-L1 expression 
of < 1% on tumor cells at base line and 3 had PD-L1 expression o f ≥ 1% on tumor cells. Seven of 
the 10 (70%) PD-L1 low baseline  samples converted to high by [CONTACT_804528]. The 
ability to alter the immune environment and increase PD-1 expre ssion on effector CD8+ T-cells 
and tumor may improve the effect iveness of anti-PD-1 blockade.  
The current study aims to demonstr ate that treatment with NKTR-214 in combination with 
nivolumab will be efficacious in patients with locally advanced  or mUC who are ineligible for 
cisplatin treatment. The availab le efficacy data from the ongoi ng Study 16-214-02 (PI[INVESTIGATOR_12964]-02), 
as well as the correlative data suggesting that NKTR-[ADDRESS_1110404] additiona l benefit can also be conferr ed in this population. 
PD-L1 expression will be assess ed using the PD-L1 IHC 22C3 pharmDx assay, which is 
approved for use with pembr olizumab in UC (P150013/S0011; Dako North America, Inc. 2018 ). 
The cut-off point defining low PD-L1 expression will be CPS < 10 (see Section 7.3 ). In this 
protocol, patients with tumors that have low PD-L1 expression w ill be referred to as low PD-L1 
patients. Patients with CPS ≥ [ADDRESS_1110405] high PD-L1 expression and will be referred to as high PD-L1 patients (see Section 7.3). 
 
 
 

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 42 of 149 
Confidential and Proprietary  27 May 2021 2.3 Benefit/Risk Aspects 
2.3.1 NKTR-214 Safety Profile 
NKTR-214 was designed to mitigate the serious toxicities associ ated with rapid systemic 
immune activation seen with administration of aldesleukin. The identified risks of NKTR-214 
include hypotension, IL -2-mediated AEs (e.g., flu-like symptoms , rash, pruritus, fatigue, hepatic 
transaminase elevations, serum creatinine elevations), infusion-related reactions/hypersensitivity 
reactions, thyroid dysfunction, a rthralgia, and eosinophilia. T he majority of these AEs are mild 
to moderate in severity and can be monitored and managed in the  clinical setting. The goal of 
engineering a PEGylated form of IL-[ADDRESS_1110406] been realized 
with NKTR-214 at the doses tested.  
Additional details on the clinical experience with NKTR-214 are  provided in the NKTR-214 
Investigator’s Brochure. 
2.3.2 Nivolumab Safety Profile 
Extensive details on the safety p rofile of nivolumab are availa ble in the Investigator’s Brochure, 
and will not be repeated herein. 
Overall, the safety profile of  nivolumab monotherapy as well as  in combination with ipi[INVESTIGATOR_804491] 10 mg/kg. Most AEs were lo w-grade (Grade 1 to 2) with 
relatively few related high-grad e (Grade 3 to 4) AEs. There was no pattern in the incidence, 
severity, or causalit y of AEs with respect to nivolumab dose le vel. 
A pattern of immune-related adverse events has been defined, mo st high-grade events were 
manageable with the use of corti costeroids or hormone replaceme nt therapy (endocrinopathies).  
Additional details on the safet y profile of nivolumab, includin g results from ot her clinical 
studies, are also available in t he nivolumab Investigator’s Brochure. 
2.3.[ADDRESS_1110407] of NKTR-214, and can 
be effectively mitigated by [CONTACT_804529]. Other risks associated with 
NKTR-214 include IL-2-mediated A Es (e.g., flu-like symptoms, ra sh, pruritus, fatigue, hepatic 
transaminase elevations, and ser um creatinine elevation), infus ion related reactions, thyroid 
dysfunction, eosinophilia, and art hralgia. These AEs are generally mild or moderate in severity, 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 43 of 149 
Confidential and Proprietary  27 May 2021 and can be monitored and managed in clinical setting. Cases of thyroid dysfunction 
(hypothyroidism, hyperthyroidism, t hyroiditis), dermatitis, pne umonitis, hepatitis , myocarditis, 
myositis/myasthenia gravis, a nd vitiligo/hypopi[INVESTIGATOR_802601]-mediated 
mechanism have been observed in patients receiving NKTR-214 plu s nivolumab;  and some of 
these cases shared clinical characteristics consistent with imm une-mediated AEs associated with 
checkpoint inhibitors. 
The continued development of NKTR-214 in combination with nivol umab for the treatment of 
various cancers is warranted based on a positive benefit-risk profile. In addition, the early 
efficacy data along with the corre lative biomarker showing conv ersion of PD-L1 negative 
patients to PD-L1 positive patien ts suggests that the addition of NKTR-214 to a checkpoint 
inhibitor (nivolumab) may change the tumor microenvironment in PD-L1 negative patients such 
that the combination may contribute to anti-tumo r activity with  an acceptable safety profile. 
In conclusion, the currently ava ilable safety data demonstrates  that NKTR-[ADDRESS_1110408] benefit in 
patients with limited alternative treatment options warrants co ntinued evaluation of the 
combination of NKTR-214 and nivol umab in the clinical setting a nd supports further 
development of the combination in patients with cancer. 
2.3.4 Independent Data Monitoring Committee 
In addition to routine safety m onitoring and pharmacovigilance activities, an Independent Data 
Monitoring Committee (IDMC) provided an initial safety review; subsequently a Sponsor 
Executive Committee (SEC) will provide formal safety reviews. T he IDMC/SEC are described 
further in Section 10.11.  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 44 of 149 
Confidential and Proprietary  27 May 2021 3.0 STUDY OBJECTIVES 
3.1 Primary Objective 
The primary objective is: 
• To evaluate the anti-tumor act ivity of NKTR-[ADDRESS_1110409] 1.1 per  blinded independent central  review (BICR) in patients 
whose tumors have low PD-L1 expression 
3.2 Secondary Objectives 
The secondary objectives are: • To evaluate the effect of NKTR-[ADDRESS_1110410] 1.1 per BICR in a ll treated patients 
• To evaluate the effect of NKTR-[ADDRESS_1110411] low PD-L1 
expression 
• To evaluate the effect of NKTR-[ADDRESS_1110412] low PD-L1 expression 
• To evaluate the safety and tol erability of NKTR-214 in combination with nivolumab 
  
 
  
 
 
  
  
 
  
 
  

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 45 of 149 
Confidential and Proprietary  27 May 2021   
 
  
  
  
 
  
 
  
 
  

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 47 of 149 
Confidential and Proprietary  27 May 2021 4.1.1 Screening Period 
Patients will provide written info rmed consent to participate i n the study before completing any 
protocol-specified procedures or  evaluations not considered to be part of the patient’s standard 
care. After signing the informed consent form (ICF), patients w ill be evaluated for entry criteria 
during the Screening period withi n [ADDRESS_1110413] 
study treatment; ECG must also be done within [ADDRESS_1110414] study treatment. Women 
of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test 
(minimum sensitivity 25 IU/L or  equivalent uni ts of human chori onic gonadotropin [HCG]) 
within 24 hours prior to t he start of study (see Appendix 3). Rescreening after s creen failure will 
be allowed once. A new ICF will be  signed if a patient is rescr eened. 
Patients must either consent to and undergo a screening biopsy at study entry to document 
PD-L1 status (see Section 7.3) or provide archival formalin- fixed paraffin-embedded (FFPE) 
tissue, either as a block or unstained slides (minimum of 10, p referably 15-25 slides). Archival 
tissue must be obtained withi n 12 months prior to enrollment and with no intervening treatment.  
4.1.2 Treatment Period 
All biopsy and archival tissue will  be sent to a central labora tory for PD-L1 evaluation (see 
Section  7.3). A valid tracking number confir ming shipment of the tissue to  the central laboratory 
must be available prior to Cycle [ADDRESS_1110415] of multiple 21-d ay (3-week) cycles with associated 
evaluations and procedures. Each c ycle is defined by [CONTACT_804530]-214 and nivolumab 
administration (q3w). Every effort should be made to sch edule visits within the proto col-specified windows ( Table 1 ). 
Patients will be treated until disease progression by [CONTACT_393] 1. 1 or loss of clinical benefit, death, 
unacceptable toxicity, symptomatic  deterioration, the Investiga tor’s decision to discontinue 
treatment, the patient decision to d iscontinue treatment or withdraw consent, the patient is lost to 
follow-up, Sponsor decides to terminate the study, or for a max imum of 2 years of treatment on 
NKTR-214/nivolumab (see Section 4.1.3 for additional details). 
Accumulating evidence indicates that a minority of patients wit h solid tumors treated with 
immunotherapy may derive clinical benefit despi[INVESTIGATOR_804492]. Given this, patients 
with PD per RECIST 1.1 but with ot herwise stable or improved performance and clinical status 
may continue to be treated in the event of a perceived benefit per Investigator.  For the patients who continue NKTR-214/nivolumab study treatment beyond progression, the 
study treatment should be discontinued permanently if an additi onal 10% or more increase is 
seen in the total tumor burde n, with a minimum 5 mm absolute in crease from time of  initial PD. 
This includes an increase in the  sum of diameter s of all target  lesions and the diameters of new 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110416] 15 mm. Any new lesions tha t are non-measurable at the time of initial appearance and 
become measurable later will be  included in the calculation of total tumor burden. In situations 
where the relative increase i n total tumor burden by 10% is sol ely due to inclusion of new lesions 
which become measurable, these ne w lesions must demonstrate an absolute increase of at least 
[ADDRESS_1110417] 1.1-defined PD as 
long as they meet the following criteria: • Investigator-assessed clinical  benefit and wit hout rapid diseas e progression. 
• Continue to meet all other study protocol eligibility criteria.  
• Patient tolerates study drug(s). 
• Patient has stable ECOG performance status. 
• Treatment beyond progression will not delay an imminent interve ntion to prevent serious 
complications of disease progres sion (e.g., central nervous sys tem [CNS] metastases). 
The assessment of clinical benefit should take into account whether the patient is clinically 
deteriorating and unlikely to receive further benefit from cont inued treatment. The patient must 
sign the treatment beyond progressive disease ICF prior to continuing study treatment. Patients who continue NKTR-214/nivolumab  study treatment beyond progress ion will be allowed to be 
treated with NKTR-214/nivolumab f or a maximum of [ADDRESS_1110418] dose of study treatment 
(C1D1). 
4.1.3 End of Treatment 
Patients may choose to disconti nue the study at any time, for any reason, and without prejudice 
to further treatment. Patients may discontinue treatment of all or one of the study drugs based on 
AEs. The end of treatment (EOT)  visit should occur ± 7 days aft er study therapy is permanently 
discontinued or before a new antineoplastic regimen starts. Rad iographic tumor assessment is 
needed at EOT unless done within 4 weeks prior to the EOT visit . 
Reasons for EOT are listed below: 
• Disease progression in the absen ce of clinical benefit as determined by [CONTACT_737]. 
• Occurrence of a clinically s ignificant AE found to be unaccepta ble or non-resolution of a 
clinically significant AE for > 8 weeks. 
• Symptomatic deterioration in t he absence of tumor progression per RECIST 1.1. 
• Noncompliance of the patient wit h protocol-mandated procedures based on the judgment and 
agreement of both the I nvestigator and Sponsor. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 49 of 149 
Confidential and Proprietary  27 May 2021 • At the discretion of the Investig ator (continued participation is no longer in the patient’s best 
interest in the opi[INVESTIGATOR_689]). 
• Pregnancy in a female patient. 
• Patient’s decision to di scontinue treatment. 
• Lost to follow-up (defined as after [ADDRESS_1110419] by [CONTACT_804531] 1 attempt by 
[CONTACT_5583] a certified letter). 
• The study is terminated by [CONTACT_1034]. 
• Patient has been treated with NKTR-214/nivolumab for a maximum of [ADDRESS_1110420] 
dose of study treatment (C1D1). 
In the event of a patient’s wit hdrawal, the Investigator will p romptly notify the Sponsor and 
make every effort to complete the EOT procedures specified in the Schedule of Events (Table 1 ). 
A patient may also be withdrawn from investigational product/st udy by [CONTACT_1034], Regulatory 
Authorities, or Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs). 
[IP_ADDRESS] Follow-Up 
After patients complete the End of  Treatment visit, follow-up should continue until patient 
withdrawal of consent , death, l oss to follow-up, or study term ination by [CONTACT_1034]. Timing for 
follow-up will be as follows: 
• Assessments should conti nue as described in Table 1 . 
• Patients must be followed for at least [ADDRESS_1110421] dose ( ± 7 days) or can be performed on 
the date of discontinuation if that date is greater than [ADDRESS_1110422] dose. Follow-up 
Visit 1 can be combined with the  EOT Visit if the visits are wi thin 7 days of each other. 
Follow-up Visit 2 occurs approx imately 100 days (± 7 days) from the last dose of all study 
drugs. Both follow-up visits should be conducted at the clinic.  
• Patients should be followe d as clinically indicated. 
• Radiologic tumor assessments wi ll occur every 90 (± 10) days from the last radiologic 
assessment and continue to be collected even if a new antineoplastic regimen has been 
initiated, until disease progression, patient withdraws consent, death, or study termination by [CONTACT_1034]. 
• In case of a clinically signifi cant AE, patient will be followe d for safety until resolution or 
permanent sequelae of all toxicities attributable to study drug s. If the patient discontinues 
study drug for a clinically signi ficant AE, the patient will be followed until resolution of the 
AE or the event is considered t o be stable and/or chronic.  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 50 of 149 
Confidential and Proprietary  27 May 2021 [IP_ADDRESS] Survival Follow-Up 
All patients will be contact[CONTACT_804532]-study therapy(ies), qua lity of life a ssessments, and 
survival every 3 months (± 14 days) following the Day-100 follow-up visit (Follow-up Visit 2) 
or following last c ontact with the patien t, if Follow-Up Visit 2 is missed.  
• Survival visits may be conducted in person or by [CONTACT_756].  
• Information about subsequent can cer therapy will also be collec ted during these contacts.  
• The Sponsor may request that survival data be collected on all treated patients outside of the 
scheduled contacts. At the time  of this request, each patient w ill be contact[CONTACT_804533] e patient has withdrawn consent for all contact [CONTACT_804534]-up. Alternative methods to determine survival status may be used (e.g., access to 
medical records and public record searches) as allowed by [CONTACT_804535]/or 
guidelines. Additional subsequent cancer therapy details such a s regimen, setting of the 
regimen, line of therapy, start date and end date of each regim en, best response to the 
regimen, and date of progression after next line of therapy wil l be collected. 
• Survival follow-up should continue until patient withdrawal of consent for survival 
follow-up, death, loss to follo w-up, or study termination by [CONTACT_3433] e Sponsor.  
4.1.[ADDRESS_1110423] patient, or until the time of OS analysis, 
whichever occurs earlier. 
Note that the maximu m duration of treatment with NKTR-214 and n ivolumab for any patient is 
2 years  (see Section 4.2.2 ). 
4.1.5 Treatment After End of Study 
At the conclusion of the study, patients who continue to demons trate clinical benefit may be 
eligible to receive Nektar-supplied study treatment for the maximum treatment duration (as 
specified in Section 4.1.2 ). Study treatment may be provide d via an extension of the study, a 
rollover study requiring approval  by [CONTACT_804536], or 
through another mechanism, at the discretion of Nektar. 
Nektar reserves the right to terminate access to Nektar-supplied study treatment if any of the following occur: a) the study is terminated due to safety concerns; b) the development of 
nivolumab and NKTR-214 is terminat ed for other reasons, including but not limited to lack of 
efficacy and/or not meeting the study objectives; c) the partic ipant can obtain medication from a 
government sponsored or private h ealth program. In all cases Ne ktar will follow local regulations 
(Section 11.0) . 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 51 of 149 
Confidential and Proprietary  27 May 2021 4.1.6 Patients Enrolled onto Gemcitabi ne/Carboplatin (GemCarbo) Treat ment in an 
Earlier Version of the Protocol 
For patients enrolled to GemCarbo on a prior protocol amendment , please see Appendix 5. 
4.[ADDRESS_1110424] s are important characteriza tions of responses with immune-
oncology treatments. 
4.2.2 Duration of Treatment with Nivolumab / NKTR-[ADDRESS_1110425] of the responses occur e arly, with a median time to 
response of 2 to 4 months ( Brahmer, 2015; Borghaei, 2015; Hellmann, 2017; Larkin, 2015 ; 
Motzer, 2015), and emerging data suggest that  benefit can be maintained in the absence of 
continued treatment. A recent analysis in a melanoma study sugg ests the majority of patients 
who discontinue nivolumab and/or ipi[INVESTIGATOR_804493] ( Schadendorf, 2016 ). Furthermore, a l imited duration of 
ipi[INVESTIGATOR_125], includi ng only 4 induction doses, r esulted in long term survival in patients with 
metastatic melanoma, with a sus tained plateau in survival start ing around 2 years after the start 
of treatment ( Schadendorf, 2015 ). 
Accumulating data sugges t that 2 years of PD-1 CPI [INVESTIGATOR_804494]-term 
benefit. CA209003, a dose-escalation cohort expansion study evaluating the safety and clinical activity of nivolumab in patients with previously treated advan ced solid tumors (including 
129 patients with NSCLC), specified a maximum treatment duratio n of 2 years. Among 
16 patients with NSCLC who discontinued nivolumab after complet ing 2 years of treatment, 
12 patients were alive > 5 years a nd remained progression-free without any subsequent therapy. 
In the CA209003 NSCLC cohort, the OS curve begins to plateau af ter 2 years, with an OS rate of 
25% at 2 years and 18% at 3 years ( Brahmer, 2017). These survival outcomes are similar to 
Phase 3 studies in previously treated NSCLC, in which nivolumab  treatment was continued until 
progression or unacceptable toxicity (2 year OS rates of 23% and 29%, and 3 year OS rates of 16% to 18% for squamous and non-squamous NSCLC respectively) ( Felip Font, 2017). 
Similar results have been reporte d in clinical studies of pembr olizumab, another PD-1 inhibitor. 
Keynote-010 was a randomized Pha se 3 study of pembrolizumab (at  either 2 mg/kg or 10 mg/kg 
q3w) versus docetaxel in patient s with previously treated, high PD-L1, advanced NSCLC which 
specified a maximum treatment duration of 2 years for pembrolizumab. OS was significantly 
longer with both pembrolizumab 2 mg/kg (hazard ratio [HR] 0.72,  P = 0.[ZIP_CODE]) and 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 52 of 149 
Confidential and Proprietary  27 May 2021 pembrolizumab 10 mg/kg (HR 0.60, P < 0.[ZIP_CODE]) compared to docet axel, with an OS plateau 
developi[INVESTIGATOR_448161] [ADDRESS_1110426] 
were able to maintain their response, including those with stab le disease, with only 2 patients 
(4%) having confirmed progression after stoppi[INVESTIGATOR_25577] 2 years ( Herbst, 2016). 
Keynote-006 was a randomized Phase 3 study of pembrolizumab versus ipi[INVESTIGATOR_448162], which a lso specified a maximum 2-year d uration of pembrolizumab 
treatment. Of 556 patients random ized to pembrolizumab, 104 (19%) completed 2 years of 
treatment. With a median follo w-up of 9 months after completion  of pembrolizumab, the 
estimated risk of progression or de ath was 9% in these patients  (Robert, 2017). 
Taken together, these data sugge st that treatment beyond [ADDRESS_1110427], a shor ter duration of nivolumab of  only 1 year was associated with 
increased risk of progression in pr eviously treated patients wi th NSCLC, suggesting that 
treatment beyond 1 year is likely needed.  
In CA209153, patients with previousl y treated advanced NSCLC wh o completed 1 year of 
nivolumab therapy were randomized t o either continue or stop treatment, with the option of 
retreatment upon progression. Amo ng 163 patients still on treat ment at 1 year and without 
progression, those who were rando mized to continue nivolumab ha d significant improvement in 
PFS compared to those who were randomized to stop treatment, wi th median PFS (post-
randomization) not reached vs. 10.3 m onths, respectively; HR = 0.42 (95% confidence interval 
[CI]:  0.25 to 0.71). With a median follow-up of 14.[ADDRESS_1110428]-randomization, there also was 
a trend for patients on continued treatment to live longer (OS HR = 0.63 [95% CI:  0.33, 1.20]). 
Of note, the PFS curves in both group s plateau approximately 1 year after randomization 
(i.e., 2 years after treatment initiation), suggesting that there may be minimal be nefit in extending 
treatment beyond a total of 2 years ( Spi[INVESTIGATOR_15174], 2017 ). 
Collectively, these data suggest that there is minimal, if any, benefit derived from continuing 
immuno-oncology treatment beyond 2 years in advanced tumors. Even though immunotherapy is well tolerated, patients will be at risk for additional toxicity with longer term treatment. Therefore, in this study, treatment will be given for a maximum  of 2 years from the start of study 
treatment. 
Given the hypothesis that co- administration of NKTR-214 with nivolumab will potentiate the 
pharmacological effects of ni volumab, the duration of NKTR-214 therapy will also be restricted 
to 2 years to match the duration of nivolumab therapy. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 53 of 149 
Confidential and Proprietary  27 May 2021 4.2.3 Justification for Dose 
[IP_ADDRESS] NKTR-214 
The dose for NKTR-214 is 0.006 mg/ kg IV q3w for adults, taking into consideration the clinical 
safety profile associated with t he robust immune system activat ion observed in Study 16-214-02 
(PI[INVESTIGATOR_12964]-02) (see Section 2.1.4). NKTR-214 dose is based on the IL- 2 protein component. Please  
refer to Section 2.1.4 for additional details  on Study 16-214-02 (PI[INVESTIGATOR_12964]-02). 
[IP_ADDRESS] Nivolumab 
Nivolumab monotherapy has been extensively studied in multiple tumor types, including 
urothelial carcinoma, melanoma , NSCLC, RCC, classical Hodgkin’s lymphoma (cHL), and 
squamous cell carcinoma of t he head and neck (SCCHN), using bod y weight normalized dosing 
(mg/kg), and has been safely administered at doses up to 10 mg/ kg q2w. Nivolumab is currently 
approved for the treatment of va rious tumors, including UC, mel anoma, NSCLC, RCC, cHL, and 
SCCHN, using a regimen of either nivolumab 240 mg q2w, nivolumab 3 mg/kg q2w, and nivolumab 480 mg q4w. 
Nivolumab has been shown to be s afe and well tolerated up to a dose level of nivolumab 
10 mg/kg q2w. Population PK (PPK) analyses have shown that the PK of nivolumab is linear 
with proportional exposures over a dose range of 0.1 to 10 mg/k g; no differences in PK across 
ethnicities and tumor types were observed. Using the PPK model,  the exposures following 
administration of several dosing regimens of nivolumab administ ered as a flat dose were 
simulated, including nivoluma b 360 mg q3w. The simulated steady state average concentration 
(C
avgss) following administr ation of nivolumab 360 mg q3w are predicted to be similar to those 
following administr ation of nivolumab 240 mg q2w and nivolumab 3 mg/kg q2w administered to 
patients weighing 80 kg, the approxim ate median weight of patie nts with NSCLC, melanoma, 
and RCC used in the PPK analyses. Given that the C avgss estimates for n ivolumab 360 mg q3w 
are predicted to be similar to  those for nivolumab 240 mg q2w and nivolumab 3 mg/kg q2w, the 
efficacy is predicted to be similar for these regimens. It shou ld be noted that the steady state C max 
following nivolumab 360 mg q3w are pr edicted to be less than th ose following the 
administration of nivolumab 10 mg/kg q2w, providing sufficient safety margins.  
Finally, nivolumab 360 mg q3w is currently being investigated in combination with a number of 
other agents, including NKTR-214 in Study 16-214-02 (PI[INVESTIGATOR_12964]-02) (see Section [IP_ADDRESS]), and platinum-doublet chemothera py dosing, with no new or increased safety events observed to date. 
By [CONTACT_804537] 360 mg q3w in thi s study, it allows for alig ning doses of nivolumab at the 
same dosing frequency of the expe rimental agent. Further details on nivolumab 360 mg q3w 
dosing can be found in the Investigator’s Brochure. 
[IP_ADDRESS] Rationale for NKTR-214 / Ni volumab Combination Dose 
Given the totality of data for NKTR-214 monotherapy (see Sectio n [IP_ADDRESS] ) and for NKTR-214 
in combination nivolumab (see Section 2.1.4), including safety/tolera bility, reproducible PK, 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 54 of 149 
Confidential and Proprietary  27 May 2021 dose-independent pharmacodynamic profile, immune cell activatio n, and promising efficacy 
data, NKTR-214 0.006 mg/kg IV q3w plus nivolumab 360 mg IV q3w is considered as the 
appropriate dose to be adminis tered in Phase 2 and 3 studies.  
4.2.4 Rationale for Open-label Design 
Due to the hydration program and the special restrictions for withholding anti-hypertensive 
medication in the NKTR-214 arm, a placebo-controlled, double-bl inded study is not appropriate. 
4.2.5 Choice of PD-L1 Assays 
Patients will be able to enroll regardless of PD-L1 status. PD-L1 expression will be assessed 
using the PD-L1 IHC 22C3 pharmD x assay approved for use with pe mbrolizumab in UC 
(P150013/S0011; Dako North America, Inc., 2018 ). This assay was sel ected based on the FDA 
announcement on [ADDRESS_1110429] 
patients with locally advanced or  metastatic urot helial carcino ma who are cisplatin-ineligible for 
treatment with Keytruda ( FDA, 2018 ).  
This assay is further  described in Section 7.3. In addition to utilizing t he PD-L1 IHC 22C3 
pharmDx assay, unstained tissue sections may be assessed retros pectively for membranous tumor 
and/or immune cell PD-L1 expression using other IHC antibody as says.  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 55 of 149 
Confidential and Proprietary  27 May 2021 5.0 SELECTION OF STUDY POPULATION 
5.1 Inclusion Criteria 
Each patient will be entered into this study only if he/she mee ts all of the following criteria: 
1) Provide written informed consent to participate in the study an d follow the study procedures. 
2) Histologically or cytologicall y documented urothelial cell carcinoma (also termed TCC) 
including renal pelvis, ureters , urinary bladder, and urethra that is inoperable, locally 
advanced (T4b, any N; or any T, N2- 3) or metastatic (M1, Stage IV). 
• Histologically or cytologically c onfirmed locally advanced and unresectable or 
metastatic urothelial cancer, including mixed urothelial cell a nd non-urothelial cell 
histologies. If the histology i s mixed with non-urothelial carc inoma (e.g., squamous cell 
carcinoma), the urothelial cell component must be dominant (> 5 0% of the total 
histology). 
3) Tumor tissue is required to be analyzed by [CONTACT_804538]-L1 status.  
• Tissue can be provided in one of two ways: 
(1) A new biopsy taken during screening 
(2) Archival tissue from either a FFPE tissue block or unstained tumor tissue sections 
(see Section 7.5). Archival tissue must be obtai ned within 12 months prior to 
enrollment and with no int ervening treatment.  
• A tracking number confirming shipment of the sample to the cent ral laboratory must be 
supplied prior to Cycle 1 Day 1. 
4) Male or female patients, age 18 years or older at the time of s igning the ICF. 
5) ECOG performance status ≤ 2 (see Appendix 1).  
6) Measurable disease per RECIST 1.1 criteria. 
7) No prior systemic chemotherapy or investigational agent for ino perable locally advanced or 
mUC.  
• For patients who received prior pe rioperative chemotherapy for urothelial bladder 
cancer, a treatment-fr ee interval of > [ADDRESS_1110430] treatment 
administration and the date of r ecurrence is required in order to be considere d treatment 
naïve in the metastatic setting.  
• Patients must not have received ne oadjuvant or adjuvant therapy  with any immuno-
oncology regimens. 
• Prior local intravesical chemot herapy or immunot herapy is allow ed if completed at least 
4 weeks prior to the initi ation of study treatment. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 56 of 149 
Confidential and Proprietary  27 May 2021 8) Ineligible for cisplatin as defined by [CONTACT_804539] (or more) of the  following criteria: 
a) Impaired renal function (calcula ted by [CONTACT_12021]-Gault or measured by 24-hour urine 
collection) defined as a creatin ine clearance (CrCl) ≥ 30 but <  60 mL/min.  
b) Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 Gr ade ≥ 2 hearing 
loss 
c) CTCAE v 5.0 Grade ≥ 2 pe ripheral neuropathy 
d) ECOG performance status of 2 
9) Prior palliative radiotherapy mus t be completed at least [ADDRESS_1110431] ha ve recovered from all Grade 2 o r higher radiation-related 
toxicities. Note:  radiated les ions cannot be used as measurable lesions unless there is clear 
evidence of progression. 
10) Demonstrated adequate organ func tion, as defined below, within 14 days of treatment 
initiation 
a) White blood cell (WBC) count ≥ 200 0/μL (after at least 7 days w ithout growth factor 
support) 
b) Absolute neutrophil count (ANC) ≥ 1500/μL (after at least 7 day s without growth factor 
support) 
c) Platelet count ≥ 100 × 103/μL 
d) Hemoglobin ≥ 9.0 g/dL (no transfusions within [ADDRESS_1110432]) 
e) CrCl rate ≥ 30 mL/min ( using the Cockcroft-Gault formula) or directly measured by 
24-hour urine: 
Female CrCl= (140 – age in ye ars) × weight in kg × 0.85 
72 × creatinine in mg/dL 
Male CrCl= (140 – age in years) × weight in kg × 1.00 
72 × creatinine in mg/dL 
f) Aspartate aminotransferase (AS T) and alanine transaminase (ALT) ≤ 3 × upper limit of 
normal (ULN) 
g) Total bilirubin ≤ 1.5 × ULN (excep t patients with Gilbert Syndr ome, who can have total 
bilirubin < 3.0 mg/dL) 
11) A documented left ventricular ejection fraction (LVEF) > 45% us ing standard 
echocardiogram or multigated acq uisition (MUGA) scan test taken  within 60 days prior to 
Cycle 1 Day 1. 
12) WOCBP must have a serum or urine pregnancy test (minimum sensit ivity 25 IU/L or 
equivalent units of HCG) within 24 hours prior to the start of study treatment.  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 57 of 149 
Confidential and Proprietary  27 May 2021 • Women must not be breastfeeding 
• WOCBP must agree to follow inst ructions for method(s) of contra ception for the duration 
of treatment with study treatment and for [ADDRESS_1110433]-treatment completion. Women 
should use an adequate method(s) of contraception as indicated in Appendix 3. WOCBP 
who are continuously not heterosexu ally active are exempt from contraceptive 
requirements, and still must under go pregnancy testing as descr ibed in this section. 
• Males who are sexually active with  WOCBP must agree to follow instructions for 
method(s) of contraception (Appendix 3) for the duration of t reatment with study 
treatment(s) and [ADDRESS_1110434] be willing to refrain from sperm donation during this time .  
• Investigators shall counsel WO CBP, and male patients who are se xually active with 
WOCBP, on the importance of pregnancy prevention and the implications of an 
unexpected pregnancy. Investigator s shall advise on the use of highly effective methods 
of contraception ( Appendix 3), which have a failure rate  of < 1% when used consistently 
and correctly. 
13) Patients must be able and willing to comply with the study visi t schedule and study 
procedures. 
5.2 Exclusion Criteria 
A patient will be excluded from this study if he/she meets any of the following criteria: 
1) Female patients who are pregnant or lactating, who plan to get pregnant, or who have a 
positive serum or urine pregnancy test. 
2) Active brain metastases or leptom eningeal metastases. Patients with brain metastases are 
eligible if these have been treated and there is no radiographi c evidence of progression for at 
least 4 weeks after treatment is complete (confirmed by [CONTACT_804540] 
28 days prior to Cycle 1 Day 1). The re must also be no requirement for immunosuppressive 
doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to Cycle 1 Day 1. Stable do se of anticonvuls ants is allow ed. Treatment for CNS 
metastases may include whole brain radiation, stereotactic radiosurgery (e.g., GammaKnife, CyberKnife, or equivalent) or ne urosurgical rese ction. Patients with CNS metastases treated 
by [CONTACT_804541] n biopsy performed within 28 days prior to Cycle 1 Day 1 
are not eligible. 
3) Prior active malignanc y within the previous [ADDRESS_1110435]. An incidental finding of prostate cancer (identified up on resection of the prostate) is 
acceptable, provided that one of the following criteria is met:   T2N0M0, or Gleason 
score ≤ 3+4, or prostate-specifi c antigen (PSA) below upper limit of normal by [CONTACT_804542]. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 58 of 149 
Confidential and Proprietary  27 May 2021 4) Patients who have an active known or suspected autoimmune disea se. Patients requiring 
systemic treatment within the pa st 3 months or a documented history of clinically severe 
autoimmune disease that requires systemic steroids or immunosup pressive agents. 
(Exceptions include any patient on 10 mg or less of prednisone or equivalent, patients with 
vitiligo, hypothyroidism stable  on hormone replacement, Type I diabetes, Graves’ disease, 
Hashimoto's disease, alopecia areata, eczema, or psoriasis.) 
5) Patients with a condition requiring systemic treatment with eit her corticosteroids (> 10 mg 
daily prednisone equivalent) or o ther immunosuppressive medicat ions within [ADDRESS_1110436] acement steroid doses > 10 mg 
daily prednisone equivalent, are pe rmitted in the absence of active autoimmune disease. 
6) Patients must not have recei ved prior IL-2 therapy. 
7) Patients who have received any live/attenuated vaccine within 3 0 days before Cycle 1 Day 1.  
8) Prior treatment with an anti PD -1, anti PD-L1, anti-PD-L2, or a nti CTLA-[ADDRESS_1110437], or any other antibody or drug specifi cally targeting T-cell 
costimulation or immune checkpoint pathways. 
9) History of allergy to study drug components. 
10) History of severe hypersensitivit y reaction to any monoclonal a ntibody. 
11) History of organ, hematopoetic, or tissue transplant that requi res the systemic use of 
immunosuppressive agents. 
12) Active infection requiring systemic therapy within 14 days prio r to Cycle 1 Day 1. 
13) Any positive test result for hepatitis B virus (HBV) or hepatit is C virus (HCV) indicating 
presence of virus, e.g., hepatitis  B surface antigen (HBsAg) positive, or hepatitis C antibody 
(anti-HCV) positive (except if HCV-RNA negative). 
14) Known history of positive test for  human immunodeficiency virus  (HIV) or known acquired 
immunodeficiency syndrome (AIDS) . NOTE:  Testing for HIV must b e performed at sites 
where mandated locally. 
15) Known cardiovascular history i ncluding unstable or deterioratin g cardiac disease within the 
previous 12 months prior to scr eening including but not limited  to the following: 
a) Unstable angina or m yocardial infarction 
b) Transient ischemic attack (TIA)/c erebrovascular accident (CVA) 
c) Congestive heart failure (NYHA Class III or IV) 
d) Uncontrolled clinically s ignificant arrhythmias 
16) History of pulmonary embolism (PE), deep vein thrombosis (DVT),  or prior clinically 
significant venous or non-CVA/TIA arterial thromboembolic event  (e.g., internal jugular 
vein thrombosis) within 3 months prior to enrollment. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 59 of 149 
Confidential and Proprietary  27 May 2021 • Patients with a history of a venous  or arterial thromboembolic event must be 
asymptomatic for at least [ADDRESS_1110438] be receiving a stable 
regimen of therapeutic anticoagu lation (preferably low molecula r weight heparin 
[LMWH] or direct oral anticoa gulation [DOAC]; see Section [IP_ADDRESS] for further 
guidance).  
• Unless there is a new medical c ontraindication observed after C ycle [ADDRESS_1110439] be maintained 
on therapeutic anticoagulation throughout the patient’s partici pation in the study 
(i.e., through the end-of-t reatment [EOT] visit). 
17) Need for > 2 antihypertensive m edications for management of hyp ertension (including 
diuretics). Patients with hypertension must be on a stable anti hypertensive regimen (defined 
as no dose adjustments to antihypertensive medications) for the  14 days prior to Cycle 1 
Day 1. Note:  An antihypertensive medication that contains 2 drugs with antihypertensive 
effects in one formulation is counted as 2 antihypertensive dru gs (e.g., angiotensin-
converting-enzyme [ACE] inhibito r plus diuretic; calcium channe l blocker plus ACE 
inhibitor). 
18) Patients with inadequately tr eated adrenal insufficiency. 
19) Known current drug or alcohol abuse. 
20) Any condition including medical, emotional, psychiatric, or logistical that, in the opi[INVESTIGATOR_15960], would preclud e the patient from adhering to the protocol or would increase 
the risk associated with study participation or study drug admi nistration or interfere with the 
interpretation of safety results.  
21) Vulnerable populations as described by [CONTACT_804543] , as applicable per country. 
22) Legally protected majors or maj ors who are unable to express th eir consent as described by 
[CONTACT_804544] , as applicable  per country.  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110440], before nivolumab. NKTR-214  is to be administered as an 
IV infusion over 30 ± 5 minut es  at a starting dose of 0.006 mg /kg every 3 weeks . Nivolumab 
administration should start at leas t 30 minutes from the end of the NKTR-214 administration. 
Patients may be dosed no less tha n 18 days from th e previous dose.  
 
 
 
 
 
  
 
 
 
  
 
  
  
 
  
 
 
  

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110441] 
are described in the Pharmacy Manual. 
6.1.5 Nivolumab 
Patients should receive nivolum ab at a dose of 360 mg as a 30-minute (± 5 minutes) IV infusion 
on Day [ADDRESS_1110442] dose of  nivolumab. Patients should be carefully monitored for infusion 
reactions during nivoluma b administration. If an acute infusion  reaction is noted, p atients should 
be managed according to directions in Section 6.6.4. Doses of nivolumab m ay be interrupted, 
delayed, or discontinued depending on how well the patient tole rates the treatment (see 
Section 6.5).  
Nivolumab injection, 100 mg/10 mL (10 mg/mL) and 40 mg/4 mL (10  mg/mL), is to be 
administered as an IV infu sion through a 0.2-micron to 1.2-micr on pore size, low-protein binding 
in-line filter at the protocol-specified doses. It is not to be  administered as an IV push or bolus 
injection. For the fixed dose (e.g., 360 mg flat dose), nivolum ab injection can be infused 
undiluted or diluted so as not to exceed a total infusion volum e of [ADDRESS_1110443] be equipped f or medical emergencies. 
Patients should be carefully m onitored for infusion reactions d uring NKTR-214 administration. 
If an acute infusion reaction is  noted, patients should be mana ged according to Section 6.6.4. If 
the patient experiences a Grade ≥ 2 infusion-related reaction o r hypotension during the days after 
NKTR-214 dosing, the pa tient may be monitored overnight at the discretion of the Investigator; 
longer periods of monitoring may be  implemented at the discretion of the Investigator. 
Treatment with NKTR-214 may be delayed or reduced as described in Section 6.5. NKTR-214 
treatment can continue in the eve nt that nivolumab is permanent ly discontinued due to toxicities; 
see Section 6.5.5. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 63 of 149 
Confidential and Proprietary  27 May 2021 6.2.1 Frequent Vital Signs 
Vital signs are to be monitored during Cycle 1 as follows:   
• Cycle 1 Day 1 Predose including o rthostatic blood pressure meas urements (with in 2 hours of 
infusion); see Section 9.13 
• Cycle 1 Day 1 Postdose:  within 30 minutes after infusion of ni volumab  
• Cycle 1 Day 3:  Including orthos tatic blood pressure measuremen t; see Section  9.13  
• Cycle 1 Day 8 
For Cycle 2 and beyond, vital signs should be monitored as foll ows: 
• Predose (within 30 minutes) 
• approximately 30 minutes after the administration of nivolumab  
If the patient experiences a Grade ≥ 2 infusion-related reactio n or hypotension during the days 
after NKTR-214/nivolumab dosing, the patient may be monitored o vernight at the discretion of 
the Investigator. Longer periods  of monitoring may be implement ed at the discretion of the 
Investigator. 
6.2.2 Hydration Guidelines 
Important safety information a nd hydration instruc tions are to be provided to patients. Hydration 
and renal function should be asse ssed within 24 hours prior to study drug administration or as 
soon as locally feasib le. Underlying reasons for decreased oral  intake (such as nausea) should be 
addressed and treatment (such as IV hydration) should be provided. Patients may receive 
additional hydration precautio ns in a patient card/handout. 
For those patients assigned to NKTR-214, administer at least 1 liter of IV fluid on NKTR-214 
dosing days (Day 1 of cycle). For the next 3 days (Days 2-4) after administration of NKTR-214, patients are to be instructed t o drink at least 2 liters per da y of self-administer ed oral hydration. 
Advise patients to refrain from activities that may contribute to dehydration (including but not 
limited to, strenuous activity, long hot showers, and saunas) f or Days [ADDRESS_1110444] the patient (by [CONTACT_804545] t) at least once to remind the patient 
of the oral hydration guidelines, t o assess for any symptomatol ogy and compliance with the 
guidelines, and document the result s of the discussion (Section  2.2). Following subsequent 
NKTR-214 administrations, the oral hydration follow-up should be conducted as clinically indicated for patients receiving NKTR-214. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110445] of the patient  (e.g., evidence of 
fluid overload). 
6.2.3 Hypotension Guidelines  
Consideration should be given to withholding antihypertensive m edications including diuretics, 
as well as other drugs with hypotensive properties (e.g., alpha  blockers for benign prostatic 
hyperplasia), particularly when therapy involves multiple anti- hypertensive drugs and classes 
other than thiazide diuretics. If withholding antihypertensive medications, withhold no less than 
12 hours and no more than 48 hours prior to each dose of NKTR-2 14. Patients who are on 
medications with antihypertensive effects for the treatment of coronary artery disease (CAD) 
(e.g., β-blockers, Ca channel blockers, nitrates, etc.) should be able to temporarily discontinue 
these drugs prior to i nitiation of treatment. 
Antihypertensive medications m ay be reinstituted in between dos es of NKTR-214 at any time as 
clinically indicated (e.g. , based on blood pressure monitoring results). 
In patients receiving beta-blockers, consider a step-wise taper ing of doses before initiation of 
NKTR-214 to avoid reflex tachycardi a. If Grade 2 or higher hype rtension is observed in any 
cycle, patients should be monitore d more frequently (at least w eekly until a new stable 
antihypertensive regim en is identified). P atients may be monito red more frequently at the 
discretion of the Investigator  as clinically warranted. 
Adequate hydration mitigates t he development of hypotension ass ociated with NKTR-214 
administration (see Section 6.2.2).  
Per clinical judgment, IV fluids  may be administered at any tim e. The Investigator may decide to 
forego administering IV fluids t o a patient or adjust the recom mendation for self-administered 
oral hydration to a particular patient if this is deemed in the  best interest of the patient 
(e.g., evidence of f luid overload). 
Patients with pre-existing adrenal  impairment requiring cortico steroid supplementation may be at 
increased risk for hypotensive epi [INVESTIGATOR_804495] N KTR-214. For these patients, it 
may be necessary to provide additio nal corticosteroid support ( see Section 6.7.2 for details). 
6.3 Method of Treatment Assignment 
Each patient will be assigned a uni que patient number after sig ning the ICF. Patient numbers will 
be used on all patients’ study inf ormation. Patient numbers wil l not be reassigned.  
An Interactive Response Technology  (IRT) will be employed to manage patient enrollment and 
drug supply.  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 65 of 149 
Confidential and Proprietary  27 May 2021 6.4 Blinding 
Not applicable. 
6.5 Dosage Modification 
Dose modification for NKTR-214 and nivolumab may be considered independently based on 
Investigator assessment of re lationship of a t oxicity to each o f the study drugs. If only one of the 
study drugs meets the criteria for  dose delay, then administrat ion of the other study drug may be 
continued or delayed at the disc retion of the Investigator.  
In the event that nivolumab is  permanently discontinued due to toxicities, NKTR-214 can 
continue to be administered. Lik ewise, if NKTR-214 is permanent ly discontinued, nivolumab 
can continue to be administere d. Any dose reductions will require discussion and consultation 
with the Medical Monitor. 
Note:  tumor assessments for al l patients should continue as pe r protocol even if dosing is 
delayed.  Patients who require delay of  nivolumab or NKTR-214 should be r e-evaluated weekly or more 
frequently if clinically indicat ed and resume treatment with co mbination of NKTR-214 and 
nivolumab (on Day 1 of the next cyc le) when re-treatment criteria are met. Immuno-oncology 
agents are associated with AEs  that can differ in severity and duration from AEs caused by [CONTACT_802656]. NKTR-214 a nd nivolumab are considered an i mmuno-oncology agent in this 
protocol. Early recognition and man agement of AEs associated with immuno-oncology agents 
may mitigate severe toxicity. 
6.5.1 NKTR-214 Dose Modifications and Delays 
Dose delays and reductions are  permitted for NKTR-214. NKTR-214  may be delayed or reduced 
to 0.003 mg/kg based on observed drug-re lated toxici ties. If th e NKTR-214 dose is reduced to 
0.003 mg/kg, the dose level should re main at this level throughout the remainder of the study. 
NKTR-214 administration should be de layed or reduced for the fo llowing reasons: 
• For persistent Grade 2 relate d toxicity, at the discretion of t he Investigator 
• Grade ≥ 2 creatinine increase: 
For patients who must delay st udy treatment due to Grade ≥ 2 cr eatinine increase due 
to a non-inflammatory cause, delay retreatment with study drug for approximately 
3 to 5 days. After the dosing dela y, the patient may resume stu dy drug when serum 
creatinine has returned to Grade ≤ 1, as assessed within 24 hou rs prior to redosing (or 
as soon as locally feasible). For  further guidance, refer to th e Renal AE Management 
Algorithm in the current nivolum ab Investigator’s Brochure. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 66 of 149 
Confidential and Proprietary  27 May 2021 • Grade ≥ [ADDRESS_1110446] po ssibly related to NKTR-214:  NKTR -[ADDRESS_1110447] be 
delayed until resolution to Grade 1 or baseline (unless the tox icity otherwise requires 
permanent discontinuation per Section 6.5.5), with the following exceptions: 
• Grade ≥ 3 lymphopenia  
• Grade ≥ 3 asymptomatic amyl ase or lipase elevation 
• Patient has acute infection (e .g., fever, upper or lower respir atory tract infection) requiring 
systemic antibiotic therapy. Patient may resume study treatment  once free of signs or 
symptoms for 72 hours after completion of antibiotic therapy (S ee Section 6.5.4). 
• Any adverse event, laboratory a bnormality, or intercurrent illn ess which, in the judgment of 
the Investigator, warrants de laying the dose of study medication. 
NKTR-214 dosing may resume at the same NKTR-214 dose or at a lower NKTR-214 dose level 
when toxicity resolves to Gra de 1 or returns to baseline, excep t for instances where the potential 
recurrence of the event poses a n undue risk for the patient. Me dical Monitor consultation is 
required for dose reduction. 
6.5.2 Nivolumab Dose Delay Criteria 
Dose reductions for nivolumab are not permitted in this study.  
Nivolumab administration should be delayed for the following: • Grade 2 non-skin, drug-related AE , with the exception of fatigu e 
• Grade [ADDRESS_1110448], ALT, and/or total bilirub in abnormalities 
• Grade 3 skin, drug-related AE 
• Grade 3 drug-related laboratory abnormality, with the following  exceptions:   
• Grade 3 lymphopenia or asymptomatic amylase or lipase does not require dose delay 
• Grade ≥ [ADDRESS_1110449], ALT, total bilirubin will require dose discontinuation (unless 
satisfying the Cycle [ADDRESS_1110450]/ALT elevation criteria outlined in S ection 6.5.3) 
• Patient has acute infection (e .g., fever, upper or lower respir atory tract infection) requiring 
systemic antibiotic therapy. Patient may resume study treatment  once free of signs or 
symptoms for 72 hours after completion of antibiotic therapy (S ee Section 6.5.4). 
• Any AE, laboratory abnormality, or intercurrent illness which, in the judgment of the 
Investigator, warrants delaying the dose of study medication. 
• Patients who require delay of nivo lumab should be re-evaluated weekly or more frequently if 
clinically indicated and resume  nivolumab dosing when re-treatm ent criteria are met.  
 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 67 of 149 
Confidential and Proprietary  27 May 2021 6.5.3 Dose Modification Criteria for  NKTR-214 and Nivolumab for Cycle  1 ALT/AST 
Elevations 
These recommendations are for C ycle [ADDRESS_1110451] Hepatic Adverse 
Event Management Algorithm in the  current nivolumab Investigato r’s Brochure. 
Rule out non-inflammatory etiologies. Consider imaging if obstr uction is suspected. If non-
inflammatory cause, treat accordingly and continue NKTR-214 and  nivolumab.  
If during monitoring ALT/AST increases, follow the guidance for the highest levels. 
− AST or ALT > 3.0 to ≤ 5 × ULN (with in first cycle of NKTR-214 a nd nivolumab) 
Increase frequency of liver function test monitoring to approxi mately every 3 days and 
delay treatment until lab abnorma lities resolve to Grade 0-1. 
If no improvement within 7 days, treat with 0.5-1 mg/kg/day pre dnisone equivalents, and taper 
steroids over at least 1 mont h before resuming treatment. 
− ALT or AST > 5.0 to ≤ 8.0 × ULN (with in first cycle of NKTR-214  and nivolumab) 
Increase frequency of monitoring to approximately every [ADDRESS_1110452] be delayed until l ab abnormalities resolve to Gr ade 0-1. 
If no improvement within 7 days (fo llow the Hepatic Adverse Eve nt Management 
Algorithm in the nivolumab Investig ator’s Brochure for appropriate management); 
• Discontinue NKTR-214 and nivolumab 
• 1 to 2 mg/kg/day prednisone equiva lents followed by [CONTACT_804546] 
• Consult gastroenterologist 
• Consider adding non-corticostero id immunosuppressive medication  if no 
improvement in > 3-5 days, worsens or rebounds while on steroid s 
− ALT or AST > 8.0 × ULN (follow Hepatic Adverse Event Management  Algorithm in 
the nivolumab Investigator’s Broc hure for appropriate managemen t) 
• Discontinue NKTR-214 and nivolumab 
• Increase frequency of monitoring to approximately 1-2 days 
• Treat with 1 to 2 mg/kg/day predni sone equivalents followed by [CONTACT_804547] 
• Consult gastroenterologist 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 68 of 149 
Confidential and Proprietary  27 May 2021 • If no improvement in > 3–5 days, worsens or rebounds, add non-corticosteroid 
immunosuppressive medication 
Please refer to Section 6.5.5 for discontinuation criteria. 
6.5.4 Criteria to Resume NKTR- 214 and/or Nivolumab Dosing 
Patients may resume treatment w hen the drug-related AE resolves to Grade ≤ 1 or baseline, with 
the following exceptions: 
• Patients who delayed dosing for acute infection requiring syste mic antibiotic therapy must be 
free of signs or symptoms of i nfection for 72 hours after completion of antibiotic therapy 
prior to resuming s tudy treatment. 
• Patients may resume treatment in the presence of Grade 2 fatigu e. 
• Patients who have not experience d a Grade 3 drug-related skin A E may resume treatment in 
the presence of Gra de 2 skin toxicity. 
• Patients with Grade [ADDRESS_1110453]/ALT and/or total bilirubin abnormalit ies, dosing may resume 
when laboratory values return t o baseline and management with corticosteroids, if needed, is 
complete. 
• Drug-related pulmonary toxicit y, diarrhea, or colitis must have  resolved to baseline before 
resuming treatment. Patients w ith persistent Grade [ADDRESS_1110454] 1 month may be eligible for retreat ment if discussed with and 
approved by [CONTACT_25290] (or designee). 
• Patients with drug-related endocri nopathies adequately controll ed with only physiologic 
hormone replacement may resume treatment after consultation wit h the Medical Monitor (or 
designee). Grade ≥ 3 adrenal i nsufficiency or Grade ≥ 4 hypophysitis require discontinuation 
regardless of control with hormone replacement. Hospi[INVESTIGATOR_804496] s evere symptoms should not requir e discontinuation .  
• For patients who must delay st udy treatment due to Grade ≥ 2 creatinine incr ease due to a 
non-inflammatory cause (see Section 6.5.1), delay retreatment with study drug for 
approximately 3 to 5 days. After t he dosing delay, the patient may resume study drug when 
serum creatinine has returne d to Grade ≤ 1, as assessed within 24 hours or as soon as locally 
feasible, prior to red osing with study drug, except where perma nent discontinuation of study 
drug is required (see Section 6.5.5). 
6.5.5 Permanent Treatment Discontinuation Criteria 
Patients meeting any of the following criteria will be required  to permanently discontinue all 
assigned study drug(s). However, pe r Investigator assessment, t reatment with NKTR-214 or 
nivolumab alone may continue as a monotherapy if the toxicities  listed below are considered 
related to only one of the study drugs, and once the criteria to resume are met (Secti
on 6.5.4). For 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 69 of 149 
Confidential and Proprietary  27 May 2021 CVA events and suspected TIA events, follow the criteria descri bed below (additional details are 
provided in the CVA management algorithm in Appendix 4).  
• Any ≥ Grade 2 drug-related uveitis , eye pain, or blurred vision  that does not respond to 
topi[INVESTIGATOR_344706] 1 severity within  8 weeks or requires systemic 
treatment. 
• Any Grade ≥ 2 drug-related pneumonitis or interstitial lung dis ease that does not resolve 
following dose delay and systemic steroids (also see Pulmonary Adverse Event Management 
Algorithm in the nivolumab I nvestigator’s Brochure). 
• Any ≥ Grade 3 non-skin, drug-related AE lasting > 7 days, with the following exceptions for 
uveitis, pneumonitis, bronchospasm, diarrhea, colitis, neurolog ic toxicity, hypersensitivity 
reactions, endocrinopathies, a nd laboratory abnormalities: 
o Grade 3 drug-related uveitis, pneumonitis, bronchospasm, diarrh ea, colitis, neurologic 
toxicity, or hypersensitivity reaction of any duration requires discontinuation. 
o Grade 3 drug-related endocrinopathie s (excluding adrenal insufficiency) adequately 
controlled with only physiologic hormone replacement do not req uire discontinuation.  
o Grade 3 drug-related laboratory a bnormalities do not require treatment discontinuation 
except: 
− Grade 3 drug-related thrombocyt openia > 7 days or associated with clinically 
significant bleeding requ ires discontinuation. 
− Any drug-related liver function test abnormality that meets the  following criteria 
require discontinuation (also see Hepatic Adverse Event Managem ent Algorithm in 
the nivolumab Investigator’s Brochure): 
 AST or ALT > 5 × ULN to 8 × ULN for > 2 weeks 
 AST or ALT > 8 × ULN 
 Total bilirubin > 5 × ULN 
 Concurrent AST or ALT > 3 × ULN  and total bilirubin > 2 × ULN 
In most cases of Grade [ADDRESS_1110455] or  ALT elevation, study treatment will be permanently 
discontinued. If the Investigat or determines a possible favorable benefit/risk rat io that warrants 
continuation of study treatment, a discussion between the Investigator and the Medical 
Monitor/designee must occur. For  IL-2-mediated ALT/AST elevatio ns < 8.0 × ULN in Cycle 1 
only, study treatment does not need  to be discontinued (see Sec tion 6.5.3 ). 
• Any Grade 4 drug-related AE or lab oratory abnormality, except f or the following events, 
which do not require discontinuation: 
o Grade 4 neutropenia ≤ 7 days 
o Grade 4 lymphopenia or leukopenia ≤ 14 days in duration 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 70 of 149 
Confidential and Proprietary  27 May 2021 o Isolated Grade 4 amylase or lip ase abnormalities that are not a ssociated with symptoms 
or clinical manifestations of pancreatitis and decrease to Grad e < 4 or return to baseline 
within 7 days. 
o Isolated Grade 4 electrolyte imb alances/abnormalit ies that are not associated with 
clinical sequelae and are corre cted with supplementation/approp riate management 
within 72 hours of their onset. 
o Grade 4 drug-related endocrinopath y adverse events (except adre nal insufficiency or 
hyophysitis) such as hyper- or hypot hyroidism or glucose intole rance, which resolve or 
are adequately controlled wit h physiologic hormone replacement (corticosteroids, 
thyroid hormones) or glucose-controlling agents, respectively, may not require 
discontinuation after discussion w ith and approval from the Medical Monitor. 
− Note:  For Grade ≥ 3 adrenal insufficiency and/or Grade ≥ [ADDRESS_1110456] less of control with hormone rep lacement 
(Hospi[INVESTIGATOR_804497] w orkup of adrenal  insufficiency  without severe 
symptoms should not requi re discontinuation). 
• Any AE, laboratory abnormality, or intercurrent illness that, i n the judgment of the 
Investigator, presents a substant ial clinical risk to the patie nt with continued treatment. 
• Any new CVA event confirmed by [CONTACT_92156] (diffusion-weighted imag ing [DWI] MRI 
preferred unless otherwise contra indicated) regardless of neurological symptoms (e.g. 
cryptogenic CVA) and for suspect ed TIA without clear alternativ e etiology (see Appendix 4). 
Tumor assessments should continue as per protocol even if dosin g is delayed, and patients must 
otherwise meet the criteria for continued treatment at the time  re-initiation of study therapy is 
considered.  
6.6 Management of Specific Adverse Events 
6.6.1 Management Algorithms for Immune -mediated AEs and Cytokine-release 
Syndrome Associated with Immuno-Oncology Agents 
[IP_ADDRESS] Management Algorithms for Immune-mediated AEs Associated with I mmuno-
Oncology Agents 
Immuno-oncology agents are associ ated with AEs that can differ in severity and duration from 
AEs caused by [CONTACT_20451]. Nivolumab and NKTR-214  are considered 
immuno-oncology agents in this pr otocol. Early recognition and management of AEs associated 
with immuno-oncology agents may mitigate severe toxicity. Manag ement algorithms including 
the use of systemic corticoste roids (see the nivolumab Investig ator’s Brochure and product 
labeling) have been developed to assist Investig ators in assess ing and managing AEs related to 
the following organs/systems:  
• Gastrointestinal 
• Renal 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 71 of 149 
Confidential and Proprietary  27 May 2021 • Pulmonary 
• Hepatic 
• Endocrinopathy 
• Skin 
• Myocarditis 
• Neurological 
and  
• Other immune-mediated AEs (as  defined in the nivolumab Investig ator’s Brochure) 
 
[IP_ADDRESS] Management Algorithm for Cytokine Release Syndrome 
Cytokine-release syndrome (CRS) is a clinical diagnosis with a constellation of symptoms often 
characterized by [CONTACT_411], tachypn ea, headache, tachycardia, hypot ension, rash, and/or hypoxia 
caused by [CONTACT_804548] s. In addition, diarrhea and e nd organ dysfunction can be seen 
in CRS. Many of these symptoms overlap with known AEs seen in N KTR-214 and nivolumab 
combination therapy (ie, pyrex ia and hypotension). These sympto ms may be seen in infusion 
reactions as well as  other known syndromes, such as tumor lysis  syndrome and macrophage 
activation syndrome. For suspected CRS of Grade [ADDRESS_1110457] signs or symptoms  of hypophysitis or adrenal 
insufficiency which includes le vels of early-morning ACTH, cort isol, thyroid-stimulating 
hormone (TSH), and free thyroxine (T4).  Co-management with a n endocrinologist is 
recommended for patients with pre- existing adrenal insufficiency. 
6.6.3 Monitoring and Management of Eosinophilia 
[IP_ADDRESS] NKTR-214-induced Eosinophilia 
Frequent and significant eosinophi lia has been observed in patients receiving NKTR-214, 
primarily starting at Cycle [ADDRESS_1110458] of IL-2 t herapy. The eosinophilia patter n demonstrates a cyclic waxing 
and waning pattern whereby [CONTACT_804549]  7 days after each infusion and 
wane before the patient’s next infusion.  
Absolute eosinophil count (AEC) should be closely monitored per protocol. If a study patient is 
suspected to have eosinophilic disorder (symptoms  may involve skin, lungs, digestive tract, 
heart, blood, and nervous systems ) with AEC at or above the 5000/µL (5 × 109/L) level, delaying 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 72 of 149 
Confidential and Proprietary  27 May 2021 NKTR-214 treatment may be considered while evaluating and treat ing the patient  as clinically 
indicated.  
[IP_ADDRESS]  Eosinophilic Disorders 
Isolated cases of hypereosinophili c syndrome (HES) and drug rea ction with eosinophilia and 
systemic symptoms (DRESS) have b een reported. If there is clini cal concern for an eosinophilic 
disorder, the Investigator is en couraged to contact [CONTACT_46449]. 
Additional details regarding eos inophilia and eosinophilic diso rders are provided in the 
Bempegaldesleukin (NKTR-214)  Investigator’s Brochure. 
 
6.6.4 Treatment of Study Drug-Related Infusion Reactions for NKTR-214 /Nivolumab 
Infusion reactions have been reported during infusions with NKTR-[ADDRESS_1110459] with 
fever, chills, rigors, headache , rash, pruritus, arthralgia, my algia, hypotension, hypertension, 
bronchospasm, or other hypersensitivity/allergic-like reactions . Infusion reactions should be 
graded as described in Section 9.1.3 ). 
Treatment recommendations are p rovided below and may be modifie d based on local treatment 
standards and guideline s, as appropriate. 
For Grade 1  symptoms (mild reaction; infusion interruption not indicated; intervention not 
indicated): 
• Remain at the bedsid e and monitor the patient until recovery from symptoms. The following 
prophylactic premedications are r ecommended for future infusions:  diphenhydramine 50 mg 
(or equivalent) and/or acetaminophen/paracetamol [ADDRESS_1110460] 30 minutes before 
subsequent infusions. 
For Grade 2  symptoms (moderate reaction re quires therapy or infusion inter ruption but responds 
promptly to symptomatic treat ment [e.g., antihistamines, nonste roidal anti-infl ammatory drugs, 
narcotics, corticosteroids, br onchodilators, IV fluids]; prophy lactic medications indicated for 
≤ 24 hours): • Stop study drug infusion, begin a n IV infusion of normal saline , and treat the patient with 
diphenhydramine 50 mg IV (or equivalent) and/or acetaminophen/p aracetamol 325 to 
1000 mg; remain at the bedside and monitor the patient until re solution of symptoms. 
Corticosteroid and/or bronchodila tor therapy may also be admini stered as appropriate. If the 
infusion is interrupted, then restart the infusion at 50% of th e original infusion rate when 
symptoms resolve; if no further  complications ensue after 30 minutes, the rate may be 
increased to 100% of the original i nfusion rate. If symptoms re cur after restarting the 
NKTR-214 or nivolumab infusion, then no further drug will be administered at that visit. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 73 of 149 
Confidential and Proprietary  27 May 2021 Consider administr ation of another do se of diphenhydramine 50 m g IV, remain at the 
bedside, and monitor the patient  until resolution of symptoms. 
• For future infusions, the following prophylactic  premedications are recommended:  
diphenhydramine 50 mg (or equivale nt) and/or acetaminophen/para cetamol [ADDRESS_1110461]  30 minutes before the infusion.  If necessary, corticosteroids 
(up to 25 mg of methylprednisolone or equivalent) may be used. 
For Grade 3  or Grade 4  symptoms (severe reaction, Grade 3:  prolonged [i.e., not rapi [INVESTIGATOR_804498]/or brief interruption of infusion]; recurrence of 
symptoms following initial impr ovement; hospi[INVESTIGATOR_327620] 
[e.g., renal impairment,  pulmonary infiltrat es]. Grade 4:  life-threatening; presso r or ventilatory 
support indicated): 
• Immediately discontinue infus ion of study drug. Begin an IV infusion of normal saline and 
treat the patient as follows:   recommend bronchodilators, epi[INVESTIGATOR_53311] 0.2 to 1 mg of a 
1:1000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution 
injected slowly for IV adminis tration, and/or diphenhydramine 5 0 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Nivolu mab and NKTR-214 will 
be permanently discontinued. T he patient should be monitored un til the Investigator is 
comfortable that the symptoms wi ll not recur. Inv estigators sho uld follow their institutional 
guidelines for the treatment of anaphylaxis. Remain at the bedside and monitor the patient until recovery of the symptoms. 
In case of late-occurring hypersensitivity symptoms (e.g., appe arance of a localized or 
generalized pruritus within 1 wee k after treatment), symptomatic treatment may be given 
(e.g., oral antihistamine or corticosteroids). 
6.6.5 Monitoring and Management of Ele vated Hepatic Transaminases 
Elevated hepatic transaminases  are an overlappi[INVESTIGATOR_197200]-214 
and nivolumab. The elevations in he patic transaminases associated with NKTR-214 typi[INVESTIGATOR_804499] (Days  4-8), and are often 
accompanied by [CONTACT_804550]-2-mediate d toxicities such as flu-like symptoms, rash or pruritus. The 
transient elevations in hepatic transaminases are usually asymp tomatic, mild or moderate in 
severity, not associated with i ncreased total bilirubin and alk aline phosphatase, resolve 
spontaneously without treatment , and predominantly occur in Cyc le 1 and Cycle 2; the 
transaminase elevations are cons idered to occur in the context of IL-[ADDRESS_1110462] without 
alternative etiologies, follow the Cycle 1 hepatic adverse even t management guideline 
(Section 6.5.3 ). 
Hepatic events, including elevated liver function tests, have a lso been observed for nivolumab. 
Most cases were of low or moderate severity. Higher grade abnor malities are concerning for 
immune-mediated hepatitis, and typi[INVESTIGATOR_197202] a later ons et (median time to onset of 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 74 of 149 
Confidential and Proprietary  27 May 2021 3.3 months). Immune mediated hepatitis generally results in a q uick rise in liver function tests, 
and responds to corticosteroids or immune-modulating agents. Fo r transaminase elevations 
occurring in Cycle 2 onwards poten tially involving an immune-me diated mechanism, follow the 
immune-mediated hepatic adverse event management guidelines in the nivolumab I nvestigator’s 
Brochure for appropriate management. 
6.7 Prior and Concomitant Medications 
All medications (prescription a nd over-the-counter [OTC]), vita min and mineral supplements, 
and/or herbs taken by [CONTACT_804551] 10 0-day follow-up visit will be 
documented and recorded, inclu ding start and s top date, dose an d route of administration, 
frequency, and indication. Medicatio ns taken for a procedure (e.g., biopsy) or prophylaxis of an 
infusion-related react ion should also be inc luded. Recording of  prior medications should include 
prior cancer treatments:  prev ious immunotherapy, chemotherapy, targeted therapy, radiation, 
OTC medications, herbs, and dietary supplements. 6.7.1 Premedication 
Pre-medication with either aceta minophen or ibuprofen for flu-l ike symptoms can be initiated on 
either Day 1 or 2 of the dosing c ycle and may continue through Day 5 or longer as needed at the 
discretion of the Investigator. 
Pre-medication for ras h and/or pruritus with anti-histamines can be initiated on either Day 1 or 2 
of the dosing cycle and may continue through Day 5 or longer as needed at the discretion of the 
Investigator. 
6.7.2 Permitted Concomitant Medications 
Patients are permitted to use topi[INVESTIGATOR_2855], ocular, intra-articular,  intranasal, and inhalational 
corticosteroids (with minimal sy stemic absorption). Patients wi th pre-existing adrenal 
impairment requiring corticosteroid supplementation may be at increased risk for hypotensive 
epi[INVESTIGATOR_197191]-214. For these patients, their existing corticosteroid dose 
may be increased to adrenal repl acement steroid doses > [ADDRESS_1110463] 4 days after administration of NKTR-2 14 based on an assessment of the 
degree of adrenal impairment and the extent of existing cortico steroid supplementation. A brief 
(less than 3 weeks) course of cor ticosteroids f or prophylaxis ( e.g., contrast dye allergy) or for 
treatment of nonautoimmune conditions (e.g., delayed-type hyper sensitivity reaction caused by a 
contact [CONTACT_20435]) is permitted. Use of corticosteroids for the management of immune mediated 
AEs as outlined in the nivolumab I nvestigator’s B rochure is permitted. 
Palliative radiation to a symptom atic, solitary lesion may be c onsidered on a case by [CONTACT_804552]. The radiation treatment f ield may not incl ude a target or 
measurable lesion by [CONTACT_393] 1.1. 
Administration of vaccines  is addressed in Section 6.7.4. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 75 of 149 
Confidential and Proprietary  27 May 2021 [IP_ADDRESS] Thromboembolism Prophylaxis and Treatment 
Patients with a history of a venous  or arterial thromboembolic event must be receiving a stable 
regimen of therapeutic anticoa gulation. Anticoagulation options  include the following: 
• Low molecular weight heparin (LMWH). 
• Oral factor Xa inhibitors (dir ect oral anti-coagulants [DOAC]) such as rivaroxaban, 
api[INVESTIGATOR_3822], or edoxaban). 
• Use of warfarin (Coumadin) is p ermitted; however, therapeutic d osing should target a 
specific INR stable for at leas t 4 weeks prior to enrollment. S ee Section [IP_ADDRESS]. 
Unless there is a new medical c ontraindication observed after C ycle [ADDRESS_1110464] be maintained on therapeutic 
anticoagulation throughout the patie nt’s participation in the s tudy (i.e., through the EOT visit; 
see Section 4.1.3). 
If anticoagulation is being newly introduced or adjusted, the Investigator may consider 
consulting the Medical M onitor for guidance. 
6.7.[ADDRESS_1110465] of NKTR-214 on PK of C oncomitant Medications 
NKTR-214 causes transient increas es in circulating cytokines la sting for about one week after 
NKTR-214 dosing in the q3w dosing sch edule. Several of these cytokines (IFN-γ, IL-6, IL-10) 
have the potential to decrease th e activity of mu ltiple drug me tabolizing enzymes and drug 
transporters. Consequently, tr eatment with NKTR-214 may lead to a temporary decrease in 
clearance of drugs that are subs trates of metabolizing enzymes or drug transporters. Where 
indicated based on decreased tolerability or the occurrence of adverse effects related to a concomitant drug, reduce the dos age of the concomitant drug dur ing Days 3 to 8 of each cycle of 
NKTR-214.  
[IP_ADDRESS] Interaction of NKTR-[ADDRESS_1110466] 4 weeks prior to NKTR- 214 administration. Because NKTR-214 has the potential to 
down regulate metabolizing enzymes  for warfarin for approximate ly 1 week after administration 
of each dose of NKTR-214, freque nt monitoring of INR and ongoing consideration of dose 
adjustments are warranted  throughout the patient’s participati on on study. 
6.7.4 Prohibited Concomitant Medications  
The following medications are prohibited: 
• Immunosuppressive agents such a s cyclosporine, tacrolimus, or s irolimus 
• Immunosuppressive doses of systemi c corticosteroids (except as stated in Section 6.7.2 ) 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 76 of 149 
Confidential and Proprietary  27 May 2021 • Any antineoplastic therapy (i.e ., chemotherapy, hormonal therapy, immunotherapy, extensive 
nonpalliative radiation therapy, or  investigational agent) is p rohibited during the study  
• Any live/attenuated vaccine (e.g., v aricella, zoster, yellow fe ver, rotavirus, oral polio and 
measles, mumps, rubella [MMR ]) during treatment and until [ADDRESS_1110467] severe acute respi[INVESTIGATOR_11520] 2 (SARS-Co V-2; COVID-19) are allowed on tr eatment. For any 
questions about COVID vaccines, please contact [CONTACT_1689]. 
• Low dose acetylsalicylic acid (a pproximately 81 mg/day) should not be combined with 
LMWH or DOAC due to incre ased risk of hemorrhage. 
6.[ADDRESS_1110468] specifics to study drug dispensation such as: 
• Records of product delivery, inve ntory, temperature monitoring,  time when drug vial is 
removed from freezer or  refrigerator, dest ruction, and return a s per Sponsor’s instructions. 
• Doses prepared, time pre pared, doses dispensed. 
• Doses and/or vials destroyed. 
The Drug Accountability Log will be reviewed by [CONTACT_804553]. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 77 of 149 
Confidential and Proprietary  27 May 2021 7.0 STUDY ASSESSMENTS AND PROCEDURES 
Assessments for efficacy, and PK are described below . See Section 9.0 for safety 
assessments, including AEs, clini cal laboratories, physical exa minations, vital signs, and other 
safety assessments. 
7.1 Tumor and Radiographic Assessments 
Tumor assessments for all patients will be performed at Screeni ng and every 9 weeks (± 7 days) 
from Cycle [ADDRESS_1110469] 12 months. Beyond 12 months, t umor assessments will decrease 
in frequency to every 12 weeks (± 7 days). A scan should also be done at EOT (unless a scan 
was done within the prior 4 weeks). Tumor response will be evaluated using RECIST 1.1 as the 
primary measure (Section 8.0). 
Patients who continue treatme nt beyond progression should conti nue to have scans every 
9 weeks (± 7 days) for the firs t [ADDRESS_1110470]-pr ogression and every 12 weeks 
(± 7 days) in the second year of t reatment post-pr ogression (for a maximum treatment duration 
of 2 years from the beginning of the study). 
Patients who discontinue study t reatment and do not have BICR-c onfirmed disease progression 
should continue to have scans ev ery 90 days (± 10 days) during the follow-up period if clinically 
feasible, until disease progre ssion is confirmed by [CONTACT_19377]. Scans should continue to be collected 
even if a new antineoplastic regimen has been initiated. 
Radiographic assessments (chest/a bdomen/pelvis) are required fo r all patients for tumor 
measurements. A magnetic reso nance imaging (MRI) scan of the br ain must be done within 
28 days prior to enrollment to dete rmine the presence of CNS me tastases at baseline. If the 
screening brain MRI reveals no evi dence of disease follow-up br ain imaging does not need to be 
done on subsequent tumor evaluatio ns unless clinically indicate d. Computed tomography (CT) 
scan of the brain (with contrast)  can be performed if MRI is co ntraindicated or not  available. If 
contrast is contraindicated in t he patient, CT of the brain wit hout contrast can be performed. An 
MRI of the brain is required to c onfirm or refute the diagnosis  of CNS metastases at baseline in 
the event of an equivocal CT scan. Documented tumor measurements a re required using CT scans, MRI,  physical examination, 
and/or digital photography, as a ppropriate. Any imaging used to  assess disease at any time point 
will be submitted for an independent radiology review. The same method of assessment (CT  or MRI) and the same techniqu e for acquisition of images 
must be used for all study assess ments (contras t must be used unless medically contraindicated). 
Radiographic assessments and efficacy analyses will be conducte d by [CONTACT_804554]. 

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 78 of 149 
Confidential and Proprietary  27 May 2021 7.1.1 Central Imaging 
Sites should submit all scans to the imaging core laboratory on  the schedule outlined in the Study 
18-214-10 Imaging Manual, through out the duration of the study.  BICR of scans will occur on a 
rolling basis, blinded to Investig ator assessment of submitted scans. Clinical information 
(palliative radiothe rapy on-study, surgical excision of any les ion, details of paracentesis and 
thoracocentesis) must be provide d to the BICR team. All details  on the timelines and associated 
process requirements will be out lined in the Imaging Manual. 
 All study treatment decisions w ill be based on the Investigato r’s assessment of tumor images 
and not on the BICR assessment.  
7.2 Pharmacokinetic and Immunogenicity Measurements  
Pharmacokinetic and immunogenicit y assessment data will be collected from study patients  at 
the time points indicated in Table 3 . All time points are relative to the start of NKTR-214 
infusion. All on-treatment time  points are intended to align wi th days on which study drug is 
administered; if dos ing occurs on a different day, the PK and immunogenicity sampling should 
be adjusted accordingly. If it is known that a dose is going to  be delayed, then the predose 
sample should be collected just prior to the delayed dose. Howe ver, if a predose sample is 
collected but the dose is subse quently delayed, an additional p redose sample should not be 
collected. All predose samples should be collected within 24 ho urs before the start of any dose 
infusion. 
Serum PK samples will be analyzed for nivolumab by a validated ligand binding assay. Plasma 
PK samples will be analyzed for NKTR-214-RC (related cytokines; mixture of compounds 
containing IL-2 independent of P EG conjugation status) and tota l PEG (mixture of compounds 
containing PEG independent of con jugation status to IL-2) by [CONTACT_804555]-214-AC (active cyto kines; mixture of 2-PEG-IL-2, 1 -PEG-IL-2 and free IL-2) by 
a qualified ligand binding assay. 
Pharmacokinetic data obtained in this study may be combined wit h data from other studies in the 
clinical development program to develop population PK models. T hese models may be used to 
evaluate the effects of intrins ic and extrinsic covariates on t he PK of NKTR-214 and/or 
nivolumab and to determine measur es of individual exposure (such as steady-state peak, trough 
and time-averaged concentration) . Model predicted exposures may  be used for exposure 
response analyses of selected e fficacy and safety endpoints. If the analyses are conducted, the 
results of population PK and expos ure response analyses will be  reported separately. 
Validated methods to detect an ti-nivolumab, anti-NKTR-214, anti-PEG, and anti-IL-2 anti-drug 
antibodies (ADA) will be used to analyze the immunogenicity sam ples. Immunogenicity sample 
testing will be done in tiers as per the 2019 FDA guidance (FDA 2019). Samples will be first 
tested with screening electrochemiluminescen ce assays (ECLA). P utative positive samples for 
anti-nivolumab, anti-NKTR-214, o r anti-IL-2 ADA will then be an alyzed in competition ECLA 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 79 of 149 
Confidential and Proprietary  27 May 2021 to confirm positivity. Confirme d anti-NKTR-214 ADA positive samples will be tested further in 
a PEG immunocompetition assay to d etermine the an tibody specifi city of the reactivity to the 
PEG or non-PEG (IL2, linker) mo iety of NKTR-214. Confirmed positive samples from anti-
nivolumab, anti-NKTR-214, and anti-IL2 ADA assays will then be tested to obtain a titer. 
Samples confirmed to be positive fo r anti-nivolumab, anti--NKTR -214, and anti-IL2 ADA may 
also be tested for neutralizing a ctivity for IL-2 and nivolumab  using validated cel l-based assays. 
PK samples may be analyzed by [CONTACT_1629] e xploratory method that measur es anti-drug antibodies for 
technology exploration purposes; exploratory results will not b e reported. Blood samples from 
PK or biomarker assessment may a lso be used for immunogenicity analysis if re quired (e.g., 
insufficient volume for comple te immunogenicity assessment or t o follow-up on suspected 
immunogenicity related AE). 
For all PK blood samples, the da te and actual time of collectio n must be recorded.  For patients 
whose only peripheral access is via a venous access device or p eripherally inserted central 
catheter, refer to the Laboratory  Manual for the proper techniq ue to ensure undiluted whole 
blood for PK assessments. Depending on the ability to process these samples, storage faci lities, or availability of courier 
pi[INVESTIGATOR_9107]/dry ice, individual sites  may opt out of these PK and immunogenicity assessments. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110471] patients with locally advanced or 
metastatic urothelial carcinoma who are cisplatin-ineligible fo r treatment with pembrolizumab. 
This assay is a qualitative imm unohistochemical assay using mon oclonal mouse anti-PD-L1, 
clone 22C3 for the detection of P D-L1 protein in FFPE tissues u sing EnVision FLEX 
visualization system on Autostainer Link 48 ( Dako North America Inc., 2018 ). PD-L1 protein 
expression in urothelial carcinom a is determined by [CONTACT_804556], which is the number of PD-L1 
staining cells (tumor cells, l ymphocytes, macrophages) divided by [CONTACT_804557], multip lied by 100. The specimen should be consider ed to have low PD-L1 
expression if CPS < 10. The specimen should be considered to ha ve high PD-L1 expression if 
CPS ≥ 10. Samples that have < 100 evaluable cells are considere d not evaluable. 
The clinical validity of PD-L 1 IHC 22C3 pharmDx in evaluating PD-L1 expression in patients 
not eligible for cisplatin-cont aining chemotherapy with locally  advanced or metastatic urothelial 
carcinoma is based on the pembroliz umab Keynote-052 study. Thirty percent of enrolled patients 
(110 of 370) had tumors that express ed PD-L1 with a CPS of grea ter than or equal to 10 (CPS ≥ 
10) and 70% (251 of 370) had a CPS less than 10 (CPS < 10) ( Agilent Technologies, Inc., 2018 ). 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
  

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110472] be provided during Screening. The fol lowing biopsy types are 
allowed: 
• core biopsy 
• punch biopsy 
• excisional biopsy 
• surgical specimen 
Biopsies should be performed on lesions that have not been expo sed to prior radiation. Tumor 
lesions used for biopsy should not be classified as target lesions, unless there are no other lesions 
suitable for biopsy.  
The following are not acceptable for submission: • Fine needle biopsies  
• Biopsies of bone lesions that do no t have a soft tissue compone nt.  
Sufficient, recent tumor tissu e FFPE block or minimum of [ADDRESS_1110473] rec eived any systemic anticancer 
therapy after the date that the submitted tumor tissue was obta ined. Please obtain consent to 
access archival tumor tissue. These biopsy samples are sent directly to a sponsor designated 
central lab for PD-L1 testing. 
 
 
 
 
 
An optional on-treatment tumor tis sue sample will be collected prior to Cycle 2 Day 1, on 
Days 14 to 21 of Cycle 1 (Table 4 ). This on-treatment bi opsy is optional but highly 
recommended. An optional tumor biopsy will also be collected upon recurrence when safe and feasible. These optional biopsie s should only be performed if t hey can be safely obtained. The 
assessment of the risk to the pa tient lies solely with the treating physician. These samples may 
be used for the assessment of markers implicated in resistance to immunotherapeutic agents, 

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 83 of 149 
Confidential and Proprietary  27 May 2021 including but not limited to other CD8+ T-cell checkpoint recep tors and ligands (e.g., Lag-3, 
Tim-3), mutations in cancer relat ed genes, and intratumoral imm une cell subsets, including but 
not limited to, Tregs and myeloid derived suppressor cells (MDS Cs).  
 
Both the pre-treatment tumor 
sample and the sample collected on-treatment and upon recurrenc e may be retrospectively 
assessed for the expression of other immune or urothelial carci noma related genes, RNAs 
and/or proteins, or for the presence of immune cell populations using a variety of 
methodologies inclusive of, but n ot limited to IHC, qRT-PCR, ge nomics, genetic mutation 
detection, and fluorescent in-situ hybridization. 
Table 4: Tumor Biopsy Sampling Schedule 
Collection Timing Tumor Biopsy 
Screening Xa
Cycle 1 Days 14-21b X 
Upon progressionb X 
a. Unstained formalin-fixed paraffin-embedded (FFPE) tumor tiss ue sections on slides (minimum of 10, 
preferably 15 to 25) or a FFPE tumor tissue block, collected wi thin 12 months prior to enrollment and without 
intervening therapy, are accepta ble in lieu of a fresh tumor biopsy prior to treatment. 
b. Sample collection is optional but highly recommended. 
 
7.5.1 Tumor Mutation Burden 
Tumor mutation burden (TMB) refe rs to the total number of nonsy nonymous somatic mutations 
that exist within a tumor’s genom e. A subset of these mutations , termed neo-antigens, may result 
in an expressed protein that is  not recognized by [CONTACT_40689]’s im mune system as self, and therefore 
has the potential to be immunogeni c, leading to an anti-tumor immune-mediated response. 
Tumors with a high mutation burden  may have a higher rate of ne o-antigens that, in principle, 
would be expected to be more immunogenic than tumors with compa ratively low mutation 
burden ( Goodman, 2017). Therefore, high TMB has bee n hypothesized to correlate with 
improved efficacy in patients tre ated with immuno-oncology therapi[INVESTIGATOR_014]. This hypothesis has been 
supported in multiple publicati ons across immuno-oncology therapi[INVESTIGATOR_014], tumor types, and lines of 
treatment. Published studies of TMB  as a biomarker of clinical outcomes was reported by 
[CONTACT_8482], 2014, 2017, where high TMB was found to be associated with efficacy in UC  and 
melanoma patients tr eated with anti-CTLA- 4 therapy. Further stu dies by [CONTACT_359320], 2015 reported 
TMB as a biomarker of pembroliz umab efficacy in second-line NSCLC patients and nivolumab 
plus ipi[INVESTIGATOR_804500] 1L NSCLC patients ( Hellmann, 2018 ). 
The recent study of atezolizumab in platinum-treated locally ad vanced or metastatic UC also 
suggests high TMB is associated with improved response. TMB was  also evaluated in post hoc 

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 84 of 149 
Confidential and Proprietary  27 May 2021 analysis in the BMS-sponsored second-line UC Phase 2 CheckMate 275 study. The results 
demonstrated that high TMB wa s significantly associated with hi gher ORR, longer PFS, and 
longer OS in patients tr eated with nivolumab ( Galsky, 2017 ). Moreover, patients with high TMB 
derived benefit from nivolumab a cross tumor PD-L1 expression levels.  
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
7.6 Sample Collection and Storage 
This protocol will include residual sample storage for additional research.  

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 85 of 149 
Confidential and Proprietary  27 May 2021 All requests for access to samples or data for additional research will be vetted through a diverse 
committee of the Sponsor’s senio r leaders in Research and Devel opment (or designee) to ensure 
the research supports appropriate  and well-defined scientific r esearch activities.  
Additional research is optional for all study patients, except where retention and/or collection is 
prohibited by [CONTACT_804558], ethic s committees, or institutional requirements.  
This collection for additional research is intended to expand the translational research and 
development capability at the Sponsor, and will support as yet undefined research aims that will 
advance our understanding of dise ase and options for treatment.  It may also be used to support 
health authority requests for analysis, and advancement of phar macodiagnostic d evelopment to 
better target drugs to the right patients.  
 
  
Samples kept for future research will be stored at the Sponsor’ s Biorepository or an independent, 
Sponsor-approved storage vendor. The  manager of these samples w ill ensure they are properly 
used throughout their usable life and will destroy the samples at the end of the scheduled storage 
period, no longer than [ADDRESS_1110474] a sample to a specific individual.  
Further details of sample collection and processing will be pro vided to the site in the Laboratory 
Manual. 
7.7 Health-Related Quality of Life (HRQoL) 
The evaluation of health-relate d quality of life (HRQoL) is an increasingly important aspect of 
clinical efficacy in oncology trials. Such data provide an unde rstanding of the impact of 
treatment from the patient’s pers pective and offer insights int o patient experience that may not be 
captured through physician reporti ng. Additionally, generic HRQ oL measures provide data 
needed for calculating utility va lues to inform health economic models. At each visit specified in 
Table 3 , prior to any other study assessments, HRQoL will be assessed.   
Patients will be asked to comple te the 3-level version of the E uroQol Group’s EQ-5D 
(EQ-5D-3L) and EORTC Quality of L ife Questionnaire (QLQ-C30) du ring screening, after 
enrollment but prior to first  dose, at on-study clinic visits occurring every [ADDRESS_1110475] be performed after dosin g on Cycle 1 Day 1; at all other 
study visits specified in Table 3 , FACIT GP5 should be performed prior to any other study 
assessments. 

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 86 of 149 
Confidential and Proprietary  27 May 2021 The questionnaires will be provi ded in the patient’s preferred language. There exists a 
standardized guide that can be us ed to facilitate telephone adm inistration of the EQ-5D-3L. 
Additional information regard ing each test ca n be found below. 
7.7.1 FACIT GP5  
A single item, FACIT GP5, from th e Functional Assessment of Can cer Therapy - General 
(FACT-G), will be used to assess the extent of perceived bother due to symptomatic adverse 
events. Evidence exists for t he validity of thi s item and its u sefulness as an overall summary 
measure of burden due to symptom atic treatment toxicities ( Pearman, 2018). The item is rated on 
a 0 (not at all) to 4 (very much) Likert type scale. 
GP5 uses a recall period of the past 7 days. 
7.7.2 EORTC QLQ-C30 
The EORTC QLQ-C30 ( Aaronson, 1993) is the most commonly used qu ality of life instrument 
in oncology trials. The instrument’ s 30 items are divided among  five functional scales (physical, 
role, cognitive, emotional, and s ocial), nine symptom scales (fatigue, pain, nausea/vomiting, 
dyspnea, insomnia, appetite lo ss, constipation, diarrhea, and f inancial difficulties), and a global 
health/quality of life scale. W ith the exception of two items included in the globa l health/quality 
of life scale, for which responses range from  1 (very poor) to 7 (excellent), item responses range 
from 1 (not at all) to 4 (very muc h). Raw scores for the QLQ-C3 [ADDRESS_1110476] week. 
7.7.3 EQ-5D-3L 
The 3-level version of the EQ-5D (EQ-5D-3L) ( EuroQol Group, 1990 ) will be used to assess 
treatment effects on perceived he alth status and to generate ut ility data for health economic 
evaluations. The EQ-5D-3L is a ge neric multi-attribute health-state classification system by 
[CONTACT_470397] 5 dimensions:  mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression. Each dime nsion is evaluated using 3 lev els:  no problems, some 
problems, and severe problems. 
Responses to these 5 dimensions are converted into 1 of 243 uni que EQ-5D health state 
descriptions, which range betw een no problems on all 5 dimensio ns ([ZIP_CODE]) to severe/extreme 
problems on all 5 dimensions ([ZIP_CODE]). Using appropriate country -specific value weighting 
algorithms, a respondent’s self-described health state can be c onverted into a utility index 
representing the societal desirability of his or her own health. In addition, the EQ-5D includes a 
visual analogue scale (VAS) allo wing a respondent to rate his/h er health on a scale ranging from 
0-[ADDRESS_1110477] health state 
imaginable. The EQ-5D-3L uses a recall period of today. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110478] 1.1 ( Eisenhauer, 2009 ). Investigator assessed response will also be done according t o 
RECIST 1.1.   
Patients will be assessed for r esponse by [CONTACT_337349] 9 wee ks (± 7 days) for the first 
12 months and every 12 weeks (± 7 days) until progression or tr eatment discontinuation, 
whichever occurs later (see Section 7.1). A scan should also be done at EOT (unless a scan was 
done within the prior 4 weeks). Patients who continue treatme nt beyond progression should conti nue to have scans every 
9 weeks (± 7 days) for the firs t [ADDRESS_1110479]-pr ogression and every 12 weeks 
(± 7 days) in the second year of t reatment post-pr ogression (for a maximum treatment duration 
of 2 years from the beginning of the study). Patients who discontinue study t reatment and do not have BICR-c onfirmed disease progression 
should continue to have scans ev ery 90 days (± 10 days) during the follow-up period if clinically 
feasible, until disease progre ssion is confirmed by [CONTACT_19377]. Scans should continue to be collected 
even if a new antineoplastic regimen has been initiated. 
8.1 Definitions 
At baseline, tumor lesions/lymph nodes will be categorized as measurable or nonmeasurable as 
described below. 
8.1.1 Measurable Disease 
Target tumor lesions:  Must be accurately measured in at least 1 dimension (longest diameter in 
the plane of measurement is to be recorded) with a minimum size  of [ADDRESS_1110480] scan 
(CT scan slice thickness no greater than 5 mm); when CT scans h ave slice thickness greater than 
5 mm, the minimum size for a m easurable lesion should be twice the slice thickness. 
Malignant lymph nodes:  To be consi dered pathologically enlarge d and measurable, a lymph 
node must be ≥ [ADDRESS_1110481] scan (CT  scan slice thickness 
recommended to be no greater tha n 5 mm). At baseline and in follow-up, only the short axis will 
be measured and followed. 8.1.2 Nonmeasurable Disease 
All other lesions, including small lesions (longest diameter < 10 mm or pathol ogical lymph 
nodes ≥ 10 to < 15 mm in short axis ) as well as truly nonmeasurable lesions, are considered 
nonmeasurable disease. Lesions considered truly nonmeasurable i nclude:  leptomeningeal 
disease, ascites, pleural or pericardial effusion, lymphangitic  involvement of skin or lung, or 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 88 of 149 
Confidential and Proprietary  27 May 2021 abdominal masses/abdominal organomegaly identified by [CONTACT_804559]. 
8.2 Specifications by [CONTACT_804560] a nd during follow-up. Imagi ng-based evaluati on should always be done rather 
than clinical examination unless the lesion(s) be ing followed c annot be imaged but are assessable 
by [CONTACT_12148]. 
8.2.1 Clinical Lesions  
Clinical lesions will only be considered measurable when they are superficial and ≥ 10 mm 
diameter as assessed using calipers (e.g., skin nodules). When lesions can be evaluated by [CONTACT_804561], imaging evaluation should be undertaken since it is more 
objective and may also be review ed at the end of the study. For  cutaneous lesions that are 
included in target lesions, digital photographs should be obtained and utilized for measurement. 
8.2.[ADDRESS_1110482] currently avail able and reproducible method to measure lesions selected for 
response assessment. If a slice thickness > [ADDRESS_1110483] diameter for a target l esion should be twice the slice thickness. MRI is also acceptable in 
certain situations (e.g., for body scans). 8.2.[ADDRESS_1110484] normalize for a patient to be considered in CR. 
8.2.4 Cytology, Histology  
These techniques can be used to di fferentiate between PR and CR  in rare cases when the nature 
of a residual lesion is in question. The cytological confirmation of the neoplastic origin of any 
effusion that appears or worsens during treatment can be consid ered if the measurable tumor has 
met criteria for response or sta ble disease in order to differentiate between response (or stable 
disease) and PD. 
8.[ADDRESS_1110485] 1 measurable les ion. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 89 of 149 
Confidential and Proprietary  27 May 2021 8.3.2 Baseline Documentation of ‘Target’ and ‘Nontarget’ Lesions 
When more than 1 measurable lesi on is present at baseline, all lesions up to a maximum of 
5 lesions total (and a maximum of 2 lesions per organ) represen tative of all involved organs 
should be identified as target lesions and will be recorded and measured at baseline (this means 
that in instances where patie nts have only 1 or 2 organ sites i nvolved a maximum of 2 and 4 
lesions, respectively, w ill be recorded). Target lesions should  be selected on the basis of their 
size (lesions with the longest di ameter), be representative of all involved organs, but in addition 
should be those that lend themsel ves to reproducible repeated m easurements. It may be the case 
that, on occasion, the largest les ion does not lend itself to r eproducible measurement, in which 
circumstance the next l argest lesion which can be measured repr oducibly should be selected. 
Pathological nodes which are defi ned as measurable and may be i dentified as target lesions must 
meet the criterion of a short axis of ≥ [ADDRESS_1110486] scan. Only the short axis of these nodes will 
contribute to the baseline sum. A ll other pathological nodes (t hose with short axis ≥ 10 mm but < 
15 mm) should be considered nontarge t lesions. Nodes that have a short axis < 10 mm are 
considered nonpathological and s hould not be recorded or follow ed. 
A sum of the diameters (longest for nonnodal lesions, short axis for nodal lesions ) for all target 
lesions will be calculated and re ported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as not ed above, only the short axis is added into the sum. The baseline 
sum diameters will be used as reference to further characterize  any objective tumor regression in 
the measurable dimens ion of the disease. 
All other lesions (or sites of  disease) including pathological lymph nodes should be identified as 
nontarget lesions and should also b e recorded at baseline. Meas urements are not required and 
these lesions should be followed a s ‘present’, ‘absent’, or in rare cases ‘unequivocal 
progression.’ 
8.3.3 Special Notes on the Assessment of Target Lesions 
[IP_ADDRESS] Lymph Nodes 
Lymph nodes identified as target lesions should always have the  actual short axis measurement 
recorded (measured in the same anatomical plane as the baseline  examination), even if the nodes 
regress to below 10 mm on study. For PR, stable disease, and PD , the actual short axis 
measurement of the nodes is to be included in the sum of target lesions. [IP_ADDRESS] Target Lesions That Become ‘Too Small to Measure’ 
While on study, all lesions ( nodal and nonnodal) recorded at baseline should have their actual 
measurements recorded at each s ubsequent evaluation, even when very small (e.g., 2 mm). 
However, if the lesion is believe d to be present and is faintly seen but is too small to measure 
with any accuracy, a default va lue of 5 mm should be assigned. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110487] 1.1 
8.4.1 Evaluation of Target Lesions 
Table 5  provides the definitions of the criteria used to determine obj ective tumor response for 
target lesions. CR and PR shoul d be confirmed 4 weeks after the initial scan. 
Table 5: Criteria to Determine Ob jective Tumor Response for Tar get Lesions 
per RECIST 1.1 
Criteria Definition 
Complete Response (CR) • Disappearance of all target lesions 
Any pathological lymph nodes (whether target or nontarget) must  have reduction 
in short axis to < 10 mm. 
Partial Response (PR) • At least a 30% decrease in the sum  of the longest diameters (SL D) of target 
lesions, taking as reference the baseline SLD.  
For lymph nodes (target lesions)  the actual short axis measurem ent should be 
recorded (measured in the same a natomical plane as the baseline  examination). 
Progressive Disease (PD) At leas t a 20% increase in the SLD of target lesions, taking as reference the 
smallest SLD on study (this inclu des the baseline sum if that i s the smallest 
on study). 
In addition to the relative incr ease of 20%, the sum must also demonstrate an 
absolute increase of at least 5 mm relative to nadir.  
Note:  the appearance of [ADDRESS_1110488] sum diameters while on stu dy 
 
 8.4.2 Evaluation of Nontarget Lesions 
Table 6  provides the definitions of the criteria used to determine the  tumor response for the 
group of nontarget lesions. Alt hough some nontarget lesions may  actually be measurable, they 
need not be measured and inste ad should be assessed only qualit atively at the time points of 
radiographic assessments. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 91 of 149 
Confidential and Proprietary  27 May 2021 Table 6: Criteria to Determine Tumor Response for Nontarget Les ions per 
RECIST 1.1 
Criteria Definition 
Complete Response (CR) Disappear ance of all non-target lesions and normalization of tumor marker level. 
All lymph nodes must be non-pat hological in size (< 10 mm short  axis). 
Non-CR/Non-PD Persistence of one or more non-target lesion(s) a nd/or maintenance of tumor 
marker level above the normal limits 
Progressive Disease (PD) Unequivocal progression of existing non-target lesions. (Note:  the appearance of 
one or more new lesions is also considered progression).a 
Note:  If tumor markers are assessed for a given patient and ar e initially above the ULN, th ey must normalize for a 
patient to be considered in CR. 
a. In this setting, when a patient has measurable disease, to achi eve “unequivocal progressi on” on the basis of the 
nontarget disease, there must be an overall level of substantia l worsening in the nontarget disease such that, 
even in the presence of  stable disease or PR in the target disease, the overall tumor burden has increased 
sufficiently to merit discontinuation of therapy. A modest incr ease in size of 1 or more nontarget lesions is 
usually not sufficient to qualify for unequivocal progression s tatus. The designation of overall progression 
solely on the basis of change in  nontarget disease in the face of stable disease or PR of target disease will 
therefore be extremely  rare (from Section 4.3.[ADDRESS_1110489] 1.1).  
 
8.4.[ADDRESS_1110490] met for 
CR/PR (whichever is first recorded) until the first date that r ecurrent or progressive disease is 
objectively documented (taking as reference for progressive dis ease the smallest measurements 
recorded on study). 
The duration of overall complete response is  measured from the time measurement criteria are 
first met for CR until the first date that recurrent disease is  objectively documented. 
Stable disease is measured from the start of the treatment (in randomized studies, from date of 
randomization) until the criteria for progression are met, taki ng as reference the smallest sum on 
study (if the baseline sum is the  smallest, this is the referen ce for calculation of PD). 
8.5 Blinded Independent Central Review 
Radiographic images will be colle cted for BICR. Details for the  analyses are described in the 
imaging core laboratory charter. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110491]. An AE can als o arise from any use of the dru g and from any route of 
administration, formulation, dose, or overdose. This definition includes intercu rrent illnesses or 
injuries, and exacerbation of preexisting conditions. Clinical laboratory, vital sign, or physical 
examination abnormalities will only be reported as AEs if they are deemed clinic ally significant 
by [CONTACT_737] (e.g., associ ated with signs and symptoms, require treatment, or require 
follow-up). 
An AE does not include: • A medical or surgical procedur e (e.g., surgery, endoscopy, tooth extraction, or transfusion); 
an AE is the underlying condition that leads to the procedure. 
• Pre-existing diseases or conditi ons present or detected before start of study drug(s) 
administration that do not worse n or increase in severity or fr equency after the administration 
of study drug(s). 
• Situations where an untoward m edical occurrence has not occurre d (e.g., hospi[INVESTIGATOR_804501]  a condition that h as not worsened on study , social and/or convenience 
admissions to grant families a re spi[INVESTIGATOR_22216] a patient) . 
• Overdose of either study drug(s) o r concomitant medication with out any signs or symptoms. 
9.1.2 Monitoring AEs 
All AEs will be assessed by [CONTACT_941] I nvestigator and recorded, incl uding but not limited to, the 
following:  the event term, the  date of onset and resolution, seriousness, severity, relationship to 
study drug(s), outcome, treatment of the event, and action take n with the study drug(s). All AEs 
will be reported starting immediat ely after the patient has bee n administered the  first dose of 
study drug(s) until [ADDRESS_1110492] dose of all study d rug(s). For treatment-related SAEs, 
additional reporting requirem ents also apply (see Section 9.2.2 ). 
An event occurring after the pa tient has provided informed consent, but before the first dose of 
study treatment or confirmed scree n failure, will be collected as medical history unless the event 
is either new and attributed to pr otocol-mandated procedures by  [CONTACT_197291] a 
significant change in the rate of  occurrence or an increase in the severity of the pre-existing 
condition which is judged to be c linically important and attrib uted to the protocol-mandated 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 93 of 149 
Confidential and Proprietary  27 May 2021 procedures by [CONTACT_737]. U nder the latter 2 circumstances, the event will  be considered an 
AE and will be captured as such. 
• Example 1:  Thrombophlebitis a ssociated with a blood draw for a ssessments required prior to 
dosing per protocol is an event t hat is related to protocol-man dated procedures. In this 
scenario, the event of “thrombophl ebitis” will be captured as a n AE, and it will be 
documented as being “unrelated” to study drug(s), as applicable . 
• Example 2:  An ankle sprain following an unexpected fall from a flight of stairs while at 
home, after the patient has provi ded informed consent, but befo re the first dose of study 
drug(s), is clearly unrelated to any protocol-mandated procedur es and would therefore be 
captured as medical history. 
9.1.3 Grading of AEs 
The severity of an event and the s eriousness are not to be cons idered synonymous. The severity 
is grading the intensity of an e vent. The seriousness of event is based on the patient/event 
outcome or action criteria. All AEs will be assessed for severity using the National Cancer Institute (NCI) CTCAE v 5.0 guidelines. If a particular AE is n ot listed in the NCI-CTCAE, the 
following criteria will be used: 
• Grade 1 = Mild (event results in  mild or transient discomfort, not requiring or needing only 
minimal intervention or treatment; does not limit or interfere with daily activities 
[e.g., insomnia, mild headache]). 
• Grade 2 = Moderate (event is sufficiently discomforting so as to limit or interfere with daily activities; may require interve ntional treatme nt [e.g., fever r equiring antipyretic medication]). 
• Grade 3 = Severe (event results  in significant sy mptoms that prevent normal daily activities; 
may require hospi[INVESTIGATOR_804502]). 
• Grade 4 = Life threatening or disabling. 
• Grade 5 = Death. 
AEs will be reported with an indi vidual start a nd stop date for  each level of severity. 
9.1.4 Causality Relationship of AEs 
The relationship of each AE to each study drug (NKTR-214 or nivolumab, or both) as applicable will be evaluated by [CONTACT_804562]: 
• Not related:  An AE that does not  follow a reasonable temporal sequence from administration 
of study drug(s), and/or that c an be reasonably explained by [CONTACT_804563]’s medical history, preexisting medical condition, under lying disease, concurrent 
illness, or concomitant medications/therapi[INVESTIGATOR_014]. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 94 of 149 
Confidential and Proprietary  27 May 2021 • Possibly related:  The AE may be r elated to the investigational  agent(s). A plausible temporal 
sequence exists between  the time of adminis tration of the inves tigational product and the 
development of the AE, and it follows a known response pattern to the investigational 
product. The reaction may have been  produced by [CONTACT_102]’s c linical state or other 
concomitant therapi[INVESTIGATOR_197213]. 
• Related:  The AE is clearly relat ed to the investigational agen t(s). A plausible temporal 
sequence exists between  the time of adminis tration of the inves tigational product and the 
development of the AE, and it follows a known response pattern to the investigational 
product. The occurrence of this AE can be confirmed with a posi tive re-challenge test or 
supporting laboratory data. 
The causality criteria of relat ed and possibly related will be considered “related” to the study 
drug(s) for regulatory reporting requirements. 
9.1.[ADDRESS_1110493] study 
drug(s) administration until [ADDRESS_1110494] dose of al l study drug(s). For SAEs, additional 
reporting requirements al so apply (see Section 9.2.2). 
All ongoing AEs will be followed until resolution, the patient is lost to follow-up, patient death, 
or until the Follow-Up Visit 2, whi chever is earlier. In case the AE has not completely resolved 
by [CONTACT_98652]-Up Visit 2, the fin al outcome of these ongoing AE s will be captured as “Not 
Recovered/Not Resolved” or “Recovering/Resolving”, whichever is  applicable.  
For specific instruct ions on identifying and reporting SAEs, se e Sections 9.2.[ADDRESS_1110495] medical occurrence that at an y dose: 
• Results in death. 
• Is life threatening, i.e., in t he opi[INVESTIGATOR_689], the AE places the patient at 
immediate risk of death from the event as it occurred; it does not include a reaction that, had 
it occurred in a more severe f orm, might have caused death. 
• Requires inpatient hospi[INVESTIGATOR_804503] (for 
≥ 24 hours) that occurs during the  course of a patient’s partic ipation in a c linical study, 
except for those due t o the following: 
− A surgery or procedure that was planned before the patient ente red the study and 
which is part of the pl anned study procedure. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 95 of 149 
Confidential and Proprietary  27 May 2021 − Nonmedical reasons (e.g., electiv e hospi[INVESTIGATOR_804504]), in t he absence of an AE. 
• Results in persistent or signifi cant disability or incapacity. 
• Is a congenital anom aly or birth defect. 
• Is an important medical event that, based upon appropriate medi cal judgment, may 
jeopardize the patient and may req uire medical or surgical inte rvention to prevent one of the 
other outcomes listed above. 
Death is an outcome of an AE a nd not an AE in itself. All events leading to death, regardless of 
relationship to study drugs, that occur during the protocol-spe cified reporting period, must be 
reported with the exception of deat hs attributed to disease pro gression (refer to Section 9.3). An 
efficacy failure is not considered an SAE. “Life-threatening” m eans that the patient was at 
immediate risk of death from the  event as it occurred. This does not include an event that might 
have led to death if it had occu rred with greater severity. “Inpatient hospi[INVESTIGATOR_059]” means the 
patient has been admitted to a hos pi[INVESTIGATOR_804505]. The 
Investigator should attempt to es tablish a diagnosis of the eve nt based on signs, symptoms, 
and/or other clinical informati on. In such cases, the diagnosis  will be documented as the AE 
and/or SAE and not the indi vidual signs/symptoms.  
9.2.[ADDRESS_1110496] dose 
of study treatment or confirmed s creen failure, will be collected as medical history unless the 
event is either new and attribut ed to protocol-mandated procedu res by [CONTACT_804564] 
a significant change in the rate  of occurrence or an increase i n the severity of the pre-existing 
condition, which is judged to be c linically important and attri buted to the protocol-mandated 
procedures by [CONTACT_737]. A ny new or clinically significa nt changes in the p atient’s medical 
and/or cancer history that occur after the first dose of drug and meet the SAE criteria will be 
recorded as SAEs.  
All SAEs, regardless of cau sality, with an onset within [ADDRESS_1110497] dose of all study 
drug(s) will be reported to Nekta r Therapeutics Drug Safety immediately without undue delay, 
under no circumstances later than 24 hours following knowledge. In addition, all SAEs that are assessed by [CONTACT_331590](s) and 
occurring after the SAE repor ting period will al so be reported to Nektar Therapeutics Drug 
Safety immediately without undue  delay, under no circumstances later than [ADDRESS_1110498] ructions regarding 
how to enter SAEs into EDC. If the study were to transition to reporting of SAEs in EDC, sites 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110499] complete t he SAE Report Form, assess the causality relationship to the 
study treatment as applicable, a nd send the completed SAE form via email or fax to Nektar 
Therapeutics Drug Safety. A follow-up report and any additional  records (such as hospi[INVESTIGATOR_2553], consultant reports, and autopsy findings) will be emai led or faxed to Nektar 
Therapeutics Drug Safety immed iately without undue delay, under no circumstances later than 
24 hours following knowledge. Any medic ation or other therapeut ic measures used to treat the 
event will be recorded. All SAEs will be followed as described in Section 9.2.3. 
Reporting of SAEs to the IRB/IEC will be done in accordance wit h the standard operating 
procedures (SOPs) and policies of  the IRB/IEC. Adequate documen tation must be provided to 
Nektar Therapeutics, showing that the IRB/IEC was properly notified. Serious AEs will be 
reported by [CONTACT_804565], per local regulations. 
9.2.[ADDRESS_1110500] not resolved by [CONTACT_197295] (Section 4.1.3 ) will be 
followed until any of the followi ng occur (whichever comes first): 
• The event resolves. 
• The event has stabilized. 
• The event returns to baseline, if a baseline value is available . 
• It is unlikely that any additional information can be obtained (e.g., patient or health care 
practitioner refuses to provide additional information; lost to  follow-up after demonstration 
of due diligence with follow-up efforts). 
• The patient dies or is lost to follow-up. 
All ongoing SAEs assessed as unrel ated to study drug(s) will be  followed until resolution or until 
the Follow-up Visit 2 (Section 4.1.3 ), whichever is earlier. In th e case where an unrelated SAE 
has not completely resolved by [CONTACT_98652]-up Visit 2, the final outcome of these ongoing 
unrelated SAEs will be captured a s “Not Recovered/Not Resolved”  or “Recovering/Resolving,” 
whichever is applicable. 
9.3 Disease Progression – Not Reportable as an AE 
It is anticipated that during this study a proportion of patien ts will experience disease progression 
prior to study discontinuati on. Disease progression should not be reported as an AE or SAE. In 
some patients disease progression may result in clinical manifestations (e.g., pleural effusion) 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 97 of 149 
Confidential and Proprietary  27 May 2021 that meet “seriousness” criteri a (e.g., hospi[INVESTIGATOR_059]). These  clinical manifestations may be 
reported as non-fatal SAEs. 
For all SAEs assessed as clinical manifestations associated wit h fatal disease progression, the 
following criteria will apply: 
• Seriousness Criteria = Cannot equal to Death 
• Severity = Cannot e qual to Grade 5 
• Outcome = Ongoing at time of Death  
Deaths that are attr ibuted solely to d isease progression by [CONTACT_804566]. 
9.4 Immune-mediated Adverse Events and Other Monitored Events  
Immune-mediated AEs (imAEs) are AEs consistent with an immune-m ediated mechanism or 
immune-mediated component for w hich non-inflammatory etiologies  (e.g., infection or tumor 
progression) have been ruled out. imAEs can include events with  an alternate etiology which 
were exacerbated by [CONTACT_804567]. Investigators should use clinical judgment 
characterizing an AE as immune mediated, including the requirem ent for steroid treatment, and 
are encouraged to rule out neopl astic, infectious, metabolic, t oxic, or other etiologies to the 
extent possible, before charact erizing an event as immune media ted. Information supporting the 
assessment of imAEs will be co llected on the case report form. Additional information may also 
be collected on imAEs.  
See Section 6.6.[ADDRESS_1110501] AEs prim arily related to NKTR-214 (eg, 
capi[INVESTIGATOR_804506]). 9.[ADDRESS_1110502]  
CVA events (any grade) are considered AESI and should be classi fied as serious or non-serious 
following the standard seriousness definition. However, all CVA s are required to follow the 
timeline for SAE reporting (within 24 hours as  described in Sec tion 9.2.2 ) from the sites to 
Nektar Drug Safety:  pharmacovigi [EMAIL_15285]. CVA Manageme nt Guidelines are 
provided in Appendix 4. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 98 of 149 
Confidential and Proprietary  27 May 2021 9.7 Pregnancy Tests/Pregnancy 
9.7.[ADDRESS_1110503] a  minimum sensitivity of 25 IU/L 
or equivalent units of HCG. A nega tive pregnancy test result mu st be obtained before the 
administration of the study drug(s). 
A pregnancy test does not need to be performed on women who are postmenopausal (see 
Appendix 3) for at least [ADDRESS_1110504] 3 months before signing the ICF. 
If a female patient becomes preg nant, administration of the study drug(s) must be discontinued 
immediately. Requireme nts for reporting a pre gnancy are provided in Section 9.7.2. 
9.7.2 Pregnancy 
[IP_ADDRESS] Pregnancies in Female Patients 
The Sponsor must be notified i mmediately without undue delay, u nder no circumstances later 
than [ADDRESS_1110505] dose of 
NKTR-214 or nivolumab for female patients. All reports should be submitted via the Pregnancy Notification Form. Pregnancy, although reportable, is not considered an AE/SAE unless a female patient experiences signs or sym ptoms of pregnancy complication s; however, the contact 
[CONTACT_804568] 9.2.2. 
Female patient(s) who become pre gnant will be followed until th e outcome of the pregnancy is 
known. Pregnancy follow-up should de scribe the outcome of the p regnancy, including any 
voluntary or spontaneous termina tion, details of the birth, and  the presence or absence of any 
congenital abnormalities or birt h defects in the offspring. 
If a female patient becomes preg nant, administration of the study drug(s) must be discontinued 
immediately. 
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients 
Any pregnancy occurring during the course of the study and for [ADDRESS_1110506] sign an informed 
consent form (See Section 13.2). 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 99 of 149 
Confidential and Proprietary  27 May 2021 Pregnancy, although reportable, i s not considered an AE/SAE unl ess a female partner of male 
patient experiences signs or sym ptoms of pregnancy complication s; however, the contact 
[CONTACT_804568] 9.2.2. 
Attempts should be mad e to collect and report details of the co urse and outcome of any 
pregnancy in the partner of a male patient exposed to study dru g with the authorization from the 
pregnant partner. Pregnancy follow-up should describe the outcome of the pregnancy, including 
any voluntary or spontaneous termination, details of the birth,  and the presence or absence of any 
congenital abnormalities or birt h defects in the offspring. 
9.8 Potential Drug Induced Liver Injury 
Wherever possible, timely confir mation of initial liver-related  laboratory abnormalities should 
occur prior to the reporting of  a potential drug induced liver injury (DILI) event. All occurrences 
of potential DILIs, meeting the defined crite ria, must be repor ted as SAEs (see Section 9.2.2 for 
reporting details). Potential  DILI is defined as: 
• Treatment-emergent ALT  or AST > [ADDRESS_1110507], 
AND 
• Total bilirubin > [ADDRESS_1110508] or  clinical jaundice, without ini tial findings of cholestasis 
(elevated serum alk aline phosphatase),  
AND • No other immediately apparent possi ble causes of elevated liver  enzymes and 
hyperbilirubinemia, including, but n ot limited to, viral hepati tis, pre-existing chronic or acute 
liver disease, or the administr ation of other drug(s) known to be hepatotoxic. 
9.[ADDRESS_1110509] 
that is considered both excessive  and medically important. Over doses that meet the regulatory 
definition of SAE will be reported as an SAE (see Section 9.2.2). All instances of accidental 
overdose and/or dosing errors should be reported on the Dosage Administration Record eCRF. 
9.[ADDRESS_1110510] of identifying 
themselves as participating in a clinical trial, and subsequent ly to give health care providers 
access to the information about this participation that may be needed to determine the course of 
the patient’s medical treatment. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110511] for this purpose. If the Investigator is available whe n an event occurs, he/she will answer 
any questions. Any subsequent action will follow the standard p rocesses established for the 
Investigators. In cases where the  Investigator is not available , the Sponsor has provided a 
24-hour contact [CONTACT_6227], whereby [CONTACT_804569] a physician 
designated by [CONTACT_804570] a ssist with the medical emerg ency. 
9.11 Clinical Laboratory Tests 
Clinical laboratory samples will  be collected according to the Schedule of Events (Table 1 ). 
Clinical laboratory tests will  be performed by a central laboratory, with the exception of 
pregnancy testing which will be done locally. A list of the cli nical laboratory analytes to be 
tested is provided in Appendix 2A . In cases of a safety concern, blood samples may be split (or 
2 samples drawn) to allow a local  laboratory anal ysis in addition to the central laboratory. For 
enrollment, if the central laboratory tests are cancelled, lost , or considered inadequate for 
analysis, the site may forward a n identical set of local labora tory samples for eligibility review 
(with central laboratory testi ng repeated prior to the first do se of study drug). If local laboratory 
results are determined to be acceptable during eligibility revi ew, enrollment may proceed. 
Additional clinical laboratory tests may be ordered at the Inve stigator’s or qualified Sub-
Investigator’s discretion. 
The Investigator or qualified Sub- Investigator must review all laboratory results for clinical 
significance and document their review. Any laboratory result deemed clinically significant 
(i.e., is associated w ith signs and symptoms,  requires treatmen t, or requires follow-up) will be 
recorded as an AE as described in Section 9.1. 
9.12 Physical Examinations 
Physical examinations should be  conducted according to the Sche dule of Events (Table 1 ). Full 
physical examinations should be c onducted at screening, and EOT  (evaluate all major organ 
systems, including the following categories:  general, head, ey es, ears, mouth/throat, neck, heart, 
lungs, abdomen, lymph nodes, joints , extremities, integumentary , neurologic, and psychiatric). 
Focused physical examinations will be done at Day 1 of each cyc le and during the follow-up 
period. Focused physical examinatio ns are at the discretion of the Investigator, to identify 
changes from baseline or evaluate changes based on the patient’ s clinical symptoms. Weight is to 
be reported at each visit for dos ing of NKTR-214/nivolumab (ie,  on the day of dosing and not 
earlier), height at screening vis it only. Other examinations ar e to be performed a s clinically 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110512] exam, 
report changes on the appropriate  non-serious or serious AE pag e. 
9.13 Vital Signs 
Vital sign measurements will be recorded according to the Schedule of Events ( Table 1). Vital 
signs include pulse rate, respi[INVESTIGATOR_92196], sys tolic and diasto lic blood pressure, oxygen saturation 
by [CONTACT_406] (oxygen saturat ion on dosing days only), and temperature. It is preferred that 
the same arm be used for all bl ood pressure readings, if possib le. Pre dose on Cycle [ADDRESS_1110513] a documented LVEF > 45% using standard echocardiogram or MUGA scan 
test within [ADDRESS_1110514] of care may be 
used if they meet the above criteria ( Table 1 ).  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110515] deviation, median, minimum, and maximu m. Categorical data will be 
summarized by [CONTACT_804571]. Unless oth erwise specified, data will be 
summarized by [CONTACT_2939]. 
A detailed description of analys is methods will be provided in the statistical ana lysis plan (SAP). 
The potential impact of COVID- 19 on this trial will be assessed . Any changes to the analyses 
that are required due to COVID-19 will be detailed in the SAP.  
10.2 Determination of Sample Size 
The original protocol planned t o enroll approximately 185 patie nts to receive NKTR-214 and 
nivolumab. Amendment 2 .0  added a GemCarbo arm and reduce d the overall number of patient s 
planned to approximately 165 ( 110 to receive NKTR-214/nivolumab , 55 to receive GemCarbo). 
Amendment 3 .0  eliminated the GemCarbo arm a fter 2 patients had enrolled in this arm, and 
modified the overall planned numbe r of NKTR-214/nivolumab patie nts to 175. With 
Amendment 5 .0, enrollment is complete at 2 pa tients who received GemCarbo and 190 patients 
who received NKTR-214/nivolumab. The study will evaluate the total ity of the data including DOR,  and ORR, and CR rate. 
Although this study is enrolli ng both PD-L1 low and PD-L1 high expressors in an unselected 
fashion, the sample size was  determined by [CONTACT_187284]-L1 low population. Review of available 
urothelial carcinoma- specific PD-L1 data suggest that approxima tely 70% of patients have 
PD-L1 low tumors, while 30% have  PD-L1 high tumors using the PD -L1 IHC 22C3 pharmDx 
assay (pembrolizumab) (CPS ≥ 10) ( Vuky, 2018;  KEYTRUDA
® Prescribing Information, 2018; 
TECENTRIQ® Prescribing Information, 2018). 
This trial will enroll at lea st [ADDRESS_1110516] tumors th at are PD-L1 low. The null 
hypothesis is that the ORR is ≤ 21%. The alterative hypothesis is that the ORR is > 21%. The 
null hypothesis was based on the  Keynote-052 study of 1L pembro lizumab in cisplatin-ineligible 
patients with locally advanced or  metastatic UCC; in that study , ORR was 20.3% in patients with 
PD-L1 CPS < 10 ( Vuky, 2020) .   
Assuming an ORR rate of at least 34%, with at least [ADDRESS_1110517] more than 
82% power to demonstrate that the  lower limit of the 95% two-si ded confidence in terval (CI) for 
ORR exceeds 21%, where the CI is calculated by [CONTACT_804572].  
10.3 Analysis Sets 
Treated PD-L1 Low Population:  A ll PD-L1 low patients who recei ve at least 1 dose (or partial 
dose) of NKTR-214/nivolumab or GemCarbo. The cut-off point defi ning low PD-L1 expression 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 103 of 149 
Confidential and Proprietary  27 May 2021 will be CPS < 10 (see Section 7.3). This is the analysis set for all efficacy and safety analyse s in 
PD-L1 low patients, as well as , corresponding demographics, bas eline characteri stics, and study 
drug administration. 
Treated PD-L1 High Population:   All PD-L1 high patients who rec eive at least 1 dose (or partial 
dose) of NKTR-214/nivolumab or Ge mCarbo. Patients with CPS ≥ [ADDRESS_1110518] 
high PD-L1 expression and will be r eferred to as high PD-L1 pat ients (see Section 7.3). This is 
the analysis set for all effic acy and safety analyses in PD-L1 high patients, as well as, 
corresponding demographics, baseli ne characteristics, and study  drug administration. 
Treated Population:  All patient s who receive at least 1 dose (or partial dose) of 
NKTR-214/nivolumab or GemCarbo. Thi s is the analysis set for al l efficacy and safety analyses 
in all NKTR-214/nivolumab or GemCarbo treated patients, as well  as, corresponding 
demographics, baseline characteristics, and study drug administ ration. 
GemCarbo Population:  All patien ts who were randomized to recei ve at least 1 dose (or partial 
dose) of GemCarbo per a prior study  amendment. This is the analysis set for all analyses in all 
GemCarbo treated patients, as we ll as, corresponding demographi cs, baseline characteristics, and 
study drug administration. Pharmacokinetic Population:  All patients in the Treated Population who have evaluable analyte 
concentration-time profiles that  allow for computation of meaningful PK parameter values. 
 
10.4 Demographics and Baseline Characteristics 
Demographic data (age, sex, ethnicity, body weight) and baselin e disease characteristics will be 
tabulated, summarized, and presented in data listings. 
10.[ADDRESS_1110519] 1.1 per BICR. The ORR and its corresponding 95% exact  CI will be calculated by 
[CONTACT_39715]-Pearson method. The primary analysis will be perfor med approximately [ADDRESS_1110520] 
occurrence of disease progressi on or recurrence (taking as refe rence for progressive disease the 

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110521] measurements recorded s ince the treatment started) or the start of a new anticancer 
therapy. 
10.5.2 Secondary Analyses 
[IP_ADDRESS] Duration of Response 
DOR is defined for patients who have a confirmed CR or PR as th e date from first documented 
CR or PR per RECIST 1.[ADDRESS_1110522] e valuable tumor assessment. The 
median DOR will be estimated usin g the Kaplan-Meier method with  corresponding 95% CI and 
range. DOR by [CONTACT_804573] a sensitivity ana lysis. 
The last evaluable tumor assessme nt is defined as the last scan  before initiation of any 
anti-cancer therapi[INVESTIGATOR_804507] a  response of CR, PR, stable dis ease, or PD measured by 
[CONTACT_393] 1.1. 
  
  
 
 
 
 
 
 
 
 
 
 
[IP_ADDRESS] Overall Survival 
OS is defined as the time betwee n the date of first dose and th e date of death due to any cause. 
Patients who do not have a date of death will be censored on th e last date for which a patient was 
known to be alive. The Kaplan-Meier method will be used to summarize OS, similar to PFS. The 
OS rates at [ADDRESS_1110523] grade per NCI 

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110524] grade NCI CTCAE v 5.0 criteria. 
10.6.1 Study Drug Exposure 
A patient’s extent of exposure to NKTR-214 and nivolumab, generated from the study drug 
administration eCRF, will be summarized by [CONTACT_335581].  
10.6.2 Adverse Events and Laboratory Evaluations 
Clinical and laboratory AEs will  be coded using the Medical Dic tionary for Regulatory Affairs 
(MedDRA). All TEAEs, treatment-related AEs, SAEs, and treatment -related SAEs will be 
summarized using the worst grad e per NCI CTCAE v 5.0 by [CONTACT_72065]. 
A TEAE is defined as:  (re gardless of intensity): 
• Any AE that happens after  treatment initiation 
• AE that was present at time of t reatment initiation but worsene d after treatment initiation 
• AE that was present and resolv ed prior to trea tment and reappea red after treatment initiation 
A separate listing and summary of all imAEs will be provided. A  listing and summary of patients 
who discontinued study drug(s) du e to an AE will be provided. 
Vital signs (including change in weight) and clinical laborator y test results will be summarized 
descriptively. Data a nd change from baseline at all scheduled t ime points will be tabulated.  
A data listing for all de aths will be provided. 
10.6.3 Other Safety Evaluations 
Any significant physical examina tion findings will be listed.  
All reported prior and concomitant medications will be mapped u sing the World Health 
Organization Drug Dictionary, and t abulated in summary tables and data listings. Individual data 
for medical history w ill also be listed a nd summarized descript ively as appropriate. 
10.7 Pharmacokinetics 
Plasma concentrations of NKTR- 214 and its metabolites, and seru m nivolumab concentrations, 
will be measured. Pharmacokine tic parameters such as C max, Tmax, AUC, clearance (CL), volume 
of distribution (V d), and half-life (t 1/2) will be estimated from concentration-time data where 
possible. Pharmacokinetic data  from this st udy may also be pool ed with data from other clinical 
studies for the purpose of PK m odeling. Pharmacokinetic paramet ers will be tabulated and 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110525] 
safety and response measurements f or assessment of exposure-res ponse relationships. Data from 
patients prematurely ending partic ipation in the study may be excluded from the PK data 
evaluation.  
10.8 Health-Related Quali ty of Life (HQRoL) 
Patient-reported outcome (PRO) me asures include EORTC QLQ-C30, FACIT GP5, and 
EQ-5D-3L. Summary statistics for PRO measures at each assessmen t point will be provided. The 
mean change from baseline will also be reported at each post-baseline assessment point. 
  
 
 
10.10 Missing Data 
Statistical considerations and methodology for handling missing data will be detailed in the SAP. 10.11 Independent Data Monitoring Committee (IDMC)/Sponsor Executive Committee 
(SEC) 
This study was monitored by [CONTACT_41774], comprised of qualified clinicians and a bi ostatistician all 
independent from Nektar Therape utics and investigational sites,  selected to avoid conflict(s) of 
interest. The IDMC reviewed data  from the first [ADDRESS_1110526] 2 cycles of 
NKTR-214 and nivolumab. 
The IDMC’s specific ac tivities are detailed in a mutually agree d upon charter, which defines the 
relevant processes, including meeting proceedings and structure , data assessments, 
documentation and recordkeepi[INVESTIGATOR_007], pr ocess for IDMC recommendatio ns, and regulatory 
reporting, as applicable. The char ter contains procedures to en sure the minimization of bias, such 
as maintaining confidential ity of any interim data.  
Following the initial IDMC revie w on safety and other relevant data, the reviews are continued 
by a Sponsor Executive Committee (SEC) consisting of Nektar’s C hief Medical Officer, Head of 
Data Science and Systems, and Hea d of Regulatory Affairs, none of whom are directly involved 
in study conduct. In addition to th e Medical Monitor’s routine review of safety, the SEC will 
formally review ongoing saf ety at 6-month intervals. 
 

Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 107 of 149 
Confidential and Proprietary  27 May 2021 11.0 STUDY OR STUDY SITE TERMINATION 
The Sponsor has the right to suspend or terminate the study or part of the study at any time for 
any reason. 
If an Investigator suspends or t erminates their study site, the  Investigator will promptly inform 
the Sponsor and the IRB/IEC and provide them with a detailed written explanation. Upon study 
completion, the Inves tigator will provide the Sponsor, IRB/IEC,  and regulatory agency with final 
reports and summaries as required by [CONTACT_19124]. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 108 of 149 
Confidential and Proprietary  27 May 2021 12.0 QUALITY CONTROL AND QUALITY ASSURANCE 
The Sponsor will implement and m aintain quality control and qua lity assurance procedures with 
written SOPs to ensure that the study is conducted and data are  generated, documented, and 
reported in compliance with the  protocol, Good Clinical Practice (GCP), and applicable 
regulatory requirements. 
12.1 Changes to the Protocol 
The Investigator may not deviate from the protocol without a fo rmal protocol amendment having 
been established and approved by a n appropriate IRB/IEC, except  when necessary to eliminate 
immediate hazards to the patient or when the change(s) involve only logistical or administrative 
aspects of the study. Any deviati on may result in the patient h aving to be withdrawn from the 
study and rendering that patient  nonevaluable. All protocol dev iations and the reasons for such 
deviations are to be documented  and reported to the Sponsor. 
12.2 Monitoring 
In accordance with Code of Federal Regulations 21 CFR 312.56, International Council for 
Harmonisation (ICH) GCP, and local  regulations, the clinical monitor will periodically inspect 
all eCRFs, study documents, res earch facilities, and clinical laboratory faciliti es associated with 
this study at mutuall y convenient times dur ing and after completion of the study. As required by 
21 CFR 312 Subpart D (Responsibil ities of Sponsors and Investigators), ICH GCP, and local 
regulations, the monitoring visits provide the Sponsor with the  opportunity to evaluate the 
progress of the study; verify th e accuracy and completeness of eCRFs; ensure that all protocol 
requirements, applicable FDA, I CH GCP, and local regulations, and Investigator’s obligations 
are being fulfilled; and resolve  any inconsistencies in the stu dy records. This includes inspection 
of all documents and records that are required to be maintained  by [CONTACT_737], including but 
not limited to medical records (office, clinic, or hospi[INVESTIGATOR_307]) for the patients in this study. The names and identities of all research patients will be kept in strict confidence and will not appear on 
eCRFs or other records provided to or retained by [CONTACT_1034]. The Investigational New Drug 
Application (IND) regulations and ICH E6 guidelines also requir e the Investigator to allow 
authorized representatives of the Sponsor, IRB/IEC, FDA, and other relevant regulatory authorities direct access to study source records, and to inspe ct and make copi[INVESTIGATOR_329620]. The names and identi ties of the patients need not be d ivulged to the Sponsor; however, 
the records must nevertheless be  available to be inspected for review. This can be accomplished 
by [CONTACT_197309]’s name  [CONTACT_233591]’s study identification 
number. If these requirements are  in conflict wit h local regula tory restrictions or institutional 
requirements, the Investigator m ust inform the Sponsor of these restrictions before initiation of 
the study. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110527] Access to Source Data/Docu ments for Audits and Inspectio ns 
Members of the Sponsor or designees may conduct monitoring and auditing activities of a 
clinical site at any t ime during or after c ompletion of the stu dy. The Investigator will be 
informed of such activities. 
Representatives of the FDA or ot her regulatory agencies, includ ing IRB/IEC representatives, 
may also conduct an inspection o r perform an audit of the study . The 
Investigator(s)/institution(s)  will permit study-related audits , IRB/IEC review, and regulatory 
inspection(s) by [CONTACT_20618]/documents and study records. If informed 
of such an inspection, the Invest igator should notify the Sponsor immediately. The Investigator 
will ensure that the inspectors and auditors have access to the  clinical supplies, study site 
facilities, and laboratory, and that all data (including origin al source documentation) and all 
study files are available, if requested. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110528] their origin in 
Declaration of Helsinki and in accordance with FDA regulations (21 CFR § 11, 50, 54, 56, and 
312), with the current ICH GCP guidelines (ICH E6), as well as with any applicable regulatory 
authority, federal, state and/or local laws and regulations. 
13.1 IRB/IEC Approval 
Before enrollment of patients  into the study, as required by [CONTACT_1260] (21 CFR § 56), ICH 
GCP, applicable regulatory authority requirements, and local re gulations, the current protocol 
and ICF will be reviewed and approved by [CONTACT_180409]. A letter documenting the 
IRB or IEC approval must be received by [CONTACT_78466] a 
clinical site. Amendments to the  protocol will be subject to th e same requirements as the original 
protocol. 
The Investigator, Sponsor, or designee will submit a progress r eport at least once yearly to the 
IRB or IEC. However, the frequen cy of these reports will depend  on IRB or IEC requirements. 
As soon as possible after comple tion or termination of the study, the Investigator will submit a 
final report to the IRB or IEC per the IRB or IEC requirements,  and in compliance with FDA 
regulations, applicable regulat ory authority requi rements, and ICH GCPs. 
The Investigator, the Sponsor , or designee shall notify the IRB  or IEC of any SAEs, suspected 
unexpected serious adverse reactions, or any other information that may affect the  safe use of the 
study drug(s) during the study, per the IRB or IEC local requirements, and in com pliance with 
FDA regulations, country and local  regulatory authority regulations, and ICH GCPs. 
13.[ADDRESS_1110529] sign an informed consent form for 
disclosure information. Information on this pregnancy will be collected on the Pregnancy Surveillance Form. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110530] KEEPI[INVESTIGATOR_1645] 
14.1 Data Collection Instruments and Source Documents 
14.1.1 Study Records 
During the study, the Investigator/institution should maintain adequate and accurate source 
documents and study records that include all pertinent observations on each of the site’s study 
patients. Source data should be a ttributable, legible, contempo raneous, original, accurate, and 
complete. Changes to source da ta should be traceable, should no t obscure the original entry, and 
should be explained if necessary ( e.g., via an audit trail). Th e Investigator should ensure the 
accuracy, completeness, legibility, and timeliness of the data reported to the sponsor in the CRFs 
and in all required reports. The  Investigator/institution shoul d, at a minimum, maintain the study 
documents as specified in Essentia l Documents for the Conduct o f a Clinical Trial (ICH E6 
section 8.0) and as required by [CONTACT_804574](s). The 
Investigator/institution should take measures to prevent accide ntal or prematur e destruction of 
these documents. 
14.1.2 Data Collection Instruments 
Data collection instruments (DCIs) (e.g., electronic CRFs [eCRFs] and paper forms) will be used 
in this study. These instruments are used to transmit the infor mation collected during the 
performance of this study to the  Sponsor or Spon sor’s designee and regulatory authorities. 
Nektar, representatives of Nekt ar, and investigational sites wi ll have access to the study data. 
Study data will be stored in a vali dated, access-controlled, password-protected database. 
The Investigator must review the DCIs for completeness and accu racy and must approve all data, 
including any changes made. Furth ermore, the Investigator retains full responsibility for the 
appropriateness and accuracy of a ll data collected in the DCIs.  
14.2 Retention of Essential Documents 
For sites in the US:  All record s and documents pertaining to t he study including, but not limited 
to, those outlined above will be maintained by [CONTACT_14344] a period of at least [ADDRESS_1110531] awal of the IND under which this 
study was conducted, whichever is longer.  
For sites outside the US:  Essent ial documents should be retain ed until at least [ADDRESS_1110532]. These documents 
should be retained for a longer period, however, if required by  [CONTACT_804575]. It is the res ponsibility of the sponsor to 
inform the Investigator/institution when these documents no lon ger need to be retained. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110533] the  Sponsor before transferring or 
destroying any study records. The Investigator will also promptly notify the Sponsor in the event 
of accidental loss or destru ction of any study records. 
14.3 Confidentiality 
Patient confidentiality will be m aintained per local legal and regulatory requirements and 
applicable US federal regulati ons and ICH GCP guidelines. To comply with GCP guidelines and 
requirements, patient records will be reviewed during monitorin g visits and audits conducted by 
[CONTACT_1034], Sponsor's representatives, or health authorities. During these activities, every 
reasonable effort will be made to keep medical information, including patient identifying 
information, as confidential  as possible as required by [CONTACT_2371]. 
Study data given to, and used by, Nek tar are protected by [CONTACT_941] u se of a patient identification 
number. The assignment of unique pa tient identifi cation number to each patient by [CONTACT_699558] (IRT) system enables de-identification.  
Demographic identifiers that wi ll be collected as part of Study  Data include year of birth, age, 
gender, race, and ethnicity. Exact date of birth and patient na me/initials are  not collected. 
The study site is not to provide any personal data relating to patient from Study Data that will be transferred to Nektar. Only the s tudy site will be able to conn ect the patient ident ification number 
a patient’s personal data. 
14.4 Security Measures 
Sites will employ both technical and organizational measures (such as, but not limited to, 
controlling access to personal patient data to only those with a need to know such data, data 
encryption, data anonymization a nd pseudonymization, and so forth) to ensure patient and 
patient data privacy. Sites w ill adhere to a “privacy by [CONTACT_8345] ” and “privacy by [CONTACT_15094]” 
approach in collecting, stor ing, and processing personal patien t data. 
In the event of a breach of th e security measures used by [CONTACT_941] S ite to ensure patient and patient 
data privacy, the Site will imm ediately notify the Sponsor. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 113 of 149 
Confidential and Proprietary  27 May 2021 15.0 PUBLICATION PLAN 
All data are the property of t he Sponsor. Any formal presentation or publication of data from this 
study will be considered for joint publication by [CONTACT_1034] p ersonnel and Investigator(s).  
Any publications or abstracts aris ing from this study must adhe re to the publication requirements 
set forth in the clin ical trial agreement  governing participation in the study. Study data shared by 
[CONTACT_699559].  
The Investigator may be requi red to sign the clinical study rep ort if it is to be used in a 
registration submission to the he alth authorities of some countries. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 114 of 149 
Confidential and Proprietary  27 May 2021 16.0 REFERENCES 
1. Aaronson NK, Ahmedzai S, Bergma n B, et al. The European Organiz ation for Research 
and Treatment of Cancer QLQ-C30:   a quality-of-life instrument for use in international 
clinical trials in oncology. J N atl Cancer Inst. 1993;3;85(5):3 65-76. 
2. Agilent Technologies, Inc. PD-L 1 IHC 22C3 pharmDx Interpretatio n Manual – 
Urothelial Carcinoma. Ag ilent Technologies, Inc, 2018. 
3. American Cancer Society. C ancer Statistics Center. 
http://cancerstatisticscente r.cancer.org. Accessed [ADDRESS_1110534]. 1989;60 (3):331-346. 
5. Anderson D, Hayes, TJ, Powers GD,  et al. Comparative toxicity a nd pathology associated 
with administration o f recombinant IL·2 to animals. Int Rev Exp  Pathol. 1993;31A:57-
77. 
6. Bajorin DF, Dodd PM, Mazumdar, M et al. Long-term survival in m etastatic transitional-
cell carcinoma and prognostic facto rs predicting outcome of the rapy. J Clin Oncol. 
1999;17:3173-81.  
7. Balar AV, Dreicer R, Loriot Y, et al. Atezolizumab (atezo) in first-line cisplatin-
ineligible or platinum-treated locally advanced or metastatic u rothelial cancer (mUC):  
Long-term efficacy from phase 2 study IMvigor210. J Clin Oncol. 2018;36 (suppl; abstr 4523). 
8. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetax el in advanced 
nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-39. 
9. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxe l in advanced 
squamous cell non–small-cell l ung cancer. N Engl J Med. 2015;373:123-35. 
10. Brahmer J, Horn L, Jackman D, et al. Five-year follow-up from the CA209-003 study of 
nivolumab in previously treate d advanced non-small cell lung ca ncer:  clinical 
characteristics of long-term su rvivors. Oral presentation presented at:  American 
Association for Cancer Research  (AACR) Annual Meeting, April 1-5, 2017, Washington, 
DC.  
11. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A . Global cancer 
statistics 2018:  GLOBOCAN estima tes of incidence and mortality  worldwide for 36 
cancers in 185 countries. CA:  a can cer journal for clinicians.  2018;68(6):394-424. 
12. Callahan MK, Kania BE, Iyer G, et al. Evaluation of the clinica l activity of ipi[INVESTIGATOR_125] 
(IPI) plus nivolumab (NIVO) in pati ents (pts) with NIVO-refract ory metastatic urothelial 
cancer (UC) J Clin Oncol. 2017; 35(suppl 6S):abstract 384. 
13. Cesana GC, DeRaffele G, Cohen S, e t.al. Character ization of CD4 +CD25+ regulatory 
T cells in patients treated with high-dose interleukin-2 for me tastatic melanoma or renal 
cell carcinoma. J Clin O ncol. 2006;24(7):1169-77. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 115 of 149 
Confidential and Proprietary  27 May 2021 14. Chalasani V, Chin JL, Izawa JI . Histologic variants of urotheli al bladder cancer and 
non-urothelial histology in bladder cancer. Can Urol Assoc. 2009 ;3:S193-8. 
15. Charych DH, Hoch U, Langowski JL, et al. NKTR-214, an engineere d cytokine with 
biased IL2 receptor binding, increased tumor exposure, and mark ed efficacy in mouse 
tumor models. Clin Cancer  Res. 2016a:22(3);680-690. 
16. Charych DH, Rubas W, Dixit V, e t al. Immune memory in nonclinic al models after 
treatment with NKTR-214, an engineered cytokine biased towards expansion of CD8+ T 
cells in tumor. Poster presented at the Annual Meeting of the A merican Society of 
Clinical Oncology (ASCO); 3-7 Jun 2016b; Chicago, IL. 
17. Charych DH, Hennessy M, Langowski JI, et al. Intra-tumoral immu ne cell mobilization 
and anti-tumor activity after tre atment with the engineered cytokine NKTR-214 in 
multiple preclinical mouse tumor  models presented at EORTC-NCI- AACR, Munich, 
[LOCATION_013], 2016c. 
18. Charych D, Khalili S, Dixit V, et al. Modeling the receptor pha rmacology, 
pharmacokinetics, and pharmacodyn amics of NKTR-214, a kinetical ly-controlled 
interleukin-2 (IL2) receptor a gonist for cancer immunotherapy. PlosOne. 
2017:12(7);e0179431. 
19. Dako North America Inc. PD-L [ADDRESS_1110535]. 2016a;126:3447-3452. 
21. Daud AI, Wolchok JD, Robert C, e t al. Programmed death-ligand 1  expression and 
response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin 
Oncol. 2016b;34:4102-4109. 
22. De Santis M, Bellmunt J, Mead G, et al. Randomized Phase II/III  Trial assessing 
gemcitabine/carboplatin and metho trexate/carboplatin/vinblastin e in patients with 
advanced urothelial cancer who are unfit for cisplatin-based ch emotherapy:  EORTC 
Study [ZIP_CODE]. J Clin Oncol. 2012;30:191-9. 
23. Diab A, Tannir NM, Bernatchez C, et al. A phase 1/[ADDRESS_1110536] locally advance d or metastatic solid 
tumors. J Clin Oncol . 2017;35(suppl):e14040. 
24. Diab A, Hurwitz ME, Cho DC, et al. NKTR-214 (CD-122-biased agon ist) plus 
nivolumab in patients with advanced  solid tumors:  Preliminary phase 1/[ADDRESS_1110537], ASCO A nnual Meeting, June 2, 2018a. 
25. Diab A, Tykodi S, Curti B, et al. NKTR- Immune Monitoring After  NKTR-214 plus 
Nivolumab (PI[INVESTIGATOR_12964]-02) in Previousl y Untreated Patients with Meta static Stage IV 
Melanoma. Presented at Annual Meeting of the Society for Immuno therapy of Cancer 
(SITC); Nov 7-11, 2018b; Washington, DC. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 116 of 149 
Confidential and Proprietary  27 May 2021 26. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting:  from immunosurveillance to 
tumor escape. Nat Imm unol. 2002;3(11):991-8. 
27. Eisenhauer EA, Therasse P, Bogaer ts J, et al. New response eval uation criteria in solid 
tumors:  Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247. 
28. European Medicines Agency. EMA restricts use of Keytruda and Te centriq in bladder 
cancer. EMA/364553/2018, 1 June 2018.  
29. EuroQol Group. EuroQol-a new fac ility for the measurement of healthrelated quality of 
life. Health Policy 1990;16:199–208. 
30. Felip Font E, Gettinger SN, Burgio MA, et al. Three-year follow -up from Checkmate 
017/057:  Nivolumab versus docetax el in patients with previously treated advanced non-
small lung cancer (NSCLC). Poste r discussion presentation at the European Society of 
Medical Oncology Annual Meeting, September 8-12, 2017, Madrid, Spain. 
31. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immu noinhibitory receptor 
by a novel B7 family member lead s to negative regulation of lym phocyte activation. 
J Exp Med. 2000;192(7):1027-34. 
32. Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with 
metastatic urothelia l cancer who are unfit for cisplatin-based chemotherapy. Lancet 
Oncol. 2011;12:211-4. 
33. Galsky MD, Saci A, Szabo, PM, et al. Impact of tumor mutation b urden on nivolumab 
efficacy in second-line urothelial carcinoma patients:  Exploratory analysis of the phase ii 
checkmate 275 study. Ann Oncol. 2017;28 (suppl 5):848PD. 
34. Galsky MD, Arija JÁ, Bamias A, e t al. Atezolizum ab with or without chemotherapy in 
metastatic urothelial cancer (IMvigor130):   a multicentre, rand omised, placebo-controlled 
phase 3 trial. The Lancet. 2020;395([ZIP_CODE]):1547-57. 
35. Goodman AM, Kato S, Bazhenova L, e t al. Tumor mutational burden  as an independent 
predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017; 
16(11):2598-2608. 
36. Gottlieb DJ, Prentice HG, Heslop HE, et.al. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood. 1989;74(7):2335-42. 
37. Greenwald RJ, Freeman GH, Sharp e AH. The B7 family revisited. A nnu Rev Immunol. 
2004;23:515-48. 
38. Harada Y and Yahara I. Pathogenesis of toxicity with human-deri ved interleukin-2 in 
experimental animals. Int Rev Exp Pathol. 1993;34 Pt A:37-55. 
39. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ip ilimumab in lung 
cancer with a high tumor mutati onal burden. N Engl J Med 2018; 378:2093-2104. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110538]-line 
treatment for advanced non-smal l-cell lung cancer (CheckMate 01 2):  results of an 
open-label, phase 1, multicohort  study. The Lancet Oncol. 2017; 18(1):31-41. 
41. Herbst RS, Garon E, Kim D-W, et al. KEYNOTE-010:  Durable clini cal benefit in 
patients with previously treat ed, PD-L1-expressing NSCLC who co mpleted 
pembrolizumab. Poster presentation at the World Conference on L ung Cancer, December 
4-7, 2016, Vienna, Austria. 
42. Ihara T, Oshima Y, Nakamura H, e t al. Teratogenic effects of recombinant human 
interleukin-2 (TGP-3) in rabbits. Kiso To Rinsho. Clinical Repo rt. 1989;23(13):33-42. 
Translated into English, 20 December 2017. 
43. KEYTRUDA® Prescribing Information. Merc k and Co, Inc, Whitehouse Station , NJ. 
Revised June 2018.  
44. KEYTRUDA® Prescribing Information. [COMPANY_006]  & Co., Inc. Whitehouse Station,  NJ. 
Revised May 2021. 
45. KEYTRUDA® Summary of Product Characteristics, available at 
https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-
information_en.pdf 
46. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolu mab and ipi[INVESTIGATOR_804508]. N Engl J Med. 2015;373:23–34 . 
47. Motzer RJ, Escudier B, McDermot t DF, et al. Nivolumab versus everolimus in advanced 
renal cell carcinoma. N E ngl J Med. 2015;373(19):1803-13. 
48. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 2.2019.  
49. Noone AM, Howlader N, Krapcho M, e t al (eds). SEER Cancer Stati stics Review, 
1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr /1975_2015/, based on November 2017 SEER data submission, 
posted to the SEER w eb site, April 2018. 
50. Oken MM, Creech RH, Tormey DC, e t al. Toxicity and response cri teria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. 
51. Pardoll D. Does the immune syste m see tumors as foreign or self ? Annu Rev Immunol. 
2003;21:807-39. 
52. Parisi G, Saco J, Hu-Lieskovan S, e t al. Antitumor activity of NKTR-[ADDRESS_1110539] in an aggressive m urine melanoma model. Present ed at:  Annual 
Meeting of the America n Association for Cancer Research (AACR);  1-5 Apr2017; 
Washington, DC. 
53. Pearman TP, Beaumont JL, Mroczek  D, et al. Validity and Usefuln ess of a Single-Item 
Measure of Patient-Reported Bothe r From Side Effects of Cancer Therapy. Cancer. 
2018;124(5):991-997. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 118 of 149 
Confidential and Proprietary  27 May 2021 54. Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape de termines sensitivity to 
PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-128. 
55. Robert C, Long GV, Schachter J , et al. Long-term outcomes in pa tients with ipi[INVESTIGATOR_125]-
naïve advanced melanoma in the Phase 3 KEYNOTE-006 study who completed 
pembrolizumab treatment. J  Clin Oncol. 2017 35:15_suppl, 9504-9 504. 
56. Schadendorf D, Hodi FS, Robert C , et al. Pooled analysis of lon g-term survival data from 
Phase II and Phase III trials of  ipi[INVESTIGATOR_222103]. J Clin 
Oncol. 2015;33:1889-94. 
57. Schadendorf D, Larkin J, Chiarion -Sileni V, et al. Efficacy and  quality of life outcomes 
in patients with advanced melan oma (MEL) who discontinued treat ment with nivolumab 
(NIVO) plus ipi[INVESTIGATOR_162] b (IPI) due to toxicit y in a phase III trial (CheckMate 067). 
Presented at the [ADDRESS_1110540] 31-Sept ember 3, 2016, Vienna, Austria. 
58. Sharma M, Fa’ak F, Louise Janssen L, et al. NKTR-214, an engineered cytokine, synergizes and improves efficacy o f anti-cancer vaccination in the treatment of 
established murine melanoma tu mors. J Immunother Cancer. 2016;[ADDRESS_1110541] 1. 
59. Sharpe AH, Wherry EJ, Ahmed R , et al. The function of programme d cell death 1 and its 
ligands in regulating autoimmun ity and infection. Nature Immuno l. 2007;8(3):239-45. 
60. Siegel RL, Miller KD, Jemal A . Cancer statistics, 2020. CA Canc er J. Clin. 2020;70(1):7-
30. 
61. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 
blockade in melanoma. N Engl J Med. 2014;371:2189–2199. 
62. Snyder A, Nathanson T, Funt SA et al. Contribution of systemic and somatic factors to 
clinical response and resistance to PD-L1 blockade in urothelia l cancer:  An exploratory 
multi-omic analysis. PLoS Med. 2017 May 26;14(5):e1002309.  
63. Spi[INVESTIGATOR_43942], et al. Randomized res ults of continuous vs 1-year fixed-duration in patients 
with advanced non-small cell lung c ancer. Oral presentation at the European Society of 
Medical Oncology Annual Meeti ng. 2017 Sep 8-12; Madrid, Spain. 
64. TECENTRIQ
® Prescribing Information. Genente ch, Inc., South San Francisco,  CA. 
Revised July 2018. 
65. TECENTRIQ® Prescribing Information. Genentech, Inc.; South San Francisco, CA. 
Revised April 2021. 
66. TECENTRIQ® Summary of Product Characteristics, available at 
https://www.ema.europa.eu/en/doc uments/product-information/tece ntriq-epar-product-
information_en.pdf 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 119 of 149 
Confidential and Proprietary  27 May 2021 67. [LOCATION_002] Food and Drug Administration. FDA Alerts Health C are Professionals and 
Oncology Clinical Investigators ab out an Efficacy Issue Identified in Clinical Trials for 
Some Patients Taking Keytruda (pembrolizumab) or Tecentriq (ate zolizumab) as 
Monotherapy to Treat Urothelial Cancer with Low Expression of P D-L1. [ADDRESS_1110542] 2018. Accessed at 
https://www.fda.gov/Drugs/DrugS afety/ucm608075.htm, 19 Septembe r 2018. 
68. Vuky J, Balar AV, Castellano DE , et al. Updated efficacy and sa fety of KEYNOTE-052:  
A single-arm phase [ADDRESS_1110543]-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). J Clin Oncol. 2018;36 (suppl; abstr 4524). 
69. Vuky J, Balar AV, Castellano D, e t al. Long-term outcomes in KE YNOTE-052:  phase II 
study investigating first-line pemb rolizumab in cisplatin-ineligible patients with locally 
advanced or metastatic uroth elial cancer. J Clin Oncol. 2020;38 (23):2658-66. 
70. Wolchok JD, Hoos A, O’Day S, et al . Guidelines for the evaluation of immune therapy 
activity in solid tumors:  immune-related response criteria. Cl in Cancer Res. 
2009;15:7412-20. 
71. Zitvogel L, Tesniere A, Kroemer G. Cancer despi[INVESTIGATOR_53899]:  immunoselection and immunosubvers ion. Nature Rev Immunol. 2006; 6(10):715-27. 
  
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 120 of 149 
Confidential and Proprietary  27 May 2021 APPENDIX 1: ECOG PERFORMANCE STATUS CRITERIA  
0  Fully active; able to carry on all pre-disease performance w ithout restriction  
1  Restricted in physically str enuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light house work, office work  
2  Ambulatory and capable of all selfcare but unable to carry o ut any work activities; up and 
about more than 50% of waking hours  
3  Capable of only limited selfc are; confined to bed or chair m ore than 50% of waking 
hours  
4  Completely disabled; cannot carry on any selfcare; totally c onfined to bed or chair  
5  Dead 
Source: Oken MM, Creech RH, Torme y DC, et al. Toxicity and resp onse criteria of the Eastern Cooperative 
Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 121 of 149 
Confidential and Proprietary  27 May 2021 APPENDIX 2: CLINICAL LABORATORY TESTS 
Descriptions of the laboratory tests performed in this study ar e provided in the following 
appendices: 
• Appendix 2A : Table of the laboratory te sts performed in this study 
• Appendix 2B : Table of the local laborator y tests to be obtained prior to study drug dosing 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 122 of 149 
Confidential and Proprietary  27 May 2021 APPENDIX 2A: LABORATORY TESTS PERFORMED IN THIS STUDY 
Clinical Laboratory Tests 
Hematology Chemistry Serology 
• Hemoglobin (Hgb) 
• Hematocrit (HCT) 
• Platelet count 
• White blood cell (WBC) count 
• Neutrophils  
• Lymphocytes 
• Monocytes 
• Eosinophils 
• Basophils • AST (SGOT) 
• ALT (SGPT) 
• Alkaline phosphatase (ALP) 
• Albumin 
• Creatinine 
• Calculated creatinine clearance 
• Calcium 
• Creatine kinase 
• Glucose (non-fasting) 
• Total protein (TP) 
• Total bilirubin 
• Sodium 
• Potassium 
• Chloride 
• CO 2 content or bicarbonate 
• Blood urea nitrogen (BUN) or serum urea 
• Lactate dehydrogenase (LDH) 
• Uric acid • Hepatitis B surface antigen (HBsAg) 
• Hepatitis C virus antibody (anti-HCV) 
• Human immunodeficiency virus 
(HIV) antibody 
Coagulation Additional Labs 
• Partial thromboplastin time 
(PTT) 
• Prothrombin time (PT) • Serum or urine pregnancy (HCG) for WOBCP 
• FSH
a 
• Thyroid stimulating hormone (TSH) 
• Free thyroxine (T4) 
• Free or total tri iodothyronine 
(T3)  
• Lipase 
• Amylase 
• C-reactive protein (Screening onl
y)
Urinalysis 
• Specific gravity 
• pH 
• Glucose 
• Protein 
• Bilirubin 
• Ketones 
• Leukocyte esterase 
• Blood 
• Creatinine For positive protein, white blood cell or blood, a microscopic examination including: 
• Red blood cells 
• White blood cells 
• Epi[INVESTIGATOR_1663] 
• Bacteria 
• Crystals 
• Casts 
WOCBP = women of ch ildbearing potential 
a. Post-menopausal females under th e age of [ADDRESS_1110544] a s erum follicle stimulating hormone (FSH) level 
> 40 mIU/mL to confirm menopause (see Appendix 3). 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 123 of 149 
Confidential and Proprietary  27 May 2021 APPENDIX 2B: LOCAL CLINICAL LA BORATORY TESTS OBTAINED PRIOR 
TO STUDY DRUG ADMINISTRATION 
Chemistry 
• AST (SGOT) 
• ALT (SGPT) 
• Serum Creatinine 
• Blood urea nitro gen • Total bilirubin 
• Sodium 
• Potassium • Pregnancy test (for WOCBP) 
• Any additional clinically relevant test related to individual 
patient monitoring 
WOCBP = women of ch ildbearing potential 
Laboratory tests must be assessed by a local labor atory within 24 hours, or as soon as loca lly feasible, prior to study 
drug administration. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 124 of 149 
Confidential and Proprietary  27 May 2021 APPENDIX 3: WOMEN OF CHILDBEARI NG POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION 
DEFINITIONS 
Woman of Childbearing P otential (WOCBP) 
A woman is considered fertile  following menarche and until becoming post-menopausal unless 
permanently sterile. Permanent s terilization me thods include hy sterectomy, bilateral 
salpi[INVESTIGATOR_1656], and bila teral oophorectomy. 
Women in the following categor ies are not considered WOCBP 
• Premenarchal 
• Premenopausal female w ith 1 of the following: 
• Documented hysterectomy 
• Documented bilateral salpi[INVESTIGATOR_1656] 
• Documented bilateral oophorectomy 
Note:  Documentation can come fro m the site personnel’s review of the patient’s medical 
records, medical examination, o r medical hist ory interview. 
• Postmenopausal female 
• A postmenopausal state is defi ned as [ADDRESS_1110545] a serum fol licle stimulating hormone leve l > 40 mIU/mL to confirm 
menopause.  
CONTRACEPTION GUIDANCE FOR FEM ALE PATIENTS OF CHILD BEARING 
POTENTIAL One of the highly effective me thods of contraception listed below is required during study 
duration for female patients a nd until the end of relevant syst emic exposure, defined as 5 months 
after the end of study treatment for female  patients treated wi th NKTR-214/nivolumab or 
6 months after the end of study tr eatment for female patients w ho received GemCarbo on a prior 
protocol amendment.* 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 125 of 149 
Confidential and Proprietary  27 May 2021 Highly Effective Contraceptive M ethods That Are User Dependent 
Failure rate of <1% per year when  used consistently and correctly.a 
• Combined (estrogen- and progestogen-containing) hormonal contra ception associated with inhibition of 
ovulationb 
• oral 
• intravaginal 
• transdermal 
• Progestogen-only hormonal contra ception associated with inhibit ion of ovulationb 
• oral 
• injectable 
Highly Effective Methods That Are User Independent 
• Implantable progestogen-only horm onal contraceptio n associated with inhibition of ovulationb 
• Hormonal methods of contraception including vaginal ring, injec tables, implants and intrauterine hormone-
releasing system (IUS)c 
• Intrauterine device (IUD)c 
• Bilateral tubal occlusion 
• Vasectomized partner 
A vasectomized partner is a highly effective contraception meth od provided that the partner  is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirme d. If not, an additional highly effective method 
of contraception should be used. 
• Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire peri od of risk associated with th e study drug. The reliability of sexual abstinence 
needs to be evaluated in relation to the duration of the study and the preferred and usua l lifestyle of the patient. 
• It is not necessary to use any other method of contraception wh en complete abstinence is elected. 
• WOCBP patients who choose complete abstinence must continue to have pregnancy tests, as specified in 
Section 1.2. 
• Acceptable alternate methods of h ighly effective contraception must be discussed in the event that the 
WOCBP patients chooses to f orego complete abstinence 
NOTES: 
a. Typi[INVESTIGATOR_804509]. Use should be consistent 
with local regulations regarding the use of contraceptive metho ds for patients participa ting in clinical studies. 
b. Hormonal contraception may be susceptible to interaction wit h the study drug, which m ay reduce the efficacy 
of the contraceptive method. Ho rmonal contraception is permissi ble only when there is sufficient evidence 
that the IMP and other study medications will not alter hormona l exposures such that contraception would be 
ineffective or result in increased exposures that could be pote ntially hazardous. In this case, alternative 
methods of contraception should be utilized. 
c. Intrauterine devices and intrauterine hormone releasing syst ems are acceptable methods of contraception in 
the absence of definitive drug interaction studies when hormone  exposures from intrauterine devices do not 
alter contraception effectiveness 
 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 126 of 149 
Confidential and Proprietary  27 May 2021 Unacceptable Methods of Contraception* 
• Male or female condom with or without spermicide. Male and female condoms cannot be used simultaneously 
• Diaphragm with spermicide 
• Cervical cap with spermicide 
• Vaginal Sponge with spermicide 
• Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mechanism of 
action 
• Periodic abstinence (calendar, symptothermal, post-ovulation me thods) 
• Withdrawal (coitus interruptus) 
• Spermicide only 
• Lactation amenorrhea method (LAM) 
* Local laws and regulations may r equire use of alternative and /or additional contraception methods. 
CONTRACEPTION GUIDANCE FOR MAL E PATIENTS WITH PARTNER(S) OF 
CHILD BEARING POTENTIAL 
Male patients with female partne rs of childbearing potential ar e eligible to part icipate if they 
agree to the following during the treatment and until the end of relevant systemic exposure. • Inform any and all partner(s) of  their participation in a clinical drug study and the need to 
comply with contraception instr uctions as directed by [CONTACT_18413]. 
• Male patients are required to us e a condom for s tudy duration a nd until end of relevant 
systemic exposure defined as [ADDRESS_1110546] dose of NK TR-214 for male patients 
treated with NKTR-214/nivolumab o r 6 months after the end of study treatment for male 
patients who received GemCarbo on a prior protocol amendment. 
• Female partners of males part icipating in the  study to consider  use of effective methods of 
contraception until the end of relevant systemic exposure, defi ned as [ADDRESS_1110547] 
dose of NKTR-214 in male patients  treated with NKTR-214/nivolum ab or 6 months after the 
end of study treatment for pati ents who received GemCarbo on a prior protocol amendment. 
• Male patients with a pregnant or br eastfeeding partner must agree to remain abstinent from 
penile vaginal intercourse or us e a male condom during each epi[INVESTIGATOR_82710] [ADDRESS_1110548] dose of NKTR-214 for male patients 
treated with NKTR-214/nivolumab o r 6 months after the end of study treatment for male 
patients who received GemCarbo on a prior protocol amendment. 
• Refrain from donating sperm for the durat ion of the study treat ment and until [ADDRESS_1110549] dose of NKTR-214 for mal e patients treated with NKTR-2 14/nivolumab or 6 months 
after the end of study treatment  for male patients who received  GemCarbo on a prior protocol 
amendment. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 127 of 149 
Confidential and Proprietary  27 May 2021 COLLECTION OF PREGNANCY INFORMATION 
Guidance for collection of Pre gnancy Information and outcome of  pregnancy on the Pregnancy 
Surveillance Form is  provided in Section 9.7 and the Appendix for Advers e Events and Serious 
Adverse Events Definitions and procedures for Evaluating, Follo w-up and Reporting. 
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 128 of 149 
Confidential and Proprietary  27 May 2021 APPENDIX 4: CEREBROVASCULAR  ACCIDENT ADVERSE EVENT 
MANAGEMENT ALGORITHM 
Table 7  provides a management algorith m for possible signs/symptoms of  CVA for patients 
treated with the combination of  NKTR-214 with a checkpoint inh ibitor. This general guideline 
constitutes guidance to the Investigator and may be supplemente d by [CONTACT_804576]/or discussions w ith the Medical Monitor repres enting the Sponsor. 
Table 7: Cerebrovascular Accident Adverse Event Management Algo rithm 
For unexplained neurological sym ptoms (such as hemiparesis, con fusion, dysarthria, or visual 
disturbances) that may be associated with CVA: perform neurological imaging with MRI including diffusion-weighted imaging (DWI) as soon as feasible after initial presentation of symptoms (preferably within 24 hours). DWI MRI is preferred, but if contraindicated, alternative imaging modalities may be used.  
If imaging is consistent with a CVA, proceed to the following:  
1 For any new CVA event confirme d by [CONTACT_9661] (DWI MRI preferred  unless 
contraindicated), regardless of neurological symptoms (eg, cryp togenic CVA), and 
for suspected TIA without clear alternativ e etiology:  
• Discontinue study treatment for p atients receiving NKTR-214 in combination 
with a checkpoint inhib itor (ie, nivolumab).
2  Neurology consultation recommended. 
3 Perform pertinent laboratory a ssessments including coagulation (D-dimer, complete 
blood count with differential, ser um blood urea nitrogen, and c reatinine)  
preferably by [CONTACT_804577] g. Local laboratory 
testing is allowed when central laboratory testing is not possible. 
4 Consider cardiac echocardiogram  (trans-esophageal as appropri ate) to evaluate for 
potential source of emboli. 
CVA = cerebrovascular accident; DW I = diffusion-we ighted imagin g; MRI = magnetic resonance imaging; TIA = 
transient ischemic attack. 
 
 

APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page 1 of 20 
Confidential and Proprietary  27 May 2021 APPENDIX 5: GUIDELINES FO R PATIENTS RANDOMIZED TO 
GEMCITABINE/CARBOPLATIN (GEMCARBO) TREATMENT IN AN EARLIER PROTOCOL VERSION 
Note: The GemCarbo arm is no longe r applicable at Amendment 3 a nd beyond. 
 129 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page 2 of 20 
Confidential and Proprietary  27 May 2021 TABLE OF CONTENTS 
1.0 SCHEDULE OF EVENTS FOR PATIENTS PREVIOUSLY RANDOMIZED TO GEMCITABINE/CARBO PLATIN (GEMCARBO) ...............................................4
 
2.0 INVESTIGATIONAL PLAN FOR PATI ENTS PREVIOUSLY RANDOMIZED 
TO GEMCITABINE/CARBO PLATIN (GEMCARBO) .............................................10  
2.1 Background ............................................................................................................10  
2.2 Screening Period ....................................................................................................10  
2.3 Treatment Period ....................................................................................................11  
3.0 GEMCARBO STUDY TREATMENTS ..................................... ...................................12  
3.1 Administration of Study Drugs ..............................................................................12  
3.1.1  Gemcitabine ..........................................................................................12  
3.1.2  Carboplatin ............................................................................................12  
3.1.3  Vital Sign Monitoring ...........................................................................13  
3.1.4  Premedication for Patients Receiving GemCarbo.................. ...............13  
3.2 Dosage Modification ........................................... ...................................................13  
3.2.1  Gemcitabine/Carboplatin Dos e Modification Criteria ............ ..............13  
[IP_ADDRESS]  Hematological Toxicity  ................................................................13  
[IP_ADDRESS]  Renal Toxicity ...............................................................................14  
[IP_ADDRESS]  Other Toxicities  ............................................................................14  
3.3 GemCarbo Cross Over to NKTR-214/Nivolumab ................................................15  
4.0 STUDY ASSESSMENTS AND PROCEDURES ..........................................................16  
4.1 Pharmacokinetic, Immunogenicity a nd Biomarker Measurements for 
GemCarbo ..............................................................................................................16  
4.2 Tumor Tissue Specimens .......................................................................................16  
5.0 ASSESSMENT OF SAFETY ..........................................................................................18  
5.1 Adverse Event and Serious Adverse Event Follow-Up .........................................18  
5.2 Pregnancy Tests/Pregnancy ..................................... ..............................................18  
5.2.1  Pregnancy Tests ............................................... .....................................18  
5.2.2  Pregnancy ..................................................... .........................................18  
[IP_ADDRESS]  Pregnancies in Female Patients  ..................................................18  
[IP_ADDRESS]  Pregnancies in Female Partners of Male Patients  ....................19  
5.3 Other Safety Assessments ......................................................................................19  
6.0 REFERENCES .................................................................................................................20  
 
 130 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutics  Page [ADDRESS_1110550] OF TABLES 
Appendix 5, Table 1:  Schedule of Events for Patients Previously Randomized to GemCar bo 
(Excluding Pharmacokinetic, Im munogenicity, and Biomarker 
Sampling) .....................................................................................................4  
Appendix 5, Table 2:  GemCarbo Treatment for Study 18-214-10 ...............................................12  
Appendix 5, Table 3:  Dose Modification and Delay for  Gemcitabine and Carboplatin Due  to 
Hematological Toxicity (Cycle 1) .............................................................14  
Appendix 5, Table 4:  Biomarker Sampling Schedule fo r the GemCarbo Combination ..............16  
Appendix 5, Table 5:  Tumor Biopsy Sampling Schedule ................................ ............................[ADDRESS_1110551] OF FIGURES 
Appendix 5, Figure 1:  Study Schematic for Amendment 2.0 ........................................................10  
 
 131 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page [ADDRESS_1110552] be provided within 5  days prior to administering 
study drugs. 
l. Unstained FFPE, tumor tissue s ections on slides (a minimum o f 10 slides, preferably 15 to 25) or a FFPE tumor tissue block,  collected within 12 months 
prior to enrollment and without intervening therapy, are accept able in lieu of a fresh tumor biopsy prior to treatment.  See A ppendix 5, Section 4.2 and 
Section 7.5 of protocol Amendment 3.0 or later.  An optional on -treatment tumor tissue sample w ill be collected prior to Cycle  2 Day 1, on Days 14 to 21 of 
Cycle 1. Sample collection upon disease progression is optional  but highly recommended. PD-L1 status is described in Section 7 .3 of protocol Amendment 
3.0 or later. If patient crosses over to NKTR-214/nivolumab tre atment, a biopsy at rescreening is not required.   
m. Tumor assessments at Screening and every 9 weeks (± 7 days) from Cycle [ADDRESS_1110553] 12 months.  Beyond 12 months, tumor assessments will 
decrease in frequency to every 12 weeks (± 7 days).  A scan sho uld also be done at EOT unless a scan was done within 4 weeks ( Section 7.0 of protocol 
Amendment 3.0 or later).  Patients who continue treatment beyond progression should continue to have scans every 9 weeks (± 7 days) for the first 
[ADDRESS_1110554]-progression and every 12 weeks (± 7 days) in the second year of treatment post-progression.  Tumor  assessments in the follow-
up period are only needed if the patient discontinued treatment  without radiographic disease progression (Section 4.1.4 of pro tocol Amendment 3.0 or later).  
Confirmation of tumor response is discussed in Section 8.[ADDRESS_1110555] of the brain (without and with 
contrast) can be performed if MRI is contraindicated.  See Sect ion 7.[ADDRESS_1110556] response 
to the regimen, and date of progression to subsequent anti-canc er therapi[INVESTIGATOR_12308]. 
q. See Section 4.1.3 of protocol Amendment 3.0 or later.  Patients not crossing over to NKTR- 214/nivolumab should continue wit h the Follow-up Visits 
[ADDRESS_1110557] dose of study treatment as well as the Survival Follow-Up Visits.   
r. Patients crossing  over to NKTR-214/niv olumab should proceed with rescreening assessment s.  See Appendix 5, Section 3.3. 
s. Patients must be followed for at least [ADDRESS_1110558] dose (± 7 days) or 
can be performed on the date of discontinuation if that date is  greater than [ADDRESS_1110559] dose .  Follow-up Visit 1 can be combined with the EOT 
Visit if the visits are within 7  days of each ot her
.  Follow-up  Visit 2 occurs approximately 100  days (± 7 days) from the last  dose of study treatment. Both 
follow-up visits should be conducted at the clinic. See Section  4.1.[ADDRESS_1110560]-study therapy(ies) a nd survival every 3 months (± 14 days) following the Day [ADDRESS_1110561].  S ee Section 4.1.4 of p rotocol Amendment 3.0 or later. 
 136 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 9 of 20 
Confidential and Proprietary  27 May 2021 u.  At each visit specified, hea lth-related qua lity of life (HR QoL) will be assessed using the EORTC Quality of Life Questionn aire (EORTC QLQ-C30); general 
health status will be measured usi ng the EuroQol Group’s EQ-5D questionnaire (EQ-5D-3L) and tr eatment burden will be captured by [CONTACT_804578] (FACIT) GP5 item. During long-term survival follow-up, th e EQ-5D-3L will be administered  by [CONTACT_756]. See 
Section 7.6 of protocol Amendment 3.0 or later.
 137 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutic s  Page 10 of 20 
Confidential and Proprietary  27 May 2021 2.0 INVESTIGATIONAL PLAN FOR PATIEN TS PREVIOUSLY RANDOMIZED TO 
GEMCITABINE/CARBOPLATIN (GEMCARBO) 
2.1 Background 
This appendix describes the treat ment plan for patients who wer e randomized to gemcitabine and 
carboplatin (GemCarbo) in an earlier version of the protocol.  This information is being included 
for reference purposes, as patients who were randomized to GemC arbo in an earlier version of 
the protocol should continue rece iving GemCarbo as described in Appendix 5, Section 2.3 . For 
information pertaining to study procedures for patients randomized to GemCarbo that is not 
covered in the appendix, refer to Amendment 2.0 of the protocol .   
In an earlier version of the pro tocol, some patients were rando mized to receive: 
gemcitabine 1000 mg/m2 intravenous (IV; on Day 1 and 8 of each 3-week cycle) and carbo platin 
IV, target area under the curve ( AUC) 4.5 mg/mL/min q3w (on Day 1 of each 3-week cycle) 
(Arm B, Reference Arm).   
Appendix 5, Figure 1 provides the study schematic for Amendment 2.0.  Appendix 5, Table 1  
outlines the study procedures in the Schedule of Events.   
Appendix 5, Figure 1: Study Schematic for Amendment 2.0 
 
AUC = area under the curve; CPS = Combined Positive Score; PD-L1 = programmed cell death ligand 1; 
q3w = every 3 weeks; PS = performance status; RECIST 1.1 = Resp onse Evaluation Criteria in Solid Tumors 
version 1.1 
a. Patients treated w ith GemCarbo may cros s over to treatment with NKTR-214/nivolumab.  See Appendix 5, 
Section 3.[ADDRESS_1110562] at your site; to refl ect this the terminology 
‘Amendment 3.0 or later’ has been utilized in this appendix. 
2.[ADDRESS_1110563] completed the screening period before randomization to GemCarbo. 
 138 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutic s  Page 11 of 20 
Confidential and Proprietary  27 May 2021 2.3 Treatment Period 
Every effort should be made to sch edule visits within the proto col-specified windows   
(Appendix 5, Table 1 ). 
GemCarbo may be administered for a total of 4 t o 6 cycles (or longer) per the treating facilities 
institutional standard, until unacceptable toxicity, or progres sive disease.  Patients who have not 
had progressive disease at the e nd of their GemCarbo treatment should continue treatment per 
Investigator recommendations. 
Patients treated with GemCarbo may cross over and receive treat ment with 
NKTR-214/nivolumab if they m eet any of the following: 
• RECIST 1.1 defined pro gressive disease 
• Unacceptable toxicity making completion of 4 to 6 cycles of Gem Carbo not feasible 
• Residual disease upon completi on of 4 to 6 cycles of GemCarbo 
See Appendix 5, Section 3.3 for additional information a bout GemCarbo cross-over. 
 139 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutic s  Page 12 of 20 
Confidential and Proprietary  27 May 2021 3.0 GEMCARBO STUDY TREATMENTS 
Study treatment for patients receiving GemCarbo are detailed in  Appendix 5, Table 2 .   
Appendix 5, Table 2: GemCarbo Treatment for Study 18-214-[ADDRESS_1110564] Description / 
Class and Dosage Form Potency IMP/ 
Non-IMPBlinded or 
Open Label Packaging / 
Appearance Storage 
Conditions 
(per label) 
Gemcitabine Powder for 
Solution for Injection 200 mg or 1 g (10 mg/mL) IMP Open-label Vial (one or more 
vials per carton) Store below 
30 °C; do not 
refrigerate. 
Carboplatin Solution for 
Injection 5 mL/15 mL/45 mL vials containing 50 mg/150 mg/450 mg (10 mg/mL) IMP Open-label Vial (one or more vials per carton) Store at room temperature 
IMP = Investigational Medicinal Product 
 3.1 Administration of Study Drugs 
3.1.1 Gemcitabine 
Gemcitabine 1000 mg/m
2 will be given on Days 1 and 8 of e ach 21-day cycle and prepare d per 
institutional guidelines and/or package insert.  An appropriate  amount of drug will be prepared 
and administered as a continuous  infusion over approximately [ADDRESS_1110565] 
should be stored below 30°C. Gemc itabine should be reconstitute d with normal saline added to 
the vial to make a solution i deally containing 10 mg/mL.  The c oncentration for 200 mg and 1 g 
vials should be no greater th an 40 mg/mL.  Once the drug has be en reconstituted it should be 
stored at room temperature a nd used within [ADDRESS_1110566] itutional guideline. 
All patients should receive pre- medications (see Appendix 5, Se ction 3.1.4 ).   
3.1.2 Carboplatin 
The total dose of carboplatin i s based on renal function and ca lculated by [CONTACT_490401] 
(Calvert, 1989 ) using the target AUC (4.5 mg/mL/min) and glomerular filtratio n rate (GFR): 
Total dose in mg = 4.5 × (GFR + 25)  
GFR will be assessed by [CONTACT_804579] (ethylene diamine te traacetic acid [EDTA] 
clearance or creatinine clear ance) or, if not available, by [CONTACT_804580]/plasma 
creatinine (Cockcroft and Gault formula).  Per institutional standard, GFR may be capped at 
125 mL/minute. 
 140 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutic s  Page 13 of 20 
Confidential and Proprietary  27 May 2021 Carboplatin is to be given on Day 1 of each treatment cycle and prepared per institutional 
guidelines and/or package inse rt.  An appropriate amount of dru g will be prepared and 
administered IV as a continuous i nfusion per institutional guid elines. 
Carboplatin is supplied in 5 mL, 15 mL, or 45 mL vials containing 50 mg, 150 mg, or 450 mg carboplatin and water for injection. 
All patients should receive pre- medications (see Appendix 5, Se ction 3.1.4 ).   
3.1.[ADDRESS_1110567] practice: 
a) Ondansetron 16 to 24 mg and dexame thasone 12 mg orally (PO) ± aprepi[INVESTIGATOR_053] 125 mg PO 
30 minutes before Day 1 of GemCarbo. 
b) Granisetron 1 mg to 2 mg and dexame thasone 12 mg PO ± aprepi[INVESTIGATOR_252366] t 125 mg PO 
30 minutes before Day 1 of GemCarbo. 
c) Dolasetron 100 mg and dexameth asone 12 mg PO ± aprepi[INVESTIGATOR_053] 125 m g PO 30 minutes 
before Day 1 of GemCarbo. 
d) Palonosetron 0.25 mg IV and dexamethasone 12 mg PO ± aprepi[INVESTIGATOR_053]  125 mg PO 
30 minutes before Day 1 of GemCarbo. 
3.2 Dosage Modification 
3.2.1 Gemcitabine/Carboplatin Dose Modification Criteria 
Dose modifications for gemcita bine or carboplatin or both may b e made for hemato logical, renal, 
or other toxicities. Investigato rs should follow the approved p rescribing guidelines in the 
country, or institutional standard of care.  Recommended dose m odifications are below, however 
institutions may follow institutional standard of care if varia nces are noted. 
[IP_ADDRESS] Hematological Toxicity 
A complete white blood cell (WBC) count, absolute neutrophil co unt (ANC), and platelet count 
is to be on Days [ADDRESS_1110568] of care.  Dose m odifications are shown in Appendix 5, Table 3 . 
 141 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutic s  Page 14 of 20 
Confidential and Proprietary  27 May 2021 Appendix 5, Table 3: Dose Modifica tion and Delay for Gemcitabin e and Carboplatin Due 
to Hematological Toxicity (Cycle 1) 
Criterion Modification 
WBC  
(× 109/L) And/Or ANC  
(× 109/L) And/Or Platelets  
(× 109/L) % Dose of 
Gemcitabine % Dose of 
Carboplatin
Day 1: 
≥ 3.0  and ≥ 1.5  and ≥ 100  100  100 
< 3.0  or < 1.5  or < 100  D elay 1 week  Delay 1 week
Day 8: 
≥ 3.0 and > 1.5  and ≥ 100  100 NA 
≥ 2.0 – 3.0  and ≥ 1.0 and >100 100 NA 
1.0 – 1.9  or > 0.5 - <1.0  or 50-99  50 NA 
< 1.0  or < 0.5  or < 50  Withhold NA 
ANC = absolute neutrophil count; NA = not applicable; WBC = whi te blood cells 
 
Dose modifications for subsequent cycles are as follows: 
• At Day 1, 25% dose reduction of each drug if during the nadir o ne or more of the 
following occurs: 
• Grade 4 neutropenia (ANC < 0.5 × 109/L) with fever > 38.5 °C or 
• Grade 4 thrombocytopenia (< 10.0 × 109/L) for more than 3 days or 
• Thrombocytopenia with activ e bleeding during the nadir. 
If a patient requires more than 2 w eeks for hematologic recovery (defined as, at minimum, WBC 
is ≥ 2.0 × 109/L, ANC ≥ 1.0 × 109/L and platelets ≥ 75 × 109/L), treatment should be continued 
with 75% of dose of each drug.   
[IP_ADDRESS] Renal Toxicity 
Carboplatin will be adjusted every cycle using Calvert’s formula.  
For gemcitabine, no dose modificati on is necessary if the GFR i s ≥ 30 mL/min.  Gemcitabine is 
withheld if the GFR is < 30 mL/min. 
[IP_ADDRESS] Other Toxicities 
Dose reductions for gemcitabine and carboplatin for drug-related toxicities are made as follows: 
• Grade 1-2: no dose reductions. 
• Grade 3: 25% dose redu ction in both drugs 
 142 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutic s  Page 15 of 20 
Confidential and Proprietary  27 May 2021 • Grade 4: the patient may be withdrawn from the study at the Investigators discretion. If the 
patient continues under treatme nt, a 50% dose reduction should be considered. 
In case of nausea and vomiting, ade quate parenteral fluid, elec trolyte substitution and application 
of modern antiemetics and dexame thasone, if necessary should be  done.  The diagnosis of 
hemolytic uremic syndrome (HUS) should be considered if the patient develops anemia with 
evidence of microangiopathic he molysis, elevation of bilirubin or lactate dehydrogenase (LDH), 
reticulocytosis, severe thrombocytopenia, and/or evidence of re nal failure (elev ation of serum 
creatinine or blood urea nitrogen [BUN]). Gemcitabine therapy s hould be discontinued 
immediately upon diagnosis of HUS. 
3.3 GemCarbo Cross Over to NKTR-214/Nivolumab 
Patients treated with GemCarbo may cross over and receive treat ment with 
NKTR-214/nivolumab if they m eet any of the following: 
• RECIST 1.1 defined pro gressive disease 
• Unacceptable toxicity making completion of 4 to 6 cycles of Gem Carbo not feasible 
• Residual disease upon completi on of 4 to 6 cycles of GemCarbo 
The decision to cross over should be made by [CONTACT_804581] t heir treating 
physician.  Patients are require d to complete the GemCarbo end of treatment (EOT) visit.  
Patients need to provide consent to cross over to NKTR-[ADDRESS_1110569] 
complete the required rescreen ing evaluations within 28 days of beginning NKTR-214 and 
nivolumab treatment.  
Upon initiation of treatment wit h NKTR-214/nivolumab patients s hould follow the assessment 
schedule outlined in the schedule of assessments (Table 1) of A mendment 3.0 or later for 
patients undergoing treatment wi th NKTR-214/nivolumab (starting with Cycle 1 Day 1).  The 
Cycle 1 Day 1 visit should occur  no more than 90 days after the  GemCarbo EOT visit.  No 
intervening treatment  between GemCarbo and NKTR-214/nivolumab i s allowed.  Patients will 
need to have immunogenicity blood samples done as per Table [ADDRESS_1110570] meet all eligibili ty criteria as defined in Sections 5.1 
and 5.2 of protocol Amendment 3.0 or later. 
 143 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutic s  Page 17 of 20 
Confidential and Proprietary  27 May 2021 Appendix 5, Table 5: Tumor B iopsy Sampling Schedule  
Collection Timing Tumor Biopsy 
Screening Xa
Cycle 1 Days 14-21b X  
Upon progressionb X 
a.  Unstained FFPE, tumor tissue sections on slides (minimum of  10, preferably 15 to 25 ) or a FFPE tumor tissue 
block, collected within 12 months prior to enrollment and witho ut intervening therapy, are acceptable in lieu of 
a fresh tumor biopsy prior to treatment.  
b.  Sample collection is optional but highly recommended. 
 145 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutic s  Page [ADDRESS_1110571] dose of study 
drug(s) until [ADDRESS_1110572] dose of study drug(s).  
For patients receiving GemCarbo, a ll SAEs, regardless of causality, with an onset within 
[ADDRESS_1110573] dose of study drug(s) will be reported to Nektar Therapeutics Drug Safety 
immediately without undue delay, un der no circumstances later than 24 hours following 
knowledge. 
Additional information pertai ning to AEs and SAEs is provided i n Sections 9.1 to 9.4 of protocol 
Amendment 3.0 or later. 
5.2 Pregnancy Tests/Pregnancy 
5.2.[ADDRESS_1110574] a minimum sensitivity of 25 IU/L or equivalent units of HCG. A 
negative pregnancy test result mu st be obtained before the admi nistration of the study drug(s). 
A pregnancy test does not need to be performed on women who are  postmenopausal (see 
Appendix 3 of protocol Amendment  3.0 or later) for at least [ADDRESS_1110575] 3 months before signing the ICF. 
If a female patient becomes preg nant, administration of the study drug(s) must be discontinued 
immediately.  Requireme nts for reporting a pregnancy are provid ed in Section 9.5.2 of protocol 
Amendment 3.0 or later. 
5.2.2 Pregnancy 
[IP_ADDRESS] Pregnancies in Female Patients 
The Sponsor must be notified i mmediately without undue delay, u nder no circumstances later 
than [ADDRESS_1110576] dose of 
study treatment for fem ale patients recei ving GemCarbo.  Women who become pregnant during 
and for up to 6 months after treatme nt with carboplatin should be offered genetic consultation by 
[CONTACT_804582].  All reports should be submitted via the Pregnancy Notification Form.  
Pregnancy, although reportable, i s not considered an AE/SAE unl ess a female patient 
experiences signs or symptoms of pregnancy complications; howev er, the contact [CONTACT_804583] 9.2.2 of protocol 
Amendment 3.0 or later.  Female patient(s) who become pregnant will be followed until the 
 146 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutic s  Page 19 of 20 
Confidential and Proprietary  27 May 2021 outcome of the pregnancy is  known.  Pregnancy follow-up should describe the outcome of the 
pregnancy, including any voluntar y or spontaneous termination, details of the birth, and the 
presence or absence of any congeni tal abnormalities or birth de fects in the offspring. 
If a female patient becomes preg nant, administration of the study drug(s) must be discontinued 
immediately. 
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients 
Any pregnancy occurring during the course of the study and for [ADDRESS_1110577] be notified immediatel y without undue delay, under no circ umstances later than 24 hours 
following knowledge of the initial  report and any follow-up information.  All reports should be 
submitted via the Pregnancy No tification Form.  Pregnancy, alth ough reportable, is not 
considered an AE/SAE unless a fe male partner of male patient ex periences signs or symptoms of 
pregnancy complications; however, the contact [CONTACT_19297] p regnancy reporting is the same 
as for SAE reporting and lis ted in Section 9.2.[ADDRESS_1110578] and repor t details of the course and outcome of any pregnancy in the 
partner of a male patient e xposed to study drug with the author ization from the p regnant partner.  
Pregnancy follow-up should descri be the outcome of the pregnanc y, including any voluntary or 
spontaneous termination, details of the birth, and the presence  or absence of any congenital 
abnormalities or birth def ects in the offspring. 
5.3 Other Safety Assessments 
Additional information pertaini ng to the assessment of safety i s provided in Sections 9.6 to 9.11 
of protocol Amendm ent 3.0 or later. 
 147 of 149
APPENDIX 5: 18-214-10 / CA045-012 Amendment 5.0  bempegaldesleu kin (NKTR-214) and nivolumab 
Nektar Therapeutic s  Page [ADDRESS_1110579], Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a 
simple formula based on renal function. J Clin Oncol. 1989;7:17 48–1756. 
 148 of 149
Protocol No. 18-214-10 / CA045-012 Amendment 5.0 bempegaldesleu kin (NKTR-214) and nivolumab  
Nektar Therapeutics  Page 149  of 149 
Confidential and Proprietary  27 May 2021 APPENDIX 6: CYTOKINE RELEASE  SYNDROME (CRS) MANAGEMENT 
ALGORITHM 
The following treatment management guidelines are provided for general guidance. These 
guidelines should not substitute f or a more individualized, tai lored approach to managing a 
patient experiencing CRS. 
CRS Management Measures/Algorithm 
As a general principle, differ ential diagnoses should be dilige ntly evaluated according to standard medical practice. 
Non-inflammatory etiologies should be considered and appropriat ely treated.  
For patients with suspected CRS:   
- For Grade 1 or Grade 2 events, implement supportive care, inclu ding management of i solated symptoms 
based on institutional practices. 
- Consider admitting the patient for monitoring and providing sup portive care, including management of 
isolated symptoms based on institutional practices and protocol  management guidelin es (e.g., hydration 
management guidelines, Section 6.2.2 ). 
- For patients with a persistent or worsening clinical condition after initial treatment of CRS, reevaluate for 
other contributing conditions. It is particularly important to reassess the patient for coexisting infections, and 
cardiac, pulmonary, thromboembolic, and other complications. 
Grading Assessment per CTCAE v.5 .0 Treatment Measures Recommended 
Grade 3 CRS - Hypotension 
managed with one pressor 
- Hypoxia requiring >40% O
2 - Vasopressin administration should be considered if the hypotensive event is refractory to >3L of fluid resuscitation 
- Oxygen therapy (nasal canula, non-invasive positive pressure 
ventilation, etc.) for respi[INVESTIGATOR_804510] a patient with sev ere respi[INVESTIGATOR_335811]  
- Supportive care for renal, hep atic, and other organ function 
deteriorations 
- Steroid therapy should be considered (e.g., hydrocortisone 100 mg 
every eight hours, dexamethasone 10 mg up to four times daily, 
1-2 mg/kg/day methylprednisolone IV or PO equivalent) 
- High dose steroid (e.g., methylprednisolone 2 mg/kg up to 1 gra m 
daily for three days) may be considered for severe CRS that fai led 
to respond after repetitive steroid treatments 
- For severe CRS cases that require simultaneously aggressive management of hypotension, oxygenation, and cardiac telemetry, consult Intensivist for ICU evaluation Grade 4 CRS - Life-threatening consequences 
- Pressor or ventilatory support indicated  
 